

JOE W. GRAY

Oregon Health & Science University • 2730 SW Moody Ave., CL3G • Portland, OR 97201-5042

(503) 494-6500 • Cell: (503) 708-7767 • Grayjo@ohsu.edu • www.ohsu.edu/ocssb

EDUCATION

Prof. Engr., Physics, Colorado School of Mines, Golden, Colorado 1967-1968
Ph.D., Physics, Kansas State University, Manhattan, Kansas 1968-1972

PROFESSIONAL EXPERIENCE

Administrative

Professor and Gordon Moore Endowed Chair 2011-Present
Department of Biomedical Engineering
Director
Center for Spatial Systems Biomedicine
Associate Director for Biophysical Oncology
Knight Cancer Institute
Oregon Health & Science University
Division Director 2007-2011
Life Sciences Division
Lawrence Berkeley National Laboratory
Associate Laboratory Director 2003-2011
Biosciences
Lawrence Berkeley National Laboratory
Program Leader 1995-2004
Cancer Genetics Program, UCSF Cancer Center
University of California, San Francisco
Interim Director 1995-1997
UCSF Cancer Center
University of California, San Francisco
Director 1991-2000
Division of Molecular Cytometry, Department of Laboratory Medicine
University of California, San Francisco

Academic

Adjunct Professor 2003-2010
Department of Laboratory Medicine and Radiation Oncology
University of California, San Francisco
Professor 1993-2003
Department of Laboratory Medicine and Radiation Oncology
University of California, San Francisco
Professor in Residence 1991-1992
Department of Laboratory Medicine and Radiation Oncology
University of California, San Francisco
Section Leader 1982-1991
Biomedical Sciences Division, University of California, Livermore
Lawrence Livermore National Laboratory
Biomedical Scientist 1972-1991
Biomedical Sciences Division, University of California, Livermore
Lawrence Livermore National Laboratory
Graduate Student 1968-1972
Physics Department, Kansas State University, Manhattan, Kansas

MAY 2017

Other

<i>Joint Appointment</i> Professor, Department of Radiation Medicine, School of Medicine Oregon Health & Science University	2011-Present
<i>Member</i> Graduate Faculty, School of Medicine Oregon Health & Science University	2011-Present
<i>Member</i> Comparative Biochemistry Graduate Group University of California, Berkeley	2008-2010
<i>Affiliate Member</i> California Institute for Quantitative Biosciences (QB3) University of California	2008-2010
<i>Member</i> Medical Information Sciences Graduate Program (MIS) University of California	1999-2007
<i>Member</i> Biomedical Sciences Graduate Program (BMS) University of California, San Francisco	1998-2006
<i>Member</i> Program in Biological Sciences, Graduate Program (PIBS) University of California, San Francisco	1998-2008
<i>Senior Scientist</i> Lawrence Berkeley National Laboratory	1992-1998
<i>Adjunct Professor</i> Laboratory Medicine University of California, San Francisco	1984-1991
<i>Member</i> Biophysics Graduate Program University of California, San Francisco	1976-2010

HONORARY MEMBERSHIPS

AWARDS AND HONORS

<i>Fellowship, National Defense Education Act</i>	1968-1969
<i>Fellowship, National Science Foundation Fellowship</i>	1969-1971
<i>Research Award, Radiation Research Society</i>	1985
<i>Distinguished Lectureship, Smith-Kline & French</i>	1986
<i>E.O. Lawrence Award, United States Department of Energy</i>	1986
<i>Fellow, American Association for the Advancement of Science</i>	1996
<i>Biological and Environmental Research Program Recognition Award United States Department of Energy</i>	1997
<i>Shiffer Award, Cell Proliferation Society</i>	1999
<i>Boerhave Professor, Leiden University, the Netherlands</i>	2000
<i>Curt Stern Award, American Society for Human Genetics</i>	2001
<i>Sponsored Projects of Research Excellence Leadership Award SPORE Program, National Cancer Institute</i>	2003
<i>Alumni Fellow, Kansas State University</i>	2005
<i>Distinguished Achievement Award, Colorado School of Mines</i>	2005

<i>Honorary Doctorate, University of Tampere, Tampere, Finland</i>	2005
<i>Innovator Award, United States Department of Defense</i>	2007
<i>Brinker Award for Scientific Distinction, Susan G. Komen® Foundation</i>	2007
<i>Team Science Award, American Association for Cancer Research</i>	2008
<i>Elected Fellow, American Institute for Medical and Biological Engineering</i>	2010
<i>Zero Breast Cancer, Community Breast Cancer Research, Honor Thy Healer Award</i>	2010
<i>Fulwyler Award, International Society for Analytical Cytology</i>	2010
<i>Elected Member, Institute of Medicine, National Academy of Sciences</i>	2011
<i>The William L. McGuire Memorial Lecture Award, San Antonio Breast Cancer Symposium</i>	2011
<i>Induction into the Lawrence Livermore National Laboratory Entrepreneur's Hall of Fame (Development of genome analysis technologies)</i>	2012
<i>The Simon M. Shubitz Cancer Prize and Lectureship Award for work in genome science University of Chicago</i>	2012
<i>Honorary Doctorate of Engineering, Colorado School of Mines</i>	2012
<i>Technology Transfer Achievement Award, Technology Transfer and Business Development Oregon Health & Science University</i>	2013
<i>Nieuwland Lecture Series, College of Science, University of Notre Dame</i>	2013
<i>18th Annual Alfred G. Knudson Award Lecture in Cancer Genetics National Cancer Institute, National Institutes of Health</i>	2014
<i>DW and ME King Endowed Lecture Award, Department of Pathology and the Cancer Biology Program, School of Medicine, University of Colorado</i>	2015
<i>Fellow, American Association of Cancer Research Academy Class of 2016</i>	2016
<i>National Cancer Institute Director's Service Award</i>	2016

PROFESSIONAL AFFILIATIONS

American Association for Cancer Research
 American Association for the Advancement of Science
 American Society for Human Genetics
 Human Genome Organization
 International Society for Analytical Cytology
 Radiation Research Society

MAJOR RESEARCH INTERESTS

- Development and application of integrated 'omic and imaging technologies to elucidate mechanisms by which cancers arise, progress and respond to therapy
- Development of strategies for earlier detection of cancers at high risk of progression to metastatic disease
- Development of more durable therapeutic approaches for advanced cancers with emphasis on breast and pancreatic cancer.
- Use measurements of tumor intrinsic (epi) genomic aberrations using massively parallel sequencing and by measurements of functional changes in the architectures of proteins, cells and cellular microenvironments that occur during progression and response to therapy made using multiscale molecular imaging (light and electron microscopy).
- Derive information from analysis of primary tumors and laboratory models thereof using a systems biology approach in these studies employing mathematical models of tumor microenvironment interactions to predict tumor behavior and response to therapy.

SCHOLARSHIP

Area(s) of Research / Scholarly Interest

The Gray Laboratory explores mechanisms by which genomic, transcriptional and proteomic abnormalities occur in selected cancers, elucidates how these abnormalities contribute to cancer pathophysiologies and assesses the ways in which these abnormalities influence responses to gene targeted therapies. Our emphasis is on RTK signaling in breast and pancreatic cancers. Current studies focus on: (a) Understanding how multiple genomic and epigenomic collaborate to influence regulatory networks intrinsic to cancer cells that control aspects of cancer genesis, progression and response to therapy and how signals from the microenvironment alter these regulatory networks. We employ a range of experimental techniques in these studies including massively parallel sequencing, high throughput imaging, and large-scale perturbation analysis. We use machine learning and pathway mapping computational procedures to integrate and interpret the resulting data. (b) Elucidation of the form and function of the multiscale, 3D “engines of life” that, when deregulated by genomic and epigenomic aberrations, influence cancer progression and therapeutic response. This team effort takes advantage of the multiscale imaging, chemistry and computational capabilities in the OHSU Center for Spatial Systems Biomedicine (OCSSB; <http://www.ohsu.edu/ocssb>) that I founded and direct. Imaging technologies in the OCSSB include transmission and scanning electron microscopy, multicolor super resolution fluorescence microscopy, correlative light and electron microscopy, confocal and lightsheet fluorescence microscopy and high content, and high throughput imaging.

Grants and Contracts

Active OHSU

Federal

U54 CA209988 (Gray) NIH/NCI	<i>Measuring, Modeling and Controlling Heterogeneity</i> Cancer Systems Biology Consortium	07/01/17 – 06/30/22	\$1,499,999
NIH U54 HG008100 (Gray) Principal Investigator	<i>Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks</i> Library of Integrated Network-based Cellular Signatures (LINCS)	09/10/14 – 06/30/20 NIH/LINCS	\$1,534,192
U54 HL127624 (Gray) Icahn School of Medicine Mount Sinai/NIH	<i>Data Coordination and Integration Center for LINCS-BD2K</i>	09/15/16 – 04/30/17	\$225,000
P30 CA69533 (Druker) Role: Co-Principal Investigator	<i>Oregon Health & Science University Knight Cancer Institute</i>	07/20/11 – 06/30/17 NIH/NCI	\$689,312

Other

U01 CA164720 (Bild) University of Utah Subaward/NIH Role: Co-Investigator	<i>Integrative Signaling Models to Decipher Complex Cancer Phenotypes</i>	08/08/12 - 06/30/17	\$59,419
U01 CA195469 (Gray) Harvard Subaward/NIH Role: PI	<i>Intratumor Heterogeneity Underlying Treatment Resistance in HER2+ Breast Tumors</i>	06/01/15 – 05/31/20	\$43,262
SRA 15-043 (Gray) Cepheid, Inc.	<i>Validation of Biomarker Signature for Breast Cancer Recurrence</i>	12/01/14 – 05/31/17	\$460,685
Prospect Creek Foundation Principal Investigator (Gray)	<i>Serial Measurement of Molecular and Architectural Responses to Therapy (SMMART)</i> <i>Managing Cancer Heterogeneity to Create more Effective, Durable Therapies for Patients</i>	10/01/15 – 09/30/17	\$4,235,000

SAC110012 (Gray) Susan G. Komen® Foundation	<i>Mechanisms of Resistance to Treatment in Metastatic Breast Cancer</i> 01/24/13 – 01/24/18	\$142,280
<u>Pending OHSU (annual funding)</u>		
R35 CA210074 (Gray) NIH/NCI	<i>Spatial Systems Biology of Cancer</i> 07/01/16 – 06/30/23	\$600,000
P30 CA69533 (Druker) NIH/NCI (renewal) Role: Co-Principal Investigator	Oregon Health & Science University Knight Cancer Institute 07/01/17 – 06/30/22	\$100,000
SBIR PA-16-302 (R44) PDX Pharmaceuticals NIH SBIR Role: Sub-Principal Investigator	<i>A Targeted Nanotherapeutic for the Treatment of Metastatic EGFR+ Breast, Lung, and Colorectal Cancers</i> 09/01/17 – 08/31/18	\$44,020
SBIR FastTrack PA-17-147 Quantitative Imaging LLC NIH SBIR Role: Sub-PI	<i>Ultra-high Content Analysis (UHCA) of Single Cells in Tissue: 60+ Channel Immunofluorescence Labeling Kits and Companion Imaging Software for Everyone</i> 09/01/17 – 02/29/20	\$109,126 (average)
R33 (Chang) NCI/NIH Role: Sub-PI	<i>Area A: Computational Approaches towards Discovery and Integrative Analyses of Tumor Immune Microenvironments Using Multi-plex immunohisto-chemistry platforms</i> 09/01/17 – 08/31/20	\$2,233
<u>No OVERLAP</u>		

TEACHING RESPONSIBILITIES – Past & Present

RESIDENTS (3 month rotation)

Daniel Sudilovsky	(October – December 1994)	
Samuel Smoot	(January-March 1995)	
Mike Teitell	(July-September 1995)	
Doug Ross	(January-March 1996)	
Jonathan Pollack	(March-June 1997)	
<i>Discussion Leader, Pediatrics 100: Medical Genetics</i>		1994-1995
<i>Discussion Leader, Pediatrics 100: Medical Genetics</i>		1953-1996
<i>Co-organizer, Biophysics 309: Cancer Genetics</i>		1953-1996
<i>Co-organizer, Spring Biomedical Sciences Graduate Program Symposium: Genomics Technology</i>		1995-1996
<i>Co-organizer, BMS 255: Genetics Faculty, 7th European Course in Genetics, Bertinoro, Italy</i>		2001-2002
<i>Co-organizer, Lab Med: 180.03: Biology of Breast Cancer</i>		2002-2004
<i>Faculty, Biochem 297, Molecular Pathology and Biology of Neoplasia</i>		2006-2007
<i>Co-organizer & Faculty Lecturer, Lab Med 180.03 Fall, Biology of Breast Cancer Focus on Translation</i>		2010
<i>Faculty, OHSU Department of Public Health and Preventive Medicine, Genomics and Public Health Policy “Genome (whole and deep exome) sequencing with a focus on personalized medicine”</i>		2011
<i>Instructor, 1097 CANB 601 02 Research, Basic Science Division, Cancer Biology Department School of Medicine, Oregon Health & Science University</i>		2013
<i>Instructor, BME601-JG Prequalifying PhD research, Biomedical Engineering Department School of Medicine, Oregon Health & Science University</i>		2014
<i>Instructor, Winter CRN: 21845 Course: BME601-JG Prequalifying Phd Research & Summer CRN: 1780 Course: BME603-JG PhD Dissertation Research, Biomedical Engineering Department School of Medicine, Oregon Health & Science University</i>		2015

Instructor, CONJ 670 Measurement Science Course Lecture, “Parallel Sequencing: Personal experiences with technology development” Biomedical Engineering Department School of Medicine, Oregon Health & Science University 2015

Guest instructor, Cancer Intersession: Medicine of tomorrow, “Understanding and managing cancer as a heterogeneous, adaptive disease” School of Medicine, Oregon Health & Science University (February, July, November, March) 2016-2017

Instructor, CONJ 670 Foundations of Measurement Science Lecture, “Parallel Sequencing: Personal experiences with technology development” Biomedical Engineering Department School of Medicine, Oregon Health & Science University 2016

GRANT REVIEW

Chair, Congressionally Directed Medical Research Programs (CDMRP) Breast Cancer/Ovarian Cancer Research Programs (BC/OCRP) proposals peer review 2012

Review Committee, Susan G. Komen® for the Cure, Investigator-Initiated Research Grants (IIR) Review, Novel Therapeutics and /or Resistance (NTR) Targeted therapies for triple negative breast cancer proposals peer review 2012 – 2013 Full Application Review Committee Therapeutic implications of tumor genomics 2012

Collaborative Project Review, University College Dublin, National University of Ireland, Dublin Rational Therapy for Breast Cancer (RATHER) Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes 2012

Selection Committee, American Association for Cancer Research, Team Science Award 2013

Review Committee, Columbia University Medical Center Multiscale Analysis of Genomic and Cellular Networks (MAGNet) Driving Biological Projects (DBPs) grant applications 2013

Selection Committee, American Association for Cancer Research -Women in Cancer Research Charlotte Friend Memorial Lectureship Award Committee 2013

Branch Review Committee, University of San Diego, Collaborative Sciences, Ludwig Institute for Cancer Research 2013

Chair, Review Panel, DOD Innovator Award, Breast Cancer Research Program (BCRP) Department of Defense Congressionally Directed Medical Research Programs (CDMRP) 2013

Executive Advisory Board review, proposed projects in Pancreatic Neuroendocrine Tumor (PNET) and Pancreatic ductal adenocarcinoma (PDAC), Pancreatic Specialized Program of Research Excellence (SPORE) Pancreas Cancer Program, Division of Hematology/Oncology, Department of Medicine University of California, San Francisco 2013-2014

Internal Advisory Committee, candidate review for award in career development and women’s health impact Building Interdisciplinary Research Careers in Women's Health (BIRCWH) 2013

Full Application Review Committee, Postdoctoral Fellowship Basic and Translational Grant Susan G. Komen® for the Cure 2013-2014

Reviewer, Cell and Molecular Fluorescence Imaging Facility Phase IV: Equipment for Advanced Immunological Analysis (proposal by Montana State University, MSU) M.J. Murdock Charitable Trust 2013

Screening Committee for the election of new member to the National Academy of Sciences Institute of Medicine (IOM) 2014

Peer reviewer, Society for Biomolecular Sciences Award, Medical Research Council, United Kingdom 2014

Chair, Terry Fox Research Institute (TFRI), Peer review committee (PRC) program project grant (PPG) competition 2014

Reviewer, The National Academies, Board on Life Sciences report on convergence (approaches to biomedical research and beyond), “Convergence: Nurturing Transdisciplinary Efforts in the Life Sciences, Physical Sciences, Engineering, and Beyond” consensus report 2014

External Scientific Advisory Committee, Research program: cancer genetics, epigenetics, & genomics, Shared resources: Genomics and flow cytometry & high throughput screening, University of New Mexico Cancer Center 2014

External Advisory Board member, Masonic Cancer Center, University of Minnesota 2014

Reviewer, Outstanding Investigator Award (OIA) Initiative, National Cancer Institute (NCI), National Institutes of Health 2014

External Reviewer, Collaborative Research Fund, University Grants Committee, Hong Kong Special Administrative Region 2014

Reviewer, Cancer, Ageing and Somatic Mutation Programme, Genetics & Molecular Sciences The Wellcome Trust Sanger Institute 2015

Scientific Reviewer, Patient-Centered Outcomes Research Institute (PCORI), Research Integration and Evaluation, Science, “The National Patient-Centered Clinical Research Network: Clinical Data Research Networks (CDRN)—Phase II” applications 2015

External Advisory Board, University of Pittsburgh Drug Discovery Institute (UPDDI) 2015-2016

External Advisory Board, National Cancer Institute, University of California, San Francisco Antibody Technology Research Center 2015

Chair, US Department of Defense, Congressionally Directed Medical Research Programs, Clinical and Experimental Therapeutics 2015

Reviewer, Susan G. Komen® for the Cure 2015-2016 Postdoctoral Fellowship – Basic/Translational and Clinical grant applications 2015

Reviewer, Program Project (P01), Special Review Group, Research Programs Review Branch National Cancer Institute 2015

Team Science Award Selection Committee, American Association for Cancer Research 2015

Reviewer, MJ Murdock Charitable Trust, University of Montana, BioSpectroscopy Core Research Laboratory proposal, “Acquisition of a time-resolved confocal microscope for education” 2015

Reviewer, Susan G. Komen® Tissue Bank application, “Lipid Metabolism (LiMe) gene expression in healthy women and the association with breast cancer risk” 2015

Reviewer, Institute of Medicine, Draft report on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies 2015

Reviewer, Swiss National Science Foundation, Division Biology and Medicine application, “Identification of intervention points for combined targeted therapies in breast cancer using a combination of iterative survival analysis and synthetic dosage lethality based prioritization” submitted by Ioannis Xenarios of Lausanne 2015

Reviewer, National Academies of Sciences, Engineering, and Medicine, “Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century: Part 2” 2016

Reviewer, “Habilitation” Boehringer Ingelheim Foundation, Institute for Molecular Biology Mainz, Germany 2016

Reviewer, National Institutes of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD), Cancer Diagnosis Program, “Cancer Immune Monitoring and Analysis Centers (CIMACs) Network” (Cooperative Agreement) 2016

Chair, Review Committee, Knight Cancer Institute Pilot Project Proposals, Oregon Health & Science University 2016

Reviewer, San Antonio Breast Cancer Symposium 2017 McGuire Award Selection Committee 2016

Reviewer, Susan G. Komen® 2016-2017 Career Catalyst Research (CCR) and Postdoctoral Fellowship Clinical Applications and Inflammatory Breast Cancer (IBC) Innovator Applications 2016-2017

Reviewer, M.J. Murdock Charitable Trust, College Research Program for Natural Science (Life Science) Proposals 2017

Reviewer, NIH-Industry Program, National Center for Advancing Translational Sciences (NCATS) Discovering New Therapeutic Uses for Existing Molecules 2017

Reviewer, San Antonio Breast Cancer Symposium, William L. McGuire Memorial Award and Lectureship 2017

Reviewer, Cancer Genetics Program, UCSF Helen Diller Family Comprehensive Cancer Center 2017
 Reviewer, M. J. Murdock Charitable Trust Proposal by Montana State University titled, “A Multi-User Cryo-
 Electron Microscope for the Cellular and Molecular Life Sciences Community in the Northern Rocky
 Mountain Region” 2017

MANUSCRIPT REVIEW & EDITORIAL RESPONSIBILITIES

<i>Editorial Board</i> , Cell and Tissue Kinetics	1980-1990
<i>Editorial Board</i> , Cell Biophysics	1981-1983
<i>Editorial Board</i> , Journal of Histochemistry and Cytochemistry	1979-1984
<i>Editorial Board</i> , Cytometry	1984-1993
<i>Editorial Board</i> , Analytical Cellular Pathology	1988-2014
<i>Editorial Board</i> , Cytometry Research	1990-2000
<i>Editorial Board</i> , Bioimaging	1992-1999
<i>Editorial Board</i> , Cancer Research	1995-2004
<i>Editorial Board</i> , Chromosome Research	1995-1998
<i>Editorial Board</i> , Cancer Research	1995-2004
<i>Advisory Board Member</i> , Cytometric Cellular Analysis Series	1995-2000
<i>Editorial Board</i> , Genes, Chromosomes & Cancer	1998-Present
<i>Editorial Board</i> , Cancer Letters	1999-Present
<i>Editorial Board</i> , Cancer Biology and Therapy	2001-Present
<i>Editorial Board</i> , Laboratory Investigation	2001-2004
<i>Editorial Board</i> , Molecular Cancer Therapeutics	2001-Present
<i>Editorial Board</i> , International Journal of Oncology	2001-Present
<i>Editorial Board</i> , Breast Cancer Research	2002-Present
<i>Editorial Board</i> , Cancer Genomics and Proteomics	2003-2009
<i>Senior Editor</i> , Cancer Research: Systems Biology	2007-2009
<i>Editorial Board</i> , Molecular Cancer	2010-Present
<i>Editorial Board</i> , Cancer Cell	2012-Present
<i>Editorial Board</i> , PLOS Currents: Precision Oncology	2013-Present
<i>Editorial Board</i> , Convergent Science Physical Oncology	2015-Present

COMMITTEE & BOARD MEMBERSHIP

International / National

Cell Kinetics Society	Councilor, 1982 Vice President, 1983 President	1981
American Cancer Society	Advisory Committee on Cell & Developmental Biology	1982-1986
International Society for Analytical Cytology	Councilor, 1994-1996 President elect 1996-1998 President, 1998-2000 Past President	1990-2000
Los Alamos National Laboratory	National Flow Cytometry Resource Chair; Advisory Committee	1992-1999
National Institutes of Health (NIH)	Advisory Council for National Institute for Human Genome Research	1990-1995
Radiation Effects Research Foundation	Scientific Consultant, Department of Genetics Advisory Council, Hiroshima, Japan	1992-2002
American Association of Cancer Research (AACR)	California State Legislative Committee (Northern Region)	1998-2000

National Science Foundation	Advanced Technological Program City College of San Francisco National Visiting Committee, Biolinks	1998-2000
National Institutes of Health	Genome Study Section, 2002-2004 Chair	1998-2000
National Institutes of Health	Program for Assessment of Clinical Cancer Tests	2000-2004
American Association of Cancer Research	National meeting, local organizing committee	2001-2002
National Institutes of Health	National Cancer Institute, Board of Scientific Advisors	2004-2016
National Institutes of Health	National Cancer Institute Translational Research Working Group	2005-2007
The National Academies of Science	National Research Council Committee on the State of the Science of Nuclear Medicine	2006-Present
Radiation Effects Research Foundation (RERF)	Senior Review Panel on Future Planning Hiroshima, Japan	2006-2010
Foundation for the NIH	Biomarkers Consortium Steering Committee	2007-Present
American Association of Cancer Research		2007-Present
	National Organizing and Team Science Award Selection Committee	2008
	Chair, Pezcoller Foundation - AACR International Award for Cancer Research	2008-2009
	Board of Directors	2009
	Selection Committee, next Editor-in-Chief of Cancer Research	2009
	Scientific Program Committee	2011
	Nominating Committee	2013-2016
	Nominating Committee, President-Elect (2016-2017)	2015
	Special Conferences Committee	2016-2017
	Women in Cancer Research Charlotte Friend Memorial Lectureship Award Committee	2016
	Annual Meeting Program Planning Committee	2018
Susan G. Komen® for the Cure		2007-Present
	Grants Review Committee	2007
	Chairperson, Molecular & Cellular Biology & Genetics	2008
	Promise Grants Review Committee	2009
	Komen Scholar	2012-present
NIH, National Cancer Institute	Process to Accelerate Translational Science (PATS)	2008-Present
Department of Defense	Congressionally Directed Medical Research Programs Chairperson, Breast Cancer Research Program, Era of Hope Scholar-Innovator Grants Review	2009
The National Academies of Science National Research Council	National Research Council Member, Nuclear Radiation Studies Board	2009-2011
Institute of Medicine (IOM)		
	Board on Health Care Services and National Cancer Policy Forum Committee on Review of Omics-Based Tests for Predicting Patient Outcomes in Clinic Trials	2011-2012
	Committee on the State of the Science in Ovarian Cancer Research	2014-Present
NIH, National Cancer Institute National Cancer Advisory Board	caBIG® Ad Hoc Information Technology Working Group	2011-2013
Radiation Effects Research Foundation (RERF), Hiroshima, Japan	United States Councilor	2016-Present

Institutional

Advisory Committee, University of California Program for Analytical Cytology	1983-1992
Biophysics Program Executive Committee	1991-1998
Bioscience Advisory Committee, Lawrence Berkeley National Laboratory	1992-1994
Chairman's Advisory Committee, UCSF Department of Laboratory Medicine	1992-Present
Basic Science Advisory Committee, UCSF Cancer Center	1992-1995
Advisory Committee, University of California Center for Molecular Cytometry	1992-1996
Human Genome Center Advisory Committee, Lawrence Berkeley National Laboratory	1993-1995
Promotion Committee, UCSF, Department of Laboratory Medicine	1993-1995
Compensation Committee, UCSF, Department of Laboratory Medicine	1993-1995
Task Force with Pathology, UCSF, Department of Laboratory Medicine	1993-1996
Joint UCB-LBNL Committee on Structural Biology	
University of California, Berkeley /Lawrence Berkeley National Laboratory	1994-1995
Committee on Research, University of California Academic Senate, San Francisco Division	1994-1995
Life Sciences Division Advisory Committee, Lawrence Berkeley National Laboratory	1994-1995
Cancer Genetics Program Leader, UCSF, Cancer Center	1995-2007
Breast Oncology Program Leader, UCSF, Cancer Center	1997-2010
Brain Tumor SPORE Advisory Committee, UCSF	2000-2008
Prostate Cancer SPORE Advisory Committee, UCSF	2008-2010
Tissue Core Oversight Committee, UCSF Helen Diller Family Comprehensive Cancer Center	2001-2010
American Institute for Medical and Biological Engineering (AIMBE) Advocacy Committee	2011-Present
Bioimaging Advisory Committee, Oregon Health & Science University (OHSU)	2011-Present
Computational Biology Group, OHSU	2011-Present
Scientific Advisory Board, OHSU Portland Shriners Research Center	2012-Present
Council for Research Opportunities and Strategies (CROS), OHSU	2012-Present
Search Committee for the Vice President and Director of Technology Transfer and Business Development (TTBD), OHSU	2014-2016
Internal Review, OHSU Department of Physiology & Pharmacology	2014
Women's Health Research & Policy (WRHP)	
Mentor, Proposed Future Women's Reproductive Health Research Scholar	2014
Search Committee, Chair, Physiology and Pharmacology, OHSU	2015-2016

ADVISORY BOARDS

Consultation

New Leaf Ventures, Susan G. Komen[®] for the Cure, KromaTiD, Abbott, Cepheid, Intel, Thermo Fisher Scientific (formerly FEI), Prospect Creek Foundation, Nanotech Biomachines, MJ Murdock Charitable Trust, PDX Pharmaceuticals, Organovo, Merrimack Pharmaceuticals, Urology Diagnostics and Ventana Medical Systems

Academic

National Cancer Institute, Frederick National Laboratory for Cancer Research; OHSU & Intel QBR Advisory Committee, Portland, OR; Stand Up to Cancer (SU2C), Washington, DC; Rational Therapy for Breast Cancer (RATHER); University of Chicago Specialized Program in Research Excellence (SPORE) in Breast Cancer,

Chicago, IL; OHSU Clinical and Translational Research Internal, Portland, OR; OHSU Dermatology Research Division, Training Program in the Molecular Basis of Skin / Mucosa Pathobiology (NIH / NCI Training Program) and Skin Diseases Research Cores Center, Portland, OR; External Advisory Board to oversee progress towards a competitive P30 CCSG, Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK; Big Data to Knowledge Center for Causal Discovery (BD2K CCD), University of Pittsburgh Cancer Institute & Carnegie Mellon University (Joint), Pittsburgh, PA; UCSF Antibody Technology Research Center on (ATRC), UCSF, San Francisco, CA; University of New Mexico (UNM) Comprehensive Cancer Center, Albuquerque, NM; APOBEC Cancer Program, University of Minnesota, MN; The College of Applied Science and Engineering (CASE) Advisory Board, Colorado School of Mines, Golden, CO; External Advisory Board Member, Office of Cancer Research, Stephenson Cancer Center, University of Oklahoma Health Sciences Center

ORIGINAL PUBLICATIONS

BIBLIOGRAPHY

1. Gray, J.W., Hartnell, G.W., Legg, J.C. (1971) A Bremsstrahlung method for locating electrical breakdown in a Van de Graaf accelerator tube. *Nucl. Instrum. Methods*, 96:217-8.
2. Gray, J.W. Legg, J.C. (1974) Analog resonances and possible T mixing in ⁷⁶Se. *Phys. Rev. C.*, 10(6):2577-83.
3. Van Dilla, M.A., Steinmetz, L.L., Davis, D.T., Calvert, R.N., Gray, J.W. (1974) High speed cell analysis and sorting with flow systems: Biological applications and new approaches. *IEEE Trans. Nucl. Sci.*, 21(1):714-21.
4. Gray, J.W. (1974) Cell cycle analysis from computer synthesis of deoxyribonucleic acid histograms. *J. Histochem. Cytochem.*, 22(7):642-50.
5. Coffino, P., Gray, J.W., Tomkins, G.M. (1975) Cyclic AMP, a nonessential regulator of the cell cycle. *Proc. Natl. Acad. Sci. USA*, 72(3):878-82.
6. Gray, J.W., Carrano, A.V., Moore, D.H. II, Steinmetz, L.L., Minkler, J., Mayall, B.H., Mendelsohn, M.L., Van Dilla, M.A. (1975) High-speed quantitative karyotyping by flow microfluorometry. *Clin. Chem.*, 21(9):1258-62.
7. Gray, J.W., Carrano, A.V., Steinmetz, L.L., Van Dilla, M.A., Moore, D.H. II, Mayall, B.H., Mendelsohn, M.L. (1975) Chromosome measurement and sorting by flow systems. *Proc. Natl. Acad. Sci. USA*, 72(4):231-4.
8. Gledhill, B.L., Lake, S., Steinmetz, L.L., Gray, J.W., Crawford, J.R., Dean, P.N., Van Dilla, M.A. (1976) Flow microfluorometric analysis of sperm DNA content: effect of cell shape on the fluorescence distribution. *J. Cell. Physiol.*, 87(3):367-76.
9. Carrano, A.V., Gray, J.W., Moore, D.H. II, Minkler, J.L., Mayall, B.H., Van Dilla, M.A., Mendelsohn, M.L. (1976) Purification of the chromosomes of the Indian muntjac by flow sorting. *J. Histochem. Cytochem.*, 24(1):348-54.
10. Heby, O., Gray, J.W., Lindl, P.A., Marton, L.J., Wilson, C.B. (1976) Changes in L-ornithine decarboxylase activity during the cell cycle. *Biochem. Biophys. Res. Comm.*, 71(1):99-105.
11. Dethlefsen, L.A., Gray, J.W., George, Y.S., Johnson, S. (1976) Flow cytometric analysis of the perturbed cellular kinetics of solid tumors: Problems and promises. *Pulse Cytophotometry*. European Press, Ghent, Belgium, pp. 188-200.
12. Gray, J.W. (1976) Cell-cycle analysis of perturbed cell populations: Computer simulation of sequential DNA distributions. *Cell Tissue Kinet.*, 9(6):499-516.

13. Gray, J.W., Carver, J.H., George, Y.S., Mendelsohn, M.L. (1977) Rapid cell cycle analysis by measurement of the radioactivity per cell in a narrow window in S-phase (RCSI). *Cell Tissue Kinet.*, 10(2):97-109.
14. Heby, O., Marton, L.J., Wilson, C.B., Gray, J.W. (1977) Effect of methylglyoxal-bis (guanylhydrazine), an inhibitor of spermidine and spermine synthesis, on cell cycle traverse. *Eur. J. Cancer*, 13(9):1009-17.
15. Latt, S.A., George, Y.S., Gray, J.W. (1977) Flow cytometric analysis of bromodeoxyuridine-substituted cells stained with 33258 Hoechst. *J. Histochem. Cytochem.*, 25(7):927-34.
16. Van Dilla, M.A., Gledhill, B.L., Lake, S., Dean, P.N., Gray, J.W., Kachel, V., Barlogie, B., Göhde, W. (1977) Measurement of mammalian sperm deoxyribonucleic acid by flow cytometry. Problems and approaches. *J. Histochem. Cytochem.*, 25(7):763-73.
17. Hoshino, T., Nomura, K., Wilson, C.B., Knebel, K.D., Gray, J.W. (1978) The distribution of nuclear DNA from human brain-tumor cells. *J. Neurosurg.*, 49(1):13-21.
18. Sapareto, S.A., Hopwood, L.E., Dewey, W.C., Raju, M.R., Gray, J.W. (1978) Effects of hyperthermia on survival and progression of Chinese hamster ovary cells. *Cancer Res.*, 38(2):393-400.
19. Heby, O., Andersson, G., Gray, J.W. (1978) Interference with S and G2 phase progression by polyamine synthesis inhibitors. *Exp. Cell Res.*, 111(2):1-464.
20. Coffino, P., Gray, J.W. (1978) Regulation of S49 lymphoma cell growth by cyclic adenosine 3':5'-monophosphate. *Cancer Res.*, 38(11 Part 2):4285-8.
21. Gray, J.W., Peters, D., Merrill, J.T., Martin, R., Van Dilla, M.A. (1979) Slit-scan flow cytometry of mammalian chromosomes. *J. Histochem. Cytochem.*, 27(1):441-4.
22. Merrill, J.T., Dean, P.N., Gray, J.W. (1979) Investigations in high-precision sorting. *J. Histochem. Cytochem.*, 27(1):280-283.
23. Pinkel, D., Dean, P., Lake, S., Peters, D., Mendelsohn, M., Gray, J., Van Dilla, M., Gledhill, B. (1979) Flow cytometry of mammalian sperm: Progress in DNA and morphology measurement. *J. Histochem. Cytochem.*, 27(1):353-8.
24. Pallavicini, M.G., Cohen, A.M., Dethlefsen, L.A., Gray, J.W. (1979) In vivo effects of 5-fluorouracil and ftorafur[1-(tetrahydrofuran-2-yl)-5-fluorouracil] on murine mammary tumors and small intestine. *Cell Tissue Kinet.*, 12(2):177-89.
25. Carrano, A.V., Gray, J.W., Langlois, R.G., Burkhart-Schultz, K.J., Van Dilla, M.A. (1979) Measurement and purification of human chromosomes by flow cytometry and sorting. *Proc. Nat. Acad. Sci. USA*, 76(3):1382-4.
26. Gray, J.W., Langlois, R.G., Carrano, A.V., Van Dilla, M.A. (1979) High resolution chromosome analysis: One and two parameter flow cytometry. *Chromosoma*, 73(1):9-27.
27. Nakeff, A., Valeriote, F., Gray, J.W., Grabske, R.J. (1979) Application of flow cytometry and cell sorting to megakaryocytopoiesis. *Blood*, 53(4):732-45.
28. Langlois, R.G., Carrano, A.V., Gray, J.W., Van Dilla, M.A. (1980) Cytochemical studies of metaphase chromosomes by flow cytometry. *Chromosoma*, 77(3):229-51.
29. Twentyman, P.R., Brown, J.M., Gray, J.W., Franko, A.J., Scoles, M.A., Kallman, R.F. (1980) A new tumor model system (RIF-1) for comparison of end-point studies. *J. Nat. Cancer Inst.*, 64(3):595-604.
30. Macevicz, S., Dean, P., Peters, D., Pinkel, D., Gray, J.W. (1981) A flow system for partial automation of plating efficiency tests. *Cytometry*, 1(5):346-50.
31. Gray, J.W., Pallavicini, M.G., George, Y.S., Groppi, V., Look, M., Dean, P.N. (1981) Rates of incorporation of radioactive molecules during the cell cycle. *J. Cell. Physiol.*, 108(2):135-44.
32. Yu, L.-C., Aten, J., Gray, J.W., Carrano, A.V. (1981) Human chromosome isolation from short-term lymphocyte culture for flow cytometry. *Nature*, 293(5828):154-5.

33. Seidenfeld, J., Gray, J.W., Marton, L.J. (1981) Depletion of 9L rat brain tumor cell polyamine content by treatment with D,L- α -difluoromethylornithine inhibits proliferation and the G1 to S transition. *Exp. Cell Res.*, 131(1):209-16.
34. Cremer, C., Cremer, T., Gray, J.W. (1981) Induction of chromosome damage by ultraviolet light and caffeine: Correlation of cytogenetic evaluation and flow karyotype. *Cytometry*, 2(5):287-90.
35. Norgren, R.M., Gray, J.W., Young, I.T. (1982) Restoration of profiles from slit-scan flow cytometry. *IEEE Trans. Biomed. Eng.*, 29(2):101-6.
36. Cremer, C., Gray, J.W. (1982) Application of the BrdU/thymidine method to flow cytogenetics: Differential quenching/enhancement of the Hoechst 33258 fluorescence of late-replicating chromosomes. *Somat. Cell Genet.*, 8(3):319-27.
37. Benaron, D.A., Gray, J.W., Gledhill, B.L., Lake, S., Wyrobek, A.J., Young, I.T. (1982) Quantification of mammalian sperm morphology by slit-scan flow cytometry. *Cytometry*, 2(5):344-9.
38. Hafeman, D.G., McConnell, H.M., Gray, J.W., Dean, P.N. (1982) Neutrophil activation monitored by flow cytometry: Stimulation by phorbol diester is an all or none event. *Science*, 215(4533):673-5.
39. Pallavicini, M.G., Gray, J.W., Folstad, L.J. (1982) Quantitative analysis of the cytokinetic response of KHT tumors in vivo to 1- β -D-arabinofuranosylcytosine. *Cancer Res.*, 42(8):3125-31.
40. Cremer, C., Gray, J.W., Ropers, H.H. (1982) Flow cytometric characterization of a Chinese hamster X man hybrid cell line retaining the human Y chromosome. *Hum. Genet.*, 60(3):262-6.
41. Cremer, C., Gray, J.W. (1982) DNA content of cells with generalized chromosome shattering induced by ultraviolet light plus caffeine. *Mutat. Res.*, 94(1):133-42.
42. Baisch, H., Beck, H.-P., Christensen, I.J., Hartmann, N.R., Fried, J., Dean, P.N., Gray, J.W., Jett, J.H., Johnston, D.A., White, R.A., Nicolini, C., Zeitz, S., Watson, J.V. (1982) A comparison of mathematical methods for the analysis of DNA histograms obtained by flow cytometry. *Cell Tissue Kinet.*, 15(3):235-49.
43. Langlois, R.G., Yu, L.-C., Gray, J.W., Carrano, A.V. (1982) Quantitative karyotyping of human chromosomes by dual beam flow cytometry. *Proc. Natl. Acad. Sci. USA*, 79(24):7876-80.
44. Kerker, M., Van Dilla, M.A., Brunsting, A., Kratochvil, J.P., Hsu, P., Wang, D.-S., Gray, J.W., Langlois, R.G. (1982) Is the central dogma of flow cytometry true: that fluorescence intensity is proportional to cellular dye content? *Cytometry*, 3(2):71-8.
45. Dean, P.N., Gray, J.W., Dolbeare, F.A. (1982) The analysis and interpretation of DNA distributions measured by flow cytometry. *Cytometry*, 3(3):188-95.
46. Cremer, C., Gray, J.W. (1983) Replication kinetics of Chinese hamster chromosomes as revealed by bivariate flow karyotyping. *Cytometry*, 3(4):282-6.
47. Gray, J.W., Bogart, E., Gavel, D.T., George, Y.S., Moore, D.H. II. (1983) Rapid cell cycle analysis. II. Phase durations and dispersions from computer analysis of RC curves. *Cell Tissue Kinet.*, 16(5):457-71.
48. Dolbeare, F., Gratzner, H., Pallavicini, M.G., Gray, J.W. (1983) Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. *Proc. Natl. Acad. Sci. USA*, 80(18):5573-7.
49. Oredsson, S.M., Gray, J.W., Deen, D.F., Marton, L.J. (1983) Decreased cytotoxicity of 1- β -D-arabinofuranosylcytosine in 9L rat brain tumor cells pretreated with α -difluoromethylornithine in vitro. *Cancer Res.*, 43(6):2541-4.
50. Lucas, J.N., Gray, J.W., Peters, D.C., Van Dilla, M.A. (1983) Centromeric index measurement by slit-scan flow cytometry. *Cytometry*, 4(2):109-16.
51. Collard, J.G., Philippus, E., Tulp, A., Lebo, R.V., Gray, J.W. (1983) Separation and analysis of human chromosomes by combined velocity sedimentation and flow sorting applying single- and dual-laser cytometry. *Cytometry*, 5(1):9-19.

52. Müller, C.R., Davies, K.E., Cremer, C., Rappold, G., Gray, J.W., Ropers, H.H. (1983) Cloning of genomic sequences from the human Y chromosome after purification by dual beam flow sorting. *Hum. Genet.*, 64(2):110-5.
53. Dean, P.N., Dolbeare, F., Gratzner, H., Rice, G.C., Gray, J.W. (1983) Cell cycle analysis using a monoclonal antibody to BrdUrd. *Cell Tissue Kinet.*, 17(4):427-36.
54. Pallavicini, M.G., Ng, C.R., Gray, J.W. (1984) Bivariate flow cytometric analysis of murine intestinal epithelial cells for cytokinetic studies. *Cytometry*, 5(1):55-62.
55. Rice, G.C., Dean, P.N., Gray, J.W., Dewey, W.C. (1984) An ultra-pure in vitro synchrony method employing centrifugal elutriation and viable flow cytometric cell sorting. *Cytometry*, 5(3):289-98.
56. Rice, G.C., Gray, J.W., Dean, P.N., Dewey, W.C. (1984) Fluorescence-activated cell sorting analysis of the induction and expression of acute thermal tolerance within the cell cycle. *Cancer Res.*, 44(6):2368-76.
57. Rice, G.C., Gray, J.W., Dewey, W.C. (1984) Cycle progression and division of viable and nonviable Chinese hamster ovary cells following acute hyperthermia and their relationship to thermal tolerance decay. *Cancer Res.*, 44(5):1802-8.
58. Halamka, J., Gray, J.W., Gledhill, B.L., Lake, S., Wyrobek, A.J. (1984) Estimation of the frequency of malformed sperm by slit scan flow cytometry. *Cytometry*, 5(4):333-8.
59. Oredsson, S.M., Gray, J.W., Marton, L.J. (1984) Progressive increase in polyamine levels in 9L cells in vitro during the cell cycle: Comparison between cells isolated by centrifugal elutriation and cells grown in synchrony. *Cell Tissue Kinet.* 17(5):437-44.
60. Pallavicini, M.G., Ng, C.R., Gray, J.W. (1984) Relationship between surviving clonogenic crypt fraction and animal lethality after cytosine arabinoside (Ara-C) exposure. *Virchows Arch. B Cell Pathol. Incl. Mol. Pathol.*, 46(1-2):33-42.
61. Rice, G.C., Gray, J.W., Dewey, W.C. (1984) FACS analysis of a hyperthermia-induced alteration in Hoechst 33342 permeability and direct measurement of its relationship to cell survival. *J. Cell. Physiol.*, 122(3):387-96.
62. Cremer, C., Rappold, G., Gray, J.W., Müller, C.R., Ropers, H.H. (1984) Preparative dual-beam sorting of the human Y chromosome and in situ hybridization of cloned DNA probes. *Cytometry*, 5(6):572-9.
63. Trask, B., van den Engh, G., Gray, J.W., Vanderlaan, M., Turner, B. (1985) Immunofluorescent detection of histone 2b on metaphase chromosomes using flow cytometry. *Chromosoma*, 90(4):290-302.
64. van den Engh, G.J., Trask, B.J., Gray, J.W., Langlois, R.G., Yu, L.-C. (1985) Preparation and bivariate analysis of suspensions of human chromosomes. *Cytometry*, 6(2):92-100.
65. Peters, D., Branscomb, E., Dean, P., Merrill, T., Pinkel, D., Van Dilla, M., Gray, J.W. (1985) The LLNL high-speed sorter: Design features, operational characteristics, and biological utility. *Cytometry*, 6(4):290-301.
66. Yanagisawa, M., Dolbeare, F., Todoroki, T., Gray, J.W. (1985) Cell cycle analysis using numerical simulation of bivariate DNA/bromodeoxyuridine distributions. *Cytometry*, 6(6):550-62.
67. Dolbeare, F., Beisker, W., Pallavicini, M.G., Gray, J.W. (1985) Cytochemistry for bromodeoxyuridine/DNA analysis: Stoichiometry and sensitivity. *Cytometry*, 6(6):521-30.
68. Pinkel, D., Thompson, L.H., Gray, J.W., Vanderlaan, M. (1985) Measurement of sister chromatid exchanges at very low bromodeoxyuridine substitution levels using a monoclonal antibody in Chinese hamster ovary cells. *Cancer Res.*, 45(11 Part 2):5795-8.
69. Pallavicini, M.G., Summers, L.J., Giroud, F.J., Dean, P.N., Gray, J.W. (1985) Multivariate analysis and list mode processing of murine hematopoietic subpopulations for cytokinetic studies. *Cytometry*, 6(6):539-49.

70. Pallavicini, M.G., Summers, L.J., Dolbeare, F.D., Gray, J.W. (1985) Cytokinetic properties of asynchronous and cytosine arabinoside perturbed murine tumors measured by simultaneous bromodeoxyuridine/DNA analyses. *Cytometry*, 6(6):602-10.
71. Waldman, F.M., Dolbeare, F., Gray, J.W. (1985) Detection of cytosine arabinoside resistant cells at low frequency using the bromodeoxyuridine/DNA assay. *Cytometry*, 6(6):657-62.
72. Pallavicini, M.G., Summers, L.J., Dean, P.N., Gray, J.W. (1985) Enrichment of murine hemopoietic clonogenic cells by multivariate analyses and sorting. *Exp. Hematol.*, 13(11):1173-81.
73. Shao-Bai, X., Pailavicini, M.G., Gray, J.W. (1985) Double label radioactivity per cell (RC) analysis in vivo: Rapid cytokinetic analysis of the KHT sarcoma. *Acta Biologica Experimentalis Sinica*, 18(2):215-24.
74. Gray, J.W., Dolbeare, F., Pallavicini, M.G., Beisker, W., Waldman, F. (1986) Cell cycle analysis using flow cytometry. *Int. J. Radiat. Biol.*, 49(2):237-55.
75. Linfoot, P.A., Gray, J.W., Dean, P.N., Marton, L.J., Deen, D.F. (1986) Effect of cell cycle position on the survival of 9L cells treated with nitrosoureas that alkylate, cross-link, and carbamoylate. *Cancer Res.*, 46(5):2402-6.
76. Pinkel, D., Straume, T., Gray, J.W. (1986) Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. *Proc. Natl. Acad. Sci. USA*, 83(9):2934-8.
77. Rice, G., Laszlo, A., Li, G., Gray, J.W., Dewey, W. (1986) Heat shock proteins within the mammalian cell cycle: Relationship to thermal sensitivity, thermal tolerance, and cell cycle progression. *J. Cell. Physiol.*, 126(2):291-7.
78. van den Engh, G.J., Trask, B.J., Gray, J.W. (1986) The binding kinetics and interaction of DNA fluorochromes used in the analysis of nuclei and chromosomes by flow cytometry. *Histochemistry*, 84(4-6):501-8.
79. Van Dilla, M.A., Deaven, L.L., Albright, K.L., Allen, N.A., Aubuchon, M.R., Bartholdi, M.F., Browne, N.C., Campbell, E.W., Carrano, A.V., Clark, L.M., Cram, L.S., Fuscoe, J.C., Gray, J.W., Hildebrand, C.E., Jackson, P.J., Jett, J.H., Longmire, J.L., Lozes, C.R., Luedemann, M.L., Martin, J.C., McNinch, J.S., Meincke, L.J., Mendelsohn, M.L., Meyne, J., Moyzis, R.K., Munk, A.C., Perlman, J., Peters, D.C., Silva, A.J., Trask, B.J. (1986) Human chromosome-specific DNA libraries: Construction and availability. *Nat. Biotech.*, 4(6):537-52.
80. Beisker, W., Dolbeare, F., Gray, J.W. (1986) An improved immunocytochemical procedure for high-sensitivity detection of incorporate bromodeoxyuridine. *Cytometry*, 8(2):235-9.
81. Kurki, P., Vanderlaan, M., Dolbeare, F., Gray, J.W., Tan, E.M. (1986) Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. *Exp. Cell Res.*, 166(1):209-19.
82. Lucas, J.N., Gray, J.W. (1987) Centromeric index versus DNA content flow karyotypes of human chromosomes measured by means of slit-scan flow cytometry. *Cytometry*, 8(3):273-9.
83. Gray, J.W., Dean, P.N., Fuscoe, J.C., Peters, D.C., Trask, B.J., van den Engh, G.J., Van Dilla, M.A. (1987) High-speed chromosome sorting. *Science*, 238(4825):323-9.
84. Aten, J.A., Buys, C.H., van der Veen, A.Y., Mesa, J.R., Yu, L.-C., Gray, J.W., Osinga, J., Stap, J. (1987) Stabilization of chromosomes by DNA intercalators for flow karyotyping and identification by banding of isolated chromosomes. *Histochemistry*, 87(4):359-66.
85. Gray, J.W., Trask, B., van den Engh, G., Silva, A., Lozes, C., Grell, S., Schonberg, S., Yu, L.-C., Golbus, M.S. (1988) Application of flow karyotyping in prenatal detection of chromosome aberrations. *Am. J. Hum. Genet.*, 42(1):49-59.
86. Mullikin, J., Norgren, R., Lucas, J., Gray, J.W. (1988) Fringe-scan flow cytometry. *Cytometry*, 9(2):111-20.

87. Trask, B., van den Engh, G., Pinkel, D., Mullikin, J., van Dekken, H., Gray, J.W. (1988) Fluorescence in situ hybridization to interphase cell nuclei in suspension allows flow cytometric analysis of chromosome content and microscopic analysis of nuclear organization. *Hum. Genet.*, 78(3):251-9.
88. van den Engh, G., Trask, B., Lansdorp, P., Gray, J.W. (1988) Improved resolution of flow cytometric measurements of Hoechst- and chromomycin-A3-stained human chromosomes after addition of citrate and sulfite. *Cytometry*, 9(3):266-70.
89. Weier, H.-U., Gray, J.W. (1988) A programmable system to perform the polymerase chain reaction. *DNA*, 7(6):441-7.
90. van Dekken, H., Pinkel, D., Mullikin, J., Gray, J.W. (1988) Enzymatic production of single-stranded DNA as a target for fluorescence in situ hybridization. *Chromosoma*, 97(1):1-5.
91. Dolbeare, F., Gray, J.W. (1988) Use of restriction endonucleases and exonuclease III to expose halogenated pyrimidines for immunochemical staining. *Cytometry*, 9(6):631-5.
92. Pinkel, D., Landegent, J., Collins, C., Fuscoe, J., Seagraves, R., Lucas, J., Gray, J.W. (1988) Fluorescence in situ hybridization with human chromosome specific libraries: detection of trisomy 21 and translocations of chromosome 4. *Proc. Natl. Acad. Sci. USA*, 85(23):9138-42.
93. Martin, A.O., Northrup, H., Ledbetter, D.H., Trask, B., van den Engh, G., Le Beau, M.M., Beaudet, A.L., Gray, J.W., Sekhon, G., Krassikoff, N., Booth, C. (1988) Prenatal detection of 46,XY,rec(5),dup q, inv(5)(p13q33) using DNA analysis, flow cytometry, and in situ hybridization to supplement classical cytogenetic analysis. *Am. J. Med. Genet.*, 31(3):643-54.
94. Lucas, J.N., Tenjin, T., Straume, T., Pinkel, D., Moore, D. II, Litt, M., Gray, J.W. (1988) Rapid human chromosome aberration analysis using fluorescence in situ hybridization. *Int. J. Radiat. Biol.*, 56(1):35-44.
95. Shibui, S., Hoshino, T., Vanderlaan, M., Gray, J.W. (1989) Double labeling with iodo- and bromodeoxyuridine for cell kinetics studies. *J. Histochem. Cytochem.*, 37(7):1007-11.
96. Fuscoe, J.C., Collins, C.C., Pinkel, D., Gray, J.W. (1989) An efficient method for selecting unique-sequence clones from DNA libraries and its application to fluorescent staining of human chromosome 21 using in situ hybridization. *Genomics*, 5(1):100-9.
97. Trask, B., van den Engh, G., Mayall, B., Gray, J.W. (1989) Chromosome heteromorphism quantified by high-resolution bivariate flow karyotyping. *Am. J. Hum. Genet.*, 45(5):738-52.
98. Trask, B., van den Engh, G., Gray, J.W. (1989) Inheritance of chromosome heteromorphisms analyzed by high-resolution bivariate flow karyotyping. *Am. J. Hum. Genet.*, 45(5):753-60.
99. van Dekken, H., Pinkel, D., Mullikin, J., Trask, B., van den Engh, G., Gray, J.W. (1989) Three-dimensional analysis of the organization of human chromosome domains in human and human-hamster hybrid interphase nuclei. *J. Cell Sci.*, 94(2):299-306.
100. Weier, H.-U., Seagraves, R., Pinkel, D., Gray, J.W. (1990) Synthesis of Y chromosome-specific labeled DNA probes by in vitro DNA amplification. *J. Histochem. Cytochem.*, 38(3):421-6.
101. Trask, B., van den Engh, G., Nussbaum, R., Schwartz, C., Gray, J.W. (1990) Quantification of the DNA content of structurally abnormal X chromosomes and X chromosome aneuploidy using high resolution bivariate flow karyotyping. *Cytometry*, 11(1):184-95.
102. Pallavicini, M.G., Rosette, C., Reitsma, M., DeTeresa, P.S., Gray, J.W. (1990) Relationship of c-myc gene copy number and gene expression: Cellular effects of elevated c-myc protein. *J. Cell. Physiol.*, 143(2):372-80.
103. Pallavicini, M.G., DeTeresa, P.S., Rosette, C., Gray, J.W., Wurm, F.M. (1990) Effects of methotrexate on transfected DNA stability in mammalian cells. *Mol. Cell. Biol.*, 10(1):401-4.

104. Tkachuk, D.C., Westbrook, C.A., Andreeff, M., Donlon, T.A., Cleary, M.L., Suryanarayan, K., Homge, M., Redner, A., Gray, J.W., Pinkel, D. (1990) Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization. *Science*, 250(4980):559-62.
105. Trask, B.J., van den Engh, G., Christensen, M., Massa, H.F., Gray, J.W., Van Dilla, M. (1991) Characterization of somatic cell hybrids by bivariate flow karyotyping and fluorescence in situ hybridization. *Somat. Cell Mol. Genet.*, 17(2):117-36.
106. Weier, H.-U., Zitzelsberger, H.F., Gray, J.W. (1991) Non-isotopical labeling of murine heterochromatin in situ by hybridization with in vitro-synthesized biotinylated gamma (major) satellite DNA. *Biotechniques*, 10(4):498-505.
107. Lucas, J.N., Mullikin, J.C., Gray, J.W. (1991) Dicentric chromosome frequency analysis using slit-scan flow cytometry. *Cytometry*, 12(4):316-22.
108. Weier, H.-U., Lucas, J.N., Poggensee, M., Segraves, R., Pinkel, D., Gray, J.W. (1991) Two-color hybridization with high complexity chromosome-specific probes and a degenerate alpha satellite probe DNA allows unambiguous discrimination between symmetrical and asymmetrical translocations. *Chromosoma*, 100(6):371-6.
109. Kuo, W.-L., Tenjin, H., Segraves, R., Pinkel, D., Golbus, M.S., Gray, J.W. (1991) Detection of aneuploidy involving chromosomes 13, 18, or 21 by fluorescence in situ hybridization (FISH) to interphase and metaphase amniocytes. *Am. J. Hum. Genet.*, 49(1):112-9.
110. Weier, H.-U., Kleine, H.D., Gray, J.W. (1991) Labeling of the centromeric region on human chromosome 8 by in situ hybridization. *Hum. Genet.*, 87(4):489-94.
111. Collins, C., Kuo, W.-L., Segraves, R., Fuscoe, J., Pinkel, D., Gray, J.W. (1991) Construction and characterization of plasmid libraries enriched in sequences from single human chromosomes. *Genomics*, 11(4):997-1006.
112. Raza, A., Miller, M.A., Mazewski, C., Sheikh, Y., Lampkin, B., Sawaya, R., Crone, K., Berger, T., Reising, J., Gray, J.W., Khan, S., Preisler, H. (1991) Observations regarding DNA replication sites in human cells in vivo following infusions of iododeoxyuridine and bromodeoxyuridine. *Cell Prolif.*, 24(2):113-26.
113. Weier, H.-U., Zitzelsberger, H.F., Gray, J.W. (1992) Differential staining of human and murine chromatin in situ by hybridization with species-specific satellite DNA probes. *Biochem. Biophys. Res. Comm.*, 182(3):1313-9.
114. Weier, H.-U., Gray, J.W. (1992) A degenerate alpha satellite probe, detecting a centromeric deletion on chromosome 21 in an apparently normal human male, shows limitations of use of satellite DNA probes for interphase ploidy analysis. *Anal. Cell. Pathol.*, 4(2):81-6.
115. Kallioniemi, O.-P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L.-C., Smith, H.S., Waldman, F.M., Pinkel, D., Gray, J.W. (1992) ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. *Proc. Natl. Acad. Sci. USA*, 89(12):5321-5.
116. Matsumura, K., Kallioniemi, O.-P., Kallioniemi, A., Hen, L., Smith, H., Pinkel, D., Gray, J., Waldman, F. (1992) Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization. *Cancer Res.*, 52(12):3474-7.
117. Kallioniemi, A., Kallioniemi, O.-P., Waldman, F.M., Chen, L.-C., Yu, L.-C., Fung, Y.K., Smith, H.S., Pinkel, D., Gray, J.W. (1992) Detection of retinoblastoma gene copy number in metaphase chromosomes and interphase nuclei by fluorescence in situ hybridization. *Cytogenet. Cell Genet.*, 60(3-4):190-3.
118. Kallioniemi, A., Kallioniemi, O.-P., Sudar, D., Rutovitz, D., Gray, J.W., Waldman, F., Pinkel, D. (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. *Science*, 258(5083):818-21.

119. Potier, M.-C., Kuo, W.-L., Dutriaux, A., Gray, J., Goedert, M. (1992) Construction and characterization of a yeast artificial chromosome library containing 1.5 equivalents of human chromosome 21. *Genomics*, 14(2):481-3.
120. Lucas, J.N., Awa, A., Straume, T., Poggensee, M., Kodama, Y., Nakano, M., Ohtaki, K., Weier, H.-U., Pinkel, D., Gray, J., Littlefield, G. (1992) Rapid translocation frequency analysis in humans decades after exposure to ionizing radiation. *Int. J. Radiat. Biol.*, 62(1):53-63.
121. Schmid, E., Zitzelsberger, H., Braselmann, H., Gray, J.W., Bauchinger, M. (1992) Radiation-induced chromosome aberrations analysed by fluorescence in situ hybridization with a triple combination of composite whole chromosome-specific DNA probes. *Int. J. Radiat. Biol.*, 62(6):673-8.
122. Vooijs, M., Yu, L.-C., Tkachuk, D., Pinkel, D., Johnson, D., Gray, J.W. (1993) Libraries for each human chromosome, constructed from sorter-enriched chromosomes by using linker-adaptor PCR. *Am. J. Hum. Genet.*, 52(3):586-97.
123. Moore, D.H. II Gray, J.W. (1993) Derivative domain fitting: A new method for resolving a mixture of normal distributions in the presence of a contaminating background. *Cytometry*, 14(5):510-8.
124. Gingrich, J.C., Lowry, S.R., Kuo, W.-L., Gray, J., Smith, C.L., Cantor, C.R. (1993) Cloning and characterization of *EagI* YACs from human chromosome 21. *Genomics*, 15(1):228-30.
125. Silverman, G.A., Kuo, W.-L., Taillon-Miller, P., Gray, J.W. (1993) Chromosomal reassignment: YACs containing both YES1 and thymidylate synthase map to the short arm of chromosome 18. *Genomics*, 15(2):442-5.
126. Thompson, C.T., LeBoit, P.E., Nederlof, P.M., Gray, J.W. (1994) Thick-section fluorescence in situ hybridization on formalin-fixed, paraffin-embedded archival tissue provides a histogenetic profile. *Am. J. Pathol.*, 144(2):237-43.
127. Miyashita, K., Vooijs, M.A., Tucker, J.D., Lee, D.A., Gray, J.W., Pallavicini, M.G. (1994) A mouse chromosome 11 library generated from sorted chromosomes using linker-adaptor polymerase chain reaction. *Cytogenet. Cell Genet.*, 66(1):54-7.
128. Matsuta, M., Matsuta, M., Kon, S., Thompson, C., LeBoit, P.E., Weier, H.-U., Gray, J.W. (1994) Interphase cytogenetics of melanocytic neoplasms: Numerical aberrations of chromosomes can be detected in interphase nuclei using centromeric DNA probes. *J. Cutan. Pathol.*, 21(1):1-6.
129. Kallioniemi, A., Kallioniemi, O.-P., Piper, J., Tanner, M., Stokke, T., Chen, L., Smith, H.S., Pinkel, D., Gray, J.W., Waldman, F.M. (1994) Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. *Proc. Natl. Acad. Sci. USA*, 91(6):2156-60.
130. Kallioniemi, O.-P., Kallioniemi, A., Mascio, L., Sudar, D., Pinkel, D., Deaven, L., Gray, J.W. (1994) Physical mapping of chromosome 17 cosmids by fluorescence in situ hybridization and digital image analysis. *Genomics*, 20(1):125-8.
131. Weier, H.-U., Polikoff, D., Fawcett, J.J., Greulich, K.M., Lee, K.H., Cram, S., Chapman, V.M., Gray, J.W. (1994) Generation of five high-complexity painting probe libraries from flow-sorted mouse chromosomes. *Genomics*, 21(3):641-614.
132. Schott, D.R., Chang, J.N., Deng, G., Kurisu, W., Kuo, W.-L., Gray, J., Smith, H.S. (1994) A candidate tumor suppressor gene in human breast cancers. *Cancer Res.*, 54(6):1393-6.
133. Tanner, M.M., Tirkkonen, M., Kallioniemi, A., Collins, C., Stokke, T., Karhu, R., Kowbel, D., Shadravan, F., Hintz, M., Kuo, W.-L., Waldman, F.M., Isola, J.J., Gray, J.W., Kallioniemi, O.-P. (1994) Increased copy number at 20q13 in breast cancer: Defining the critical region and exclusion of candidate genes. *Cancer Res.*, 54(16):4257-60.
134. Kallioniemi O.-P., Kallioniemi, A., Piper, J., Isola, J., Waldman, F.M., Gray, J.W., Pinkel, D. (1994) Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. *Genes Chromosomes Cancer*, 10(4):231-43.

135. Levin, N.A., Brzoska, P., Gupta, N., Minna, J.D., Gray, J.W., Christman, M.F. (1994) Identification of frequent novel genetic alterations in small cell lung carcinoma. *Cancer Res.*, 54(19):5086-91.
136. Gordon, K.B., Thompson, C.T., Char, D.H., O'Brien, J.M., Kroll, S., Ghazvini, S., Gray, J.W. (1994) Comparative genomic hybridization in the detection of DNA copy number abnormalities in uveal melanoma. *Cancer Res.*, 54(17):4764-4748.
137. Sasaki, K., Pinkel, D., Tsukahara, M., Murano, I., Gray, J.W. (1994) Detection of a human chromosomal translocation t(8;9) in a baby with multiple malformations using two-color fluorescence in situ hybridization. *Pathol. Int.*, 44(2):145-50.
138. Pallavicini, M.G., George, T., Deteresa, P.S., Amendola, R., Gray, J.W. (1994) Intracellular dynamics of c-myc mRNA traffic in single cells in situ. *J. Cell. Physiol.*, 158(2):223-30.
139. Weier, H.-U., Rosette, C., Matsuta, M., Zitzelsberger, H., Matsuta, M., Gray, J.W. (1994) Generation of highly specific DNA hybridization probes for chromosome enumeration in human interphase cell nuclei: Isolation and enzymatic synthesis of alpha satellite DNA probes for chromosome 10 by primer directed DNA amplification. *Meth. Mol. Cell. Biol.*, 4:231-48.
140. Mascio, L.N., Verbeek, P.W., Sudar, D., Kuo, W.-L., Gray, J.W. (1995) Semiautomated DNA probe mapping using digital imaging microscopy: I. System development. *Cytometry*, 19(1):51-9.
141. Sakamoto, M., Pinkel, D., Mascio, L., Sudar, D., Peters, D., Kuo, W.-L., Yamakawa, K., Nakamura, Y., Drabkin, H., Jericevic, Z., Smith, L., Gray, J.W. (1995) Semiautomated DNA probe mapping using digital imaging microscopy: II. System performance. *Cytometry*, 19(1):60-69.
142. Piper, J., Rutovitz, D., Sudar, D., Kallioniemi, A., Kallioniemi, O.-P., Waldman, F.M., Gray, J.W., Pinkel, D. (1995) Computer image analysis of comparative genomic hybridization. *Cytometry*, 19(1):10-26.
143. Kuo, W.-L., Stafford, D.W., Cruces, J., Gray, J., Solera, J. (1995) Chromosomal localization of the gamma-glutamyl carboxylase gene at 2p12. *Genomics*, 25(3):746-8.
144. Stokke, T., Collins, C., Kuo, W.-L., Kowbel, D., Shadravan, F., Tanner, M., Kallioniemi, A., Kallioniemi, O.-P., Pinkel, D., Deaven, L., Gray, J.W. (1995) A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. *Genomics*, 26(1):134-7.
145. Donehower, L.A., Godley, L.A., Aldaz, C.M., Pyle, R., Shi, Y.-P., Pinkel, D., Gray, J., Bradley, A., Medina, D., Varmus, H.E. (1995) Deficiency of p53 accelerates mammary tumorigenesis in *Wnt-1* transgenic mice and promotes chromosomal instability. *Genes Dev.*, 9(7):882-95.
146. Balazs, M., Matsumura, K., Moore, D., Pinkel, D., Gray, J.W., Waldman, F.M. (1995) Karyotypic heterogeneity and its relation to labeling index in interphase breast tumor cells. *Cytometry*, 20(1):62-73.
147. Brzoska, P.M., Levin, N.A., Fu, K.K., Kaplan, M.J., Singer, M.I., Gray, J.W., Christman, M.F. (1995) Frequent novel DNA copy number increase in squamous cell head and neck tumors. *Cancer Res.*, 55(14):3055-9.
148. Levin, N.A., Brzoska, P.M., Warnock M.L., Gray, J.W., Christman, M.F. (1995) Identification of novel regions of altered DNA copy number in small cell lung tumors. *Genes Chromosomes Cancer*, 13(3):175-85.
149. Weier, H.-U., Wang, M., Mullikin, J.C., Zhu, Y., Cheng, J.-F., Greulich, K.M., Bensimon, A., Gray, J.W. (1995) Quantitative DNA fiber mapping. *Hum. Mol. Genet.*, 4(10):1903-10.
150. Iwabuchi, H., Sakamoto, M., Sakunaga, H., Ma, Y.Y., Carcangiu, M.L., Pinkel, D., Yang-Feng, T.L., Gray, J.W. (1995) Genetic analysis of benign, low-grade, and high-grade ovarian tumors. *Cancer Res.*, 55(24):6172-80.
151. Tanner, M.M., Tirkkonen, M., Kallioniemi, A., Holli, K., Collins, C., Kowbel, D., Gray, J.W., Kallioniemi, O.-P., Isola, J. (1995) Amplification of chromosomal region 20q13 in invasive breast cancer: Prognostic implications. *Clin. Cancer Res.*, 1(12):1455-61.

152. Tanner, M.M., Tirkkonen, M., Kallioniemi, A., Isola, J., Kuukasjärvi, T., Collins, C., Kowbel, D., Guan, X.-Y., Trent, J., Gray, J.W., Meltzer, P., Kallioniemi, O.-P. (1996) Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. *Cancer Res.* 56(15):3441-5.
153. Brzoska, P.M., Chen, H., Levin, N.A., Kuo, W.-L., Collins, C., Fu, K.K., Gray, J.W., Christman, M.F. (1996) Cloning, mapping, and in vivo localization of a human member of the PKCI-1 protein family (PRKCNH1). *Genomics*, 36(1):151-6.
154. Wang, M., Duell, T., Gray, J.W., Weier, H.-U.G. (1996) High sensitivity, high resolution physical mapping by fluorescence in situ hybridization on to individual straightened DNA molecules. *Bioimaging*, 4(2):73-83.
155. Savelieva, E., Belair, C.D., Newton, M.A., DeVries, S., Gray, J.W., Waldman, F., Reznikoff, C.A. (1997) 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells. *Oncogene*, 14(5):551-60.
156. Chang, C.-H., Scott, G.K., Kuo, W.-L., Xiong, X., Suzdaltseva, Y., Park, J.W., Sayre, P., Erny, K., Collins, C., Gray, J.W., Benz, C.C. (1997) ESX: A structurally unique Ets overexpressed early during human breast tumorigenesis. *Oncogene*, 14(13):1617-22.
157. Shi, Y.-P., Naik, P., Dietrich, W.F., Gray, J.W., Hanahan, D., Pinkel, D. (1997) DNA copy number changes associated with characteristic LOH in islet cell carcinomas of transgenic mice. *Genes Chromosomes Cancer*, 19(2):104-11.
158. Moore, D.H. II, Pallavicini, M., Cher, M.L., Gray, J.W. (1997) A t-statistic for objective interpretation of comparative genomic hybridization (CGH) profiles. *Cytometry*, 28(3):183-90.
159. Yu, L.-C., Moore, D.H. II, Magrane, G., Cronin, J., Pinkel, D., Lebo, R.V., Gray, J.W. (1997) Objective aneuploidy detection for fetal and neonatal screening using comparative genomic hybridization (CGH). *Cytometry*, 28(3):191-7.
160. Barsky, S.H., Sternlicht, M.D., Safarians, S., Nguyen, M., Chin, K., Stewart, S.D., Hiti, A.L., Gray, J.W. (1997) Evidence of a dominant transcriptional pathway which regulates an undifferentiated and complete metastatic phenotype. *Oncogene*, 15(17):2077-91.
161. Shi, Y.-P., Mohapatra, G., Miller, J., Hanahan, D., Lander, E., Gold, P., Pinkel, D., Gray, J. (1997) FISH probes for mouse chromosome identification. *Genomics*, 45(1):42-7.
162. Fejzo, M.S., Godfrey, T., Chen, C., Waldman, F., Gray, J.W. (1998) Molecular cytogenetic analysis of consistent abnormalities at 8q12-q22 in breast cancer. *Genes Chromosomes Cancer*, 22(2):105-13.
163. Lucito, R., Nakimura, M., West, J.A., Han, Y., Chin, K., Jensen, K., McCombie, R., Gray, J.W., Wigler, M. (1998) Genetic analysis using genomic representations. *Proc. Natl. Acad. Sci. USA*, 95(8):4487-92.
164. Collins, C., Rommens, J.M., Kowbel, D., Godfrey, T., Tanner, M., Hwang, S.I., Polikoff, D., Nonet, G., Cochran, J., Myambo, K., Jay, K.E., Froula, J., Cloutier, T., Kuo, W.-L., Yaswen, P., Dairkee, S., Giovanola, J., Hutchinson, G.B., Isola, J., Kallioniemi, O.-P., Palazzolo, M., Martin, C., Ericsson, C., Pinkel, D., Alberston, D., Li, W.-B., Gray, J.W. (1998) Positional cloning of ZNF217 and NABC1: Genes amplified at 20q13.2 and overexpressed in breast carcinoma. *Proc. Natl. Acad. Sci. USA*, 95(15):8703-8.
165. Lockett, S.J., Sudar, D., Thompson, C.T., Pinkel, D., Gray, J.W. (1998) Efficient, interactive, and three-dimensional segmentation of cell nuclei in thick tissue sections. *Cytometry*, 31(4):275-86.
166. Hiraguri, S., Godfrey, T., Nakamura, H., Graff, J., Collins, C., Shayesteh, L., Doggett, N., Johnson, K., Wheelock, M., Herman, J., Baylin, S., Pinkel, D., Gray, J. (1998) Mechanisms of inactivation of E-cadherin in breast cancer cell lines. *Cancer Res.*, 58(9):1972-7.
167. Pinkel, D., Segreaves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo, W.-L., Chen, C., Zhai, Y., Dairkee, S.H., Ljung, B.M., Gray, J.W., Albertson, D.G. (1998) High resolution analysis of

DNA copy number variation using comparative genomic hybridization to microarrays. *Nat. Genet.*, 20(2):207-11.

168. Zhou, H., Kuang, J., Zhong, L., Kuo, W.-L., Gray, J.W., Sahin, A., Brinkley, B.R., Sen, S. (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. *Nat. Genet.*, 20(2):189-93.
169. Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G.B., Gray, J.W. (1999) *PIK3CA* is implicated as an oncogene in ovarian cancer. *Nat. Genet.*, 21(1):99-102.
170. Yu, Y., Xu, F., Peng, H., Fang, X., Zhao, S., Li, Y., Cuevas, B., Kuo, W.-L., Gray, J.W., Siciliano, M., Mills, G.B., Bast, R.C. Jr. (1999) NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. *Proc. Natl. Acad. Sci. USA*, 96(1):214-9.
171. Ortiz de Solórzano, C., García Rodríguez, E., Jones, A., Pinkel, D., Gray, J.W., Sudar, D., Lockett, S.J. (1999) Segmentation of confocal microscope images of cell nuclei in thick tissue sections. *J. Microscopy*, 193(Pt 3):212-26.
172. Sternlicht, M.D, Lochter, A., Sympton, C.J., Huey, B., Rougier, J.P., Gray, J.W., Pinkel, D., Bissell, M.J., Werb, Z. (1999) The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. *Cell*, 98(2):137-46.
173. Gray, J.W., Collins, C. (2000) Genome changes and gene expression in human solid tumors. *Carcinogenesis*, 21(3):443-52.
174. Frost, G.I., Mohapatra, G., Wong, T.M., Csóka, A.B., Gray, J.W., Stern, R. (2000) *HYAL1LUC1A-1*, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA. *Oncogene*, 19(7):870-7.
175. Albertson, D.G., Ylstra, B., Seagraves, R., Collins, C., Dairkee, S.H., Kowbel, D., Kuo, W.-L., Gray, J.W., Pinkel, D. (2000) Quantitative mapping of amplicon structure by array CGH identifies *CYP24* as a candidate oncogene. *Nat. Genet.*, 25(2):144-6.
176. Peng, H., Xu, F., Pershad, R., Hunt, K.K., Frazier, M.L., Berchuck, A., Gray, J.W., Hogg, D., Bast, R.C. Jr., Yu, Y. (2000) ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. *Int. J. Cancer*, 86(5):690-4.
177. Hu, L., Zaloudek, C., Mills, G.B., Gray, J., Jaffe, R.B. (2000) In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). *Clin. Cancer Res.*, 6(3):880-6.
178. Suzuki, S., Moore, D.H. II, Ginzinger, D.G., Godfrey, T.E., Barclay, J., Powell, B., Pinkel, D., Zaloudek, C., Lu, K., Mills, G., Berchuck, A., Gray, J.W. (2000) An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. *Cancer Res.*, 60(19):5382-5.
179. Ginzinger, D.G., Godfrey, T.E., Nigro, J., Moore, D.H. II, Suzuki, S., Pallavicini, M.G., Gray, J.W., Jensen, R.H. (2000) Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. *Cancer Res.*, 60(19):5405-9.
180. Cheung, V.G., Nowak, N., Jang, W., Kirsch, I.R., Zhao, S., Chen, X.-N., Furey, T.S., Kim, U.-J., Kuo, W.-L., Olivier, M., Conroy, J., Kasprzyk, A., Massa, H., Yonescu, R., Sait, S., Thoreen, C., Snijders, A., Lemyre, E., Bailey, J.A., Bruzel, A., Burrill, W.D., Clegg, S.M., Collins, S., Dhimi, P., Friedman, C., Han, C.S., Herrick, S., Lee, J., Ligon, A.H., Lowry, S., Morley, M., Narasimhan, S., Osoegawa, K., Peng, Z., Plajzer-Frick, I., Quade, B.J., Scott, D., Sirotkin, K., Thorpe, A.A., Gray, J.W., Hudson, J., Pinkel, D., Ried, T., Rowen, L., Shen-Ong, G.L., Strausberg, R.L., Birney, E., Callen, D.F., Cheng, J.-F., Cox, D.R., Doggett, N.A., Carter, N.P., Eichler, E.E., Haussler, D., Korenberg, J.R., Morton, C.C., Albertson D., Schuler, G., de Jong, P.J., Trask, B.J. (2001) Integration of cytogenetic landmarks into the draft sequence of the human genome. *Nature*, 409(6822):953-8.

181. Nonet, G.H., Stampfer, M.R., Chin, K., Gray, J.W., Collins, C.C., Yaswen, P. (2001) The *ZNF217* gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. *Cancer Res.*, 61(4):1250-4.
182. Godfrey, T.E., Kim, S.H., Chavira, M., Ruff, D.W., Warren, R.S., Gray, J.W., Jensen, R.H. (2000) Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction. *J. Mol. Diagn.*, 2(2):84-91.
183. Collins, C., Volik, S., Kowbel, D., Ginzinger, D., Ylstra, B., Cloutier, T., Hawkins, T., Predki, P., Martin, C., Wernick, M., Kuo, W.-L., Alberts, A., Gray, J.W. (2001) Comprehensive genome sequence analysis of a breast cancer amplicon. *Genome Res.*, 11(6):1034-42.
184. Parrott, J.A., Nilsson, E., Mosher, R., Magrane, G., Albertson, D., Pinkel, D., Gray, J.W., Skinner, M.K. (2001) Stromal-epithelial interactions in the progression of ovarian cancer: Influence and source of tumor stromal cells. *Mol. Cell. Endocrinol.* 175(1-2):29-39.
185. Jain, A.N., Chin, K., Børresen-Dale, A.-L., Erikstein, B., Eynstein Lonning, P., Kaaresen, R., Gray, J.W. (2001) Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. *Proc. Natl. Acad. Sci. USA*, 98(14):7952-7.
186. Lu, X., Magrane, G., Yin, C., Louis, D.N., Gray, J., Van Dyke, T. (2001) Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability. *Mol. Cell. Biol.*, 21(17):6017-30.
187. Snijders, A.M., Nowak, N., Segreaves, R., Blackwood, S., Brown, N., Conroy, J., Hamilton, G., Hindle, A.K., Huey, B., Kimura, K., Law, S., Myambo, K., Palmer, J., Ylstra, B., Yue, J.P., Gray, J.W., Jain, A.N., Pinkel, D., Albertson, D.G. (2001) Assembly of microarrays for genome-wide measurement of DNA copy number. *Nat. Genet.*, 29(3):263-4.
188. Hodgson, G., Hager, J.H., Volik, S., Hariono, S., Wernick, M., Moore, D., Nowak, N., Albertson, D.G., Pinkel, D., Collins, C., Hanahan, D., Gray, J.W. (2001) Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. *Nat. Genet.*, 29(4):459-64.
189. Massion, P.P., Kuo, W.-L., Stokoe, D., Olshen, A.B., Treseler, P.A., Chin, K., Chen, C., Polikoff, D., Jain, A.N., Pinkel, D., Albertson, D.G., Jablons, D.M., Gray, J.W. (2002) Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: Implications of the phosphatidylinositol 3-kinase pathway. *Cancer Res.*, 62(13):3636-40.
190. Anand, N., Murthy, S., Amann, G., Wernick, M., Porter, L.A., Cukier, I.H., Collins, C., Gray, J.W., Diebold, J., Demetrick, D.J., Lee, J.M. (2002) Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. *Nat. Genet.*, 31(3):301-305.
191. Li, Z., Moore, D.H., Meng, Z.H., Ljung, B.M., Gray, J.W., Dairkee, S.H. (2002) Increased risk of local recurrence is associated with allelic loss in normal lobules of breast cancer patients. *Cancer Res.*, 62(4):1000-3.
192. Li, Z., Meng, Z.H., Chandrasekaran, R., Kuo, W.-L., Collins, C.C., Gray, J.W., Dairkee, S.H. (2002) Biallelic inactivation of the thyroid hormone receptor $\beta 1$ gene in early stage breast cancer. *Cancer Res.*, 62(7):1939-43.
193. Gaudet, F., Hodgson, J.G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J.W., Leonhardt, H., Jaenisch, R. (2003) Induction of tumors in mice by genomic hypomethylation. *Science*, 300(5618):489-92.
194. Ortiz de Solórzano, C., Chin, K., Gray, J.W., Lockett, S.J. (2003) In situ quantification of genomic instability in breast cancer progression. *IEEE EMBS*, 4:3578-81.
195. Volik, S., Zhao, S., Chin, K., Brebner, J.H., Herndon, D.R., Tao, Q., Kowbel, D., Huang, G., Lapuk, A., Kuo, W.-L., Magrane, G., de Jong, P., Gray, J.W., Collins, C. (2003) End-sequence profiling: Sequence-based analysis of aberrant genomes. *Proc. Natl. Acad. Sci. USA*, 100(13):7696-701.

196. Hackett, C.S., Hodgson, J.G., Law, M.E., Fridlyand, J., Osoegawa, K., de Jong, P.J., Nowak, N.J., Pinkel, D., Albertson, D.G., Jain, A., Jenkins, R., Gray, J.W., Weiss, W.A. (2003) Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. *Cancer Res.*, 63(17):5266-73.
197. Albertson, D.G., Collins, C., McCormick, F., Gray, J.W. (2003) Chromosome aberrations in solid tumors. *Nat. Genet.*, 34(4):369-76.
198. Lapuk, A., Volik, S., Vincent, R., Chin, K., Kuo, W.-L., de Jong, P., Collins, C., Gray, J.W. (2004) Computational BAC clone contig assembly for comprehensive genome analysis. *Genes Chromosomes Cancer*, 40(1):66-71.
199. Hager, J.H., Hodgson, J.G., Fridlyand, J., Hariono, S., Gray, J.W., Hanahan, D. (2004) Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomas. *Cancer Res.*, 64(7):2406-10.
200. Zhao, X., Li, C., Paez, J.G., Chin, K., Jänne, P.A., Chen, T.-H., Girard, L., Minna, J., Christiani, D., Leo, C., Gray, J.W., Sellers, W.R., Meyerson, M. (2004) An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. *Cancer Res.*, 64(9):3060-71.
201. Kuperwasser, C., Chavarria, T., Wu, M., Magrane, G., Gray, J.W., Carey, L., Richardson, A., Weinberg, R.A. (2004) Reconstruction of functionally normal and malignant human breast tissues in mice. *Proc. Natl. Acad. Sci. USA*, 101(14):4966-71.
202. Verschuren, E.W., Hodgson, J.G., Gray, J.W., Kogan, S., Jones, N., Evan, G.I. (2004) The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. *Cancer Res.*, 64(2):581-9.
203. Sonoda, I., Imoto, I., Inoue, J., Shibata, T., Shimada, Y., Chin, K., Imamura, M., Amagasa, T., Gray, J.W., Hirohashi, S., Inazawa, J. (2004) Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. *Cancer Res.*, 64(11):3741-7.
204. Chin, K., de Solorzano, C.O., Knowles, D., Jones, A., Chou, W., Rodriguez, E.G., Kuo, W.-L., Ljung, B.M., Chew, K., Myambo, K., Miranda, M., Krig, S., Garbe, J., Stampfer, M., Yaswen, P., Gray, J.W., Lockett, S.J. (2004) In situ analyses of genome instability in breast cancer. *Nat. Genet.*, 36(9):984-8.
205. Raap, A.K., van der Burg, M.J., Knijnenburg, J., Meershoek, E., Rosenberg, C., Gray, J.W., Wiegant, J., Hodgson, J.G., Tanke, H.J. (2004) Array comparative genomic hybridization with cyanin cis-platinum-labeled DNAs. *Biotechniques*, 37(1):130-4.
206. Alazawi, W., Pett, M., Strauss, S., Moseley, R., Gray, J., Stanley, M., Coleman, N. (2004) Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: Associations with lesion grade, state of the HPV16 E2 gene and clinical outcome. *Brit. J. Cancer*, 91(12):2063-70.
207. Cheng, K.W., Lahad, J.P., Kuo, W.-L., Lapuk, A., Yamada, K., Auersperg, N., Liu, J., Smith-McCune, K., Lu, K.H., Fishman, D., Gray, J.W., Mills, G.B. (2004) The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. *Nat. Med.*, 10(11):1251-6.
208. Fan, W., Huang, X., Chen, C., Gray, J., Huang, T. (2004) TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. *Cancer Res.*, 64(15):5132-9.
209. Scacheri, P.C., Kennedy, A.L., Chin, K., Miller, M.T., Hodgson, J.G., Gray, J.W., Marx, S.J., Spiegel, A.M., Collins, F.S. (2004) Pancreatic insulinomas in multiple endocrine neoplasia, type I knockout mice can develop in the absence of chromosome instability or microsatellite instability. *Cancer Res.*, 64(19):7039-44.
210. Kim, S., Chin, K., Gray, J.W., Bishop, J.M. (2004) A screen for genes that suppress loss of contact inhibition: Identification of ING4 as a candidate tumor suppressor gene in human cancer. *Proc. Natl. Acad. Sci. USA*, 101(46):16251-16256.

211. Zhang, X., Snijders, A., Se Graves, R., Zhang, X., Niebuhr, A., Albertson, D., Yang, H., Gray, J., Niebuhr, E., Bolund, L., Pinkel, D. (2004) High-resolution mapping of genotype-phenotype relationships in cri du chat syndrome using array comparative genomic hybridization. *Am. J. Hum. Genet.*, 76(2):312-26.
212. Bast, R.C. Jr., Lilja, H., Urban, N., Rimm, D.L., Fritsche, H., Gray, J., Veltri, R., Klee, G., Allen, A., Kim, N., Gutman, S., Rubin, M.A., Hruszkewycz, A. (2005) Translational crossroads for biomarkers. *Clin. Cancer Res.*, 11(17):6103-8.
213. Hui, A.B., Takano, H., Lo, K.W., Kuo, W.-L., Lam, C.N., Tong, C.Y. Chang, Q., Gray, J.W., Ng, H.K. (2005) Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis. *Clin. Cancer Res.*, 11(13):4707-16.
214. Macrae, M., Neve, R.M., Rodriguez-Viciano, P., Haqq, C., Yeh, J., Chen, C., Gray, J.W., McCormick, F. (2005) A conditional feedback loop regulates Ras activity through EphA2. *Cancer Cell*, 8(2):111-8.
215. Cheng, K.W., Lahad, J.P., Gray, J.W., Mills, G.B. (2005) Emerging role of RAB GTPases in cancer and human disease. *Cancer Res.*, 65(7):2516-9.
216. Hui, A.B., Or, Y.-Y., Takano, H., Tsang, R.K., To, K.F., Guan, X.-Y., Sham, J. S., Hung, K.W., Lam, C.N., van Hasselt, C.A., Kuo, W.-L., Gray, J.W., Huang, D.P., Lo, K.-W. (2005) Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. *Cancer Res.*, 65(18):8125-33.
217. Hodgson, J.G., Malek, T., Bornstein, S., Hariono, S., Ginzinger, D.G., Muller, W.J., Gray, J.W. (2005) Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. *Cancer Res.*, 65(21):9695-704.
218. Ding, L., Stilwell, J., Zhang, T., Elboudwarej, O., Jiang, H., Selegue, J.P., Cooke, P.A., Gray, J.W., Chen, F.F. (2005) Molecular characterization of the cytotoxic mechanism of multiwall carbon nanotubes and nano-onions on human skin fibroblast. *Nano Lett.*, 5(12):2448-64.
219. Kresse, S.H., Berner, J.M., Meza-Zepeda, L.A., Gregory, S.G., Kuo, W.-L., Gray, J.W., Forus, A., Myklebost, O. (2005) Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH. *Mol. Cancer*, 4:39.
220. Baldocchi, R.A., Glynne, R.J., Chin, K., Kowbel, D., Collins, C., Mack, D.H., Gray, J.W. (2005) Design considerations for array CGH to oligonucleotide arrays. *Cytometry A*, 67(2):129-36.
221. Gupta, P.B., Kuperwasser, C., Brunet, J.P., Ramaswamy, S., Kuo, W.-L., Gray, J.W., Naber, S.P., Weinberg, R.A. (2005) The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. *Nat. Genet.*, 37(10):1047-54.
222. Eder, A.M., Sui, X., Rosen, D.G., Nolden, L.K., Cheng, K.W., Lahad, J.P., Kango-Singh, M., Lu, K.H., Warneke, C.L., Atkinson, E.N., Bedrosian, I., Keyomarsi, K., Kuo, W.-L., Gray, J.W., Yin, J.C., Liu, J., Halder, G., Mills, G.B. (2005) Atypical PKC ζ contributes to poor prognosis through loss of apical-basal polarity and Cyclin E overexpression in ovarian cancer. *Proc. Natl. Acad. Sci. USA*, 102(35):12519-24.
223. Shingyoji, M., Gerion, D., Pinkel, D., Gray, J.W., Chen, F. (2005) Quantum dots-based reverse phase protein microarray. *Talanta*, 67(3):472-8.
224. Volik, S., Raphael, B.J., Huang, G., Stratton, M.R., Bignel, G., Murnane, J., Brebner, J.H., Bajsarowicz, K., Paris, P.L., Tao, Q., Kowbel, D., Lapuk, A., Shagin, D.A., Shagina, I.A., Gray, J.W., Cheng, J.F., de Jong, P.J., Pevzner, P., Collins, C. (2006) Decoding the fine-scale structure of a breast cancer genome and transcriptome. *Genome Res.*, 16(3):394-404.
225. Nam, J.M., Nair, P.M., Neve, R.M., Gray, J.W., Groves, J.T. (2006) A fluid membrane-based soluble ligand-display system for live-cell assays. *Chembiochem*, 7(3):436-40.
226. Park, C.C., Zhang, H., Pallavicini, M., Gray, J.W., Baehner, F., Park, C.J., Bissell, M.J. (2006) β_1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. *Cancer Res.*, 66(3):1526-35.

227. Rai, R., Dai, H., Multani, A.S., Li, K., Chin, K., Gray, J., Lahad, J.P., Liang, J., Mills, G.B., Meric-Bernstam, F., Lin, S.-Y. (2006) BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. *Cancer Cell*, 10(2):145-57.
228. Zhang, T., Stilwell, J.L., Gerion, D., Ding, L., Elboudwarej, O., Cooke, P.A., Gray, J.W., Alivisatos, A.P., Chen, F.F. (2006) Cellular effect of high doses of silica-coated quantum dot profiled with high throughput gene expression analysis and high content cellomics measurements. *Nano Lett.*, 6(4):800-8.
229. Fridlyand, J., Snijders, A.M., Ylstra, B., Li, H., Olshen, A., Segraves, R., Dairkee, S., Tokuyasu, T., Ljung, B.M., Jain, A.N., McLennan, J., Ziegler, J., Chin, K., Devries, S., Feiler, H., Gray, J.W., Waldman, F., Pinkel, D., Albertson, D.G. (2006) Breast tumor copy number aberration phenotypes and genomic instability. *BMC Cancer*, 6:96.
230. Zhang, S., Lovejoy, K.S., Shima, J.E., Lagpacan, L.L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J.W., Chen, X., Lippard, S.J., Giacomini, K.M. (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. *Cancer Res.*, 66(17):8847-57.
231. Bussey, K.J., Chin, K., Lababidi, S., Reimers, M., Reinhold, W.C., Kuo, W.-L., Gwadry, F., Kouros-Mehr, H., Fridlyand, J., Jain, A., Collins, C., Nishizuka, S., Tonon, G., Roschke, A., Gehlhaus, K., Kirsch, I., Scudiero, D.A., Gray, J.W., Weinstein, J.N. (2006) Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. *Mol. Cancer Ther.*, 5(4):853-67.
232. Eastman, P.S., Ruan, W., Doctolero, M., Nuttall, R., de Feo, G., Park, J.S., Chu, J.S., Cooke, P., Gray, J.W., Li, S., Chen, F.F. (2006) Qdot nanobarcode for multiplexed gene expression analysis. *Nano Lett.*, 6(5):1059-64.
233. Lorenzi, P.L., Reinhold, W.C., Rudelius, M., Gunsior, M., Shankavaram, U., Bussey, K.J., Scherf, U., Eichler, G.S., Martin, S.E., Chin, K., Gray, J.W., Kohn, E.C., Horak, I.D., Von Hoff, D.D., Raffeld, M., Goldsmith, P.K., Caplen, N.J., Weinstein, J.N. (2006) Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. *Mol. Cancer Ther.*, 5(11):2613-23.
234. Chin, K., DeVries, S., Fridlyand, J., Spellman, P.T., Roydasgupta, R., Kuo, W.-L., Lapuk, A., Neve, R.M., Qian, Z., Ryder, T., Chen, F., Feiler, H., Tokuyasu, T., Kingsley, C., Dairkee, S., Meng, Z., Chew, K., Pinkel, D., Jain, A., Ljung, B.M., Esserman, L., Albertson, D.G., Waldman, F.M., Gray, J.W. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. *Cancer Cell*, 10(6):529-41.
235. Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F., Fevr, T., Clark, L., Bayani, N., Coppé, J.P., Tong, F., Speed, T., Spellman, P.T., DeVries, S., Lapuk, A., Wang, N.J., Kuo, W.-L., Stilwell, J.L., Pinkel, D., Albertson, D.G., Waldman, F.M., McCormick, F., Dickson, R.B., Johnson, M.D., Lippman, M., Ethier, S., Gazdar, A., Gray, J.W. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell*, 10(6):515-27. PMC2730521
236. Sternlicht, M.D., Dunning, A.M., Moore, D.H., Pharoah, P.D., Ginzinger, D.G., Chin, K., Gray, J.W., Waldman, F.M., Ponder, B.A., Werb, Z. (2006) Prognostic value of PAI1 in invasive breast cancer: Evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. *Cancer Epidemiol. Biomarkers Prev.*, 15(11):2107-2114.
237. Zhou, Q., Cheung, Y.B., Jada, S.R., Lim, W.T., Kuo, W.-L., Gray, J.W., Lee, A.S., Chowbay, B. (2006) EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues. *Cancer Biol. Ther.*, 5(11):1445-9.
238. Liu, G.L., Yin, Y., Kunchakarra, S., Mukherjee, B., Gerion, D., Jett, S.D., Bear, D.G., Gray, J.W., Alivisatos, A.P., Lee, L.P., Chen, F.F. (2006) A nanoplasmonic molecular ruler for measuring nuclease activity and DNA footprinting. *Nat. Nanotechnol.*, 1(1):47-52.
239. Stilwell, J.L., Guan, Y., Neve, R.M., Gray, J.W. (2007) Systems biology in cancer research: Genomics to cellomics. *Methods Mol. Biol.*, 356:353-65.

240. Climent, J., Dimitrow, P., Fridlyand, J., Palacios, J., Siebert, R., Albertson, D.G., Gray, J.W., Pinkel, D., Luch, A., Martinez-Climent, J.A. (2007) Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. *Cancer Res.*, 67(2):818-26.
241. Li, P., Maines-Bandiera, S., Kuo, W.L., Guan, Y., Sun, Y., Hills, M., Huang, G., Collins, C.C., Leung, P.C., Gray, J.W., Auersperg, N. (2007) Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. *Int. J. Cancer*, 120(9):1863-73.
242. Zhou, Y., Yau, C., Gray, J.W., Chew, K., Dairkee, S.H., Moore, D.H., Eppenberger, U., Eppenberger-Castori, S., Benz, C.C. (2007) Enhanced NF κ B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. *BMC Cancer*, 7:59.
243. Nanjundan, M., Nakayama, Y., Cheng, K.W., Lahad, J., Liu, J., Lu, K., Kuo, W.-L., Smith-McCune, K., Fishman, D., Gray, J.W., Mills, G.B. (2007) Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. *Cancer Res.*, 67(7):3074-84.
244. Parvin, B., Ghosh, N., Heiser, L., Knapp, M., Talcott, C., Laderoute, K., Gray, J., Spellman, P. (2007) Spectral decomposition of signaling networks. *IEEE Symposium on Computational Intelligence and Bioinformatics and Computational Biology (CIBCB)*, 76-81.
245. Mao, J.H., Wu, D., Perez-Losada, J., Jiang, T., Li, Q., Neve, R.M., Gray, J.W., Cai, W.W., Balmain, A. (2007) Crosstalk between Aurora-A and p53: Frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. *Cancer Cell*, 11(2):161-73.
246. Kenny, P.A., Lee, G.Y., Myers, C.A., Neve, R.M., Semeiks, J.R., Spellman, P.T., Lorenz, K., Lee, E.H., Barcellos-Hoff, M.H., Petersen, O.W., Gray, J.W., Bissell, M.J. (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. *Mol. Oncol.*, 1(1):84-96.
247. Yau, C., Fedele, V., Roydasgupta, R., Fridlyand, J., Hubbard, A., Gray, J.W., Chew, K., Dairkee, S.H., Moore, D.H., Schittulli, F., Tommasi, S., Paradiso, A., Albertson, D.G., Benz, C.C. (2007) Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. *Breast Cancer Res.*, 9(5):R59.
248. Guan, Y., Kuo, W.-L., Stilwell, J.L., Takano, H., Lapuk, A.V., Fridlyand, J., Mao, J.-H., Yu, M., Miller, M.A., Santos, J.L., Kalloger, S.E., Carlson, J.W., Ginzinger, D.G., Celniker, S.E., Mills, G.B., Huntsman, D.G., Gray, J.W. (2007) Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. *Clin. Cancer Res.*, 13(19):5745-5755.
249. Wang, Y., Moorhead, M., Karlin-Neumann, G., Wang, N.J., Ireland, J., Lin, S., Chen, C., Heiser, L.M., Chin, K., Esserman, L., Gray, J.W., Spellman, P.T., Faham, M. (2007) Analysis of molecular inversion probe performance for allele copy number determination. *Genome Biol.*, 8(11):R246.
250. Press, J.Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S.E., Blood, K.A., Smith, M., Spellman, P.T., Wang, Y., Miller, D.M., Horsman, D., Faham, M., Gilks, C.B., Gray, J., Huntsman, D.G. (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. *BMC Cancer*, 8:17. PMC2245962
251. Rizki, A., Weaver, V.M., Lee, S.-Y., Rozenberg, G.I., Chin, K., Myers, C.A., Bascom, J.L., Mott, J.D., Semeiks, J.R., Grate, L.R., Mian, I.S., Borowsky, A.D., Jensen, R.A., Idowu, M.O., Chen, F., Chen, D.J., Petersen, O.W., Gray, J.W., Bissell, M.J. (2008) A human breast cell model of preinvasive to invasive transition. *Cancer Res.*, 68(5):1378-87. PMC2662716
252. Raphael, B.J., Volik, S., Yu, P., Wu, C., Huang, G., Linardopoulou, E.V., Trask, B.J., Waldman, F., Costello, J., Pienta, K.J., Mills, G.B., Bajsarowicz, K., Kobayashi, Y., Sridharan, S., Paris, P.L., Tao, Q., Aerni, S.J., Brown, R.P., Bashir, A., Gray, J.W., Cheng, J.-F., de Jong, P., Nefedov, M., Ried, T., Padilla-Nash, H.M., Collins, C.C. (2008) A sequence-based survey of the complex structural organization of tumor genomes. *Genome Biol.*, 9(3):R59. PMC2397511

253. Chin, L., Gray, J.W. (2008) Translating insights from the cancer genome into clinical practice. *Nature*, 452(7187):553-63. PMC2730524
254. Hennessy, B.T., Murph, M., Nanjundan, M., Carey, M., Auersperg, N., Almeida, J., Coombes, K.R., Liu, J., Lu, Y., Gray, J.W., Mills, G.B. (2008) Ovarian cancer: Linking genomics to new target discovery and molecular markers – the way ahead. *Adv. Exp. Med. Biol.*, 617:23-40. PMC2844243
255. Brown, L.A., Hoog, J., Chin, S.-F., Tao, Y., Zayed, A.A., Chin, K., Teschendorff, A.E., Quackenbush, J.F., Marioni, J.C., Leung, S., Perou, C.M., Neilsen, T.O., Ellis, M., Gray, J.W., Bernard, P.S., Huntsman, D.G., Caldas, C. (2008) ESR1 gene amplification in breast cancer: A common phenomenon? *Nat. Genet.*, 40(7):806-7. PMC2846830
256. Nanjundan, M., Cheng, K.W., Zhang, F., Lahad, J., Kuo, W.-L., Schmandt, R., Smith-McCune, K., Fishman, D., Gray, J.W., Mills, G.B. (2008) Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: A role in ovarian pathogenesis. *Mol. Oncol.*, 2(2):164-81. PMC2598416
257. Stemke-Hale, K., Gonzalez-Angulo, A.M., Lluch, A., Neve, R.M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., Symmans, W.F., Pusztai, L., Nolden, L.K., Horlings, H., Berns, K., Hung, M.-C., van de Vijver, M.J., Valero, V., Gray, J.W., Bernard, R., Mills, G.B., Hennessy, B.T. (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. *Cancer Res.*, 68(15):6084-91. PMC2680495
258. Sun, Y., Wong, N., Guan, Y., Salamanca, C.M., Cheng, J.C., Lee, J.M., Gray, J.W., Auersperg, N. (2008) The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas. *Int. J. Cancer*, 123(8):1761-9. PMC2606039
259. Srivastava, S., Gray, J.W., Reid, B.J., Grad, O., Greenwood, A., Hawk, E.T. for the Translational Research Working Group. (2008) Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. *Clin. Cancer Res.*, 14(18):5672-7. PMC2737183
260. Cancer Genome Atlas Research Network. (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*, 455(7216):1061-8. PMC2671642
261. Tutt, A., Wang, A., Rowland, C., Gillett, C., Lau, K., Chew, K., Dai, H., Kwok, S., Ryder, K., Shu, H., Springall, R., Cane, P., McCallie, B., Kam-Morgan, L., Anderson, S., Buerger, H., Gray, J., Bennington, J., Esserman, L., Hastie, T., Broder, S., Sninsky, J., Brandt, B., Waldman, F. (2008) Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. *BMC Cancer*, 8(1):339. PMC2631011
262. Merritt, W.M., Lin, Y.G., Han, L.Y., Kamat, A.A., Spanuth, W.A., Schmandt, R., Urbauer, D., Pennacchio, L.A., Cheng, J.-F., Nick, A.M., Deavers, M.T., Mourad-Zeidan, A., Wang, H., Mueller, P., Lenburg, M.E., Gray, J.W., Mok, S., Birrer, M.J., Lopez-Berestein, G., Coleman, R.L., Bar-Eli, M., Sood, A.K. (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. *New Engl. J. Med.*, 359(25):2641-50. PMC2710981
263. Mirzoeva, O.K., Das, D., Heiser, L.M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N.J., Neve, R.M., Guan, Y., Hu, Z., Knight, Z., Feiler, H.S., Gascard, P., Parvin, B., Spellman, P.T., Shokat, K.M., Wyrobek, A.J., Bissell, M.J., McCormick, F., Kuo, W.L., Mills, G.B., Gray, J.W., Korn, W.M. (2009) Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. *Cancer Res.*, 69(2):565-72. PMC2737189
264. Mukherjee, S., Pelech, S., Neve, R.M., Kuo, W.-L., Ziyad, S., Spellman, P.T., Gray, J.W., Speed, T.P. (2009) Sparse combinatorial inference with an application in cancer biology. *Bioinformatics*, 25(2):265-71. PMC2639004
265. Das, D., Pellegrini, M., Gray, J.W. (2009) A primer on regression methods for decoding *cis*-regulatory logic. *PLoS Comput. Biol.*, 5(1):e1000269. PMC2607548

266. Matsumura, N., Huang, Z., Baba, T., Lee, P.S., Barnett, J.C., Mori, S., Chang, J.T., Kuo, W.-L., Gusberg, A.H., Whitaker, R.S., Gray, J.W., Fujii, S., Berchuck, A., Murphy, S.K. (2009) Yin yang 1 modulates taxane response in epithelial ovarian cancer. *Mol. Cancer Res.*, 7(2):210-20. PMC2675878
267. Wang, Y., Carlton, V.E.H., Karlin-Neumann, G., Sapolsky, R., Zhang, L., Moorhead, M., Wang, Z.C., Richardson, A.L., Warren, R., Walther, A., Bondy, M., Sahin, A., Krahe, R., Tuna, M., Thompson, P.A., Spellman, P.T., Gray, J.W., Mills, G.B., Faham, M. (2009) High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. *BMC Med. Genomics*, 2(1):8. PMC2649948
268. Bouchard, L.S., Anwar, M.S., Liu, G.L., Hann, B., Xie, Z.H., Gray, J.W., Wang, X., Pines, A., Chen, F.F. (2009) Picomolar sensitivity MRI and photoacoustic imaging of cobalt nanoparticles. *Proc. Natl. Acad. Sci. USA*, 106(11):4085-9. PMC2657430
269. Heiser, L.M., Wang, N.J., Talcott, C.L., Laderoute, K.R., Knapp, M., Guan, Y., Hu, Z., Ziyad, S., Weber, B.L., Laquerre, S., Jackson, J.R., Wooster, R.F., Kuo, W.-L., Gray, J.W., Spellman, P.T. (2009) Integrated analysis of breast cancer cell lines reveals unique signaling pathways. *Genome Biol.*, 10(3):R31.1-R31.17. PMC2691002
270. Hennessy, B.T., Gonzalez-Angulo, A.M., Stemke-Hale, K.A., Gilcrease, M.Z., Krishnamurthy, S., Lee, J.-S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., Liu, W., Stivers, D., Baggerly, K., Carey, M., Lluch, A., Monteagudo, C., He, X., Weigman, V., Fan, C., Palazzo, J., Hortobagyi, G.N., Nolden, L.K., Wang, N.J., Valero, V., Gray, J.W., Perou, C.M., Mills, G.B. (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. *Cancer Res.*, 69(10):4116-24. PMC2737191
271. Agarwal, R., Gonzalez-Angulo, A.M., Myhre, S., Carey, M., Lee, J.S., Overgaard, J., Alsner, J., Stemke-Hale, K., Lluch, A., Neve, R.M., Kuo, W.-L., Sorlie, T., Sahin, A., Valero, V., Keyomarsi, K., Gray, J.W., Børresen-Dale, A.L., Mills, G.B., Hennessy, B.T. (2009) Integrative analysis of cyclin protein levels identifies cyclin B1 as a classifier and predictor of outcomes in breast cancer. *Clin. Cancer Res.*, 15(11):3654-62. PMC2887710
272. Han, J., Chang, H., Fontenay, G., Wang, N.J., Gray, J.W., Parvin, B. (2009) Morphometric subtyping for a panel of breast cancer cell lines. *Proc IEEE Int. Symp. Biomed. Imaging*, (6):791-794. PMC2791417
273. Dairkee, S.H., Sayeed, A., Luciani, G., Champion, S., Meng Z., Jakkula, L.R., Feiler, H.S., Gray, J.W., Moore, D.H. (2009) Immutable functional attributes of histologic grade revealed by context-independent gene expression in primary breast cancer cells. *Cancer Res.*, 69(19):7826-34. PMC2757757
274. Hodgson, J.G., Yeh, R.F., Ray, A., Wang, N.J., Smirnov, I., Yu, M., Hariono, S., Silber, J., Feiler, H.S., Gray, J.W., Spellman, P.T., Vandenberg, S.R., Berger, M.S., James, C.D. (2009) Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. *Neuro. Oncol.*, 11(5):477-87. PMC2765338
275. Ong, D.C., Ho, Y.M., Rudduck, C., Chin, K., Kuo, W.-L., Lie, D.K., Chua, C.L., Tan, P.H., Eu, K.W., Seow-Choen, F., Wong, C.Y., Hong, G.S., Gray, J.W., Lee, A.S. (2009) LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer. *Oncogene*, 28(47):4189-200. PMC2844776
276. Kuo, W.-L., Das, D., Ziyad, S., Bhattacharya, S., Gibb, W.J., Heiser, L.M., Sadanandam, A., Fontenay, G.V., Hu, Z., Wang, N.J., Bayani, N., Feiler, H.S., Neve, R.M., Wyrobek, A.J., Spellman, P.T., Marton, L.J., Gray, J.W. (2009) A systems analysis of chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. *BMC Med.*, 7:77. PMC2803786
277. Weigelt, B., Lo, A.T., Park, C.C., Gray, J.W., Bissell, M.J. (2010) HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. *Breast Cancer Res. Treat.*, 122(1):35-43 PMC2935800
278. Langland, G.T., Yannone, S.M., Langland, R.A., Nakao, A., Guan, Y., Long, S.B.T., Vonguyen, L., Chen, D.J., Gray, J.W., Chen, F. (2010) Radiosensitivity profiles from a panel of ovarian cancer cell lines

exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities. *Oncology Reports*, 23:1021-26. PMC2909445

279. Han, J., Chang, H., Giricz, O., Lee, G.Y., Baehner, F.L., Gray, J.W., Bissell, M.J., Kenny, P.A., Parvin, B. (2010) Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. *PLoS Comput. Biol.*, 6(2): e1000684. PMC2829039
280. Rejniak, K.A., Wang, S.E., Bryce, N.S., Chang, H., Parvin, B., Jourquin, J., Estrada, L., Gray, J.W., Arteaga, C.L., Weaver, A.M., Quaranta, V., Anderson, A.R. (2010) Linking changes in epithelial morphogenesis to cancer mutations using computational modeling. *PLoS Comput. Biol.*, 6(8): e1000900. PMC2928778
281. Purcell, J.W., Davis, J., Reddy, M., Martin, S., Samayoa, K., Vo, H., Thomsen, K., Bean, P., Kuo, W.-L., Ziyad, S., Billig, J., Feiler, H.S., Gray, J.W., Wood, K.W., Cases, S. (2010) Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer. *Clin. Cancer Res.*, 16(2):566-76. PMC2844774
282. Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B.A., Gabriel S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H.S., Hodgson, J.G., James, C.D., Sarkaria, J.N., Brennan, C., Kahn, A., Spellman, P.T., Wilson, R.K., Speed, T.P., Gray, J.W., Meyerson, M., Getz, G., Perou, C.M., Hayes, D.N. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell*, 17(1):98-110. PMC2818769
283. Salaita, K., Nair, P.M., Petit, R.S., Neve, R.M., Debo, D., Gray, J.W., Groves, J.T. (2010) Restriction of receptor movement alters cellular response: physical force sensing by EphA2. *Science*, 12;327(5971):1380-85. PMC2895569
284. Hu, Z., Huang, G., Sadanandam, A., Gu, S., Lenburg, M.E., Pai, M., Bayani, N., Blakely, E.A., Gray, J.W., Mao, J.-H. (2010) The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. *Breast Cancer Res.*, 12(2):R18. PMC2879562
285. Loss, L.A., Sadanandam, A., Durinck, S., Flaucher, D., Carlton, V.E., Moorhead, M., Lu, Y., Gray, J.W., Faham, M., Spellman, P., Parvin, B. (2010) Prediction of epigenetically regulated genes in breast cancer cell lines. *BioMed Central BMC Bioinformatics*, 4;11:305. PMC2903569
286. Creighton, C.J., Fu, X., Hennessy, B.T., Casa, A.J., Zhang, Y., Gonzalez-Angulo, A.M., Lluch, A., Gray, J.W., Brown, P.H., Hilsenbeck, S.G., Osborne, C.K., Mills, G.B., Lee, A.V., Schiff, R. (2010) Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen receptor (ER) levels and activity in ER+ breast cancer. *Breast Cancer Res.*, 12(3):R40. PMC2917035
287. Lapuk, A., Marr, H., Jakkula, L., Pedro, H., Bhattacharya, S., Purdom, E., Hu, Z., Simpson, K., Pachter, L., Durinck, S., Wang, N., Parvin, B., Fontenay, G., Speed, T., Garbe, J., Stampfer, M., Bayandorian, H., Dorton, S., Clark, T.A., Schweitzer, A., Wyrobek, A., Feiler, H., Spellman, P., Conboy, J., Gray, J.W. (2010) Exon-level microarray analyses identify alternative splicing programs in breast cancer. *Mol. Cancer Res.*, 8(7): 961-74. PMC2911965
288. Zhang, K., Gray, J.W., Parvin, B. (2010) Sparse multitask regression for identifying common mechanism of response to therapeutic targets. *Bioinformatics*, 26(12):i97-105. PMC2881366
289. Nautiyal, S., Carlton, V.E., Lu, Y., Ireland, J.S., Flaucher, D., Moorhead, M., Gray, J.W., Spellman, P., Mindrinos, M., Berg, P., Faham, M. (2010) A high throughput method for analyzing methylation of CpGs in targeted genomic regions. *Proc. Natl. Acad. Sci. USA*, 107(28):12587-92. PMC2906552
290. Prathapam, T., Aleshin, A., Guan, Y., Gray, J.W., Martin, G.S. (2010) p27KIP1 mediates addiction of ovarian cancer cells to MYCC (C-MYC) and their dependence on MYC paralogs. *J. Biol. Chem.*, 285(42):32529-38. PMC2952255

291. Hennessy, B.T., Lu, Y., Gonzalez-Angulo, A.M., Carey, M.S., Myhre, S., Ju, Z., Davies, M.A., Liu, W., Coombes, K., Meric-Bernstam, F., Bedrosian, I., McGahren, M., Agarwal, R., Zhang, F., Overgaard, J., Alsner, J., Neve, R.M., Kuo, W.L., Gray J.W., Borresen-Dale, A.L., Mills, G.B. (2010) A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. *Clin. Proteomics*, 6:129-51. PMC3116520
292. Nabavizadeh, N., Klifa, C., Newitt, D., Lu, Y., Chen, Y.Y., Hsu, H., Fisher, C., Tokayasu, T., Olshen, A.B., Spellman, P., Gray, J.W., Hylton, N., Park, C.C. (2011) Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. *Integr. Biol. (Camb.)*, 3(4):490-96. PMC3698966
293. Collisson, E.A., Sadanandam, A., Olson, P., Gibb, W.J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G.E., Jakkula, L., Feiler, H.S., Ko, A.H., Olshen, A.B., Danenberg, K.L., Tempero, M.A., Spellman, P.T., Hanahan, D., Gray, J.W. (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. *Nature Med.*, 17:500-503. PMC3755490
294. The Cancer Genome Atlas Group (TCGA). (2011) Integrated genomic analyses of ovarian carcinoma. *Nature*, 474(7353):609-615. PMC3163504
295. Durinck, S., Ho, C., Wang, N.J., Liao, W., Jakkula, L.R., Collisson, E.A., Pons, J., Chan, S.-W., Lam, E.T., Chu, C., Park, K., Hong, S.-W., Hur, J.S., Huh, N., Neuhaus, I.M., Yu, S.S., Grekin, R.T., Mauro, T.M., Cleaver, J.E., Kwok, P.-Y., LeBoit, P.E., Getz, G., Cibulskis, K., Aster, J.C., Huang, H., Purdom, E., Li, J., Bolund, L., Arron, S.T., Gray, J.W., Spellman, P.T., Cho, R.J. (2011) Temporal dissection of tumorigenesis in primary cancers. *Cancer Discovery*, 1:137-143. PMC3187561
296. Krig, S., Fietze, S., Simion, C., Miller, J.K., Fry, W.H., Rafidi, H., Kotelawala, L., Qi, L., Griffith, O., Gray, J.W., Carraway, K.L., Sweeney, C. (2011) Lrig1 is an estrogen regulated growth suppressor and correlates with longer relapse free survival in ER- α positive breast cancer. *Mol. Cancer Res.*, 9:1406-17. PMC3196675
297. Fackler, M.J., Umbricht, C., Williams, D., Argani, P., Cruz, L.A, Merino, V.F., Teo, W.W., Zhang, Z., Huang, P., Visvanathan, K., Marks, J., Gray, J.W., Ethier, S., Wolff, A.C., Cope, L.M., Sukumar, S.(2011) Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. *Cancer Res.*, 71:6195-207. PMC3308629
298. Wang, N.J., Sanborn, Z., Arnett, K.L., Bayston, L.J., Liao, W., Proby, C.M., Leigh, I.M., Collisson, E.A., Gordon, P.B., Jakkula, L., Pennypacker, S., Zou, Y., Sharma, M., North, J.P., Vemula, S.S., Mauro, T.M., Neuhaus, I.M., Leboit, P.E., Hur, J.S., Park, K., Huh, N., Kwok, P.Y., Arron, S.T., Massion, P.P., Bale, A.E., Haussler, D., Cleaver, J.E., Gray, J.W., Spellman, P.T., South, A.P., Aster, J.C., Blacklow, S.C., Cho, R.J. (2011) Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. *Proc. Natl. Acad. Sci. USA.*, 108(43):17761-6. PMC3203814
299. Griffith, O.L., Gray, J.W., (2011) ‘Omic’ approaches to preventing or managing metastatic breast cancer. *Breast Cancer Res.*, 13(6):230. PMC3326544
300. Chang, H., Fontenay, G.V., Ju Han, Cong, G., Baehner, F.L., Gray, J.W., Spellman, P.T., Parvin, B. (2011) Morphometric analysis of TCGA glioblastoma multiforme. *BMC Bioinformatics*, 12(1):484. PMC3271112
301. Esserman, L.J., Berry, D.A., Cheang, M.C., Yau, C., Perou, C.M., DeMichele, A., Gray, J.W., Conway-Dorsey, J., Lenburg, M.E., Buxton, M.B., Davis, S.E., Van’t Veer, L.J., Hudis, C., Chin, K., Wolf, D., Krontiras, H., Montgomery, L., Tripathy, D., Lehman, C., Liu, M.C., Olopade, O.I., Rugo, H.S., Carpenter, J.T., Livasy, C., Dressler, L., Chhieng, D., Singh, B., Mies, C., Rabban, J., Chen, Y.Y., Giri, D., Au, A., Hylton, N., The I-SPY 1 TRIAL Investigators. (2011) Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). *Breast Cancer Res. Treat.*, 132(3):1049-1062. PMC3332388

302. Han, J., Chang, H., Loss, L., Zhang, K., Baehner, F.L., Gray, J.W., Spellman, P.T., Parvin, B. (2011) Comparison of sparse coding and kernel methods for histopathological classification of glioblastoma multiforme. *Proc. IEEE Int. Symp. Biomed. Imaging (ISBI)*, 711-714. PMC3521607
303. Heiser, L.M., Sadanandam, A., Kuo, W.L., Benz, S.C., Goldstein, T.C., Ng, S., Gibb, W.J., Wang, N.J., Ziyad, S., Tong, F., Bayani, N., Hu, Z., Billig, J.I., Dueregger, A., Lewis, S., Jakkula, L., Korkola, J.E., Durinck, S., Pepin, F., Guan, Y., Purdom, E., Neuvial, P., Bengtsson, H., Wood, K.W., Smith, P.G., Vassilev, L.T., Hennessy, B.T., Greshock, J., Bachman, K.E., Hardwicke, M.A., Park, J.W., Marton, L.J., Wolf, D.M., Collisson, E.A., Neve, R.M., Mills, G.B., Speed, T.P., Feiler, H.S., Wooster, R.F., Haussler, D., Stuart, J.M., Gray, J.W., Spellman, P.T. (2012) Subtype and pathway specific responses to anticancer compounds in breast cancer. *Proc. Natl. Acad. Sci. USA.*, 109(8):2724-2729. PMC3286973
304. Cheng, K.W., Agarwal, R., Mitra, S., Lee, J.S., Carey, M., Gray, J.W., Mills, G.B. (2012) Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. *EMBO Mol. Med.*, 4(2):125-41. PMC3306554
305. Drake, P.M., Schilling, B., Niles, R.K., Prakobphol, A., Li, B., Jung, K., Cho, W., Braten, M., Inerowicz, H.D., Williams, K., Albertolle, M., Held, J.M., Iacovides, D., Sorensen, D.J., Griffith, O.L., Johansen, E., Zawadzka, A.M., Cusack, M.P., Allen, S., Gormley, M., Hall, S.C., Witkowska, H.E., Gray, J.W., Regnier, F.E., Gibson, B.W., Fisher, S.J. (2012) Lectin chromatography/mass spectrometry discovery workflow identified putative biomarkers of aggressive breast cancers. *J. Proteome Res.*, 11(4):2508-20. PMC3383053
306. Engler, D.A., Gupta, S., Growdon, W.B., Drapkin, R.I., Nitta, M., Sergent, P.A., Allred, S.F., Gross, J., Deavers, M.T., Kuo, W.-L., Karlan, B.Y., Rueda, B.R., Orsulic, S., Gerhenson, D.M., Birrer, M.J., Gray, J.W., Mohapatra, G. (2012) Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. *PLoS One*, 7(2):e30996. PMC3280266
307. Garay, J.P., Gray, J.W. (2012) Omics and therapy - A basis for precision medicine. *Mol. Oncol.*, 6(2):128-39. PMC3779147
308. Hill, S.M., Neve, R.M., Bayani, N., Kuo, W.-L., Ziyad, S., Spellman, P.T., Gray, J.W., Mukherjee, S. (2012) Integrating biological knowledge into variable selection: an empirical Bayes approach with application in cancer biology. *BMC Bioinformatics*, 13(1):94. PMC3503557
309. Akhavan, A., Griffith, O.L., Soroceanu, L., Leonoudakis, D., Luciani-Torres, M.G., Daemen, A., Gray, J.W., Muschler, J.L. (2012) Loss of cell-surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes. *Cancer Res.*, 72(10):2578-88. PMC3354772
310. Mukhtar, R.A., Moore, A.P., Tandon, V.J., Nseyo, O., Twomey, P., Adisa, C.A., Eleweke, N., Au, A., Baehner, F.L., Moore, D.H., McGrath, M.S., Olopade, O.I., Gray, J.W., Campbell, M.J., Esserman, L.J. (2012) Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer. *Ann. Surg. Oncol.*, 19(12):3979-86. PMID: 22622474
311. Collisson, E.A., Trejo, C.L., Gu, S., Korkola, J.E., Heiser, L.M., Charles, R.P., Rabinovich, B.A., Hann, B., Dankort, D., Spellman, P.T., Philips, W.A., Gray, J.W., McMahon, M. (2012) A central role for RAF →MEK →ERK signaling in the genesis of pancreatic ductal adenocarcinoma. *Cancer Discovery*, 2(8):685-93. PMC3425446
312. Esserman, L.J., Berry, D.A., DeMichele, A., Carey, L., Davis, S.E., Buxton, M.B., Hudis, C., Gray, J.W., Perou, C., Yau, C., Livasy, C., Krontiras, H., Montgomery, L., Tripathy, D., Lehman, C., Liu, M.C., Olopade, O.I., Rugo, H.S., Carpenter, J.T., Dressler, L., Chhieng, D., Singh, B., Mies, C., Rabban, J., Chen, Y.Y., Giri, D., van 't Veer, L., Hylton, N. on behalf of the I-SPY 1 TRIAL Investigators. (2012) Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). *J. Clin. Oncol.*, 30(26):3242-9. PMC3434983

313. Littlepage, L.E., Adler, A.S., Kouros-Mehr, H., Huang, G., Chou, J., Krig, S.R., Griffith, O.L., Korkola, J.E., Qu, K., Lawson, D.A., Xue, Q., Sternlicht, M.D., Dijkgraaf, G.J., Yaswen, P., Rugo, H.S., Sweeney, C.A., Collins, C.C., Gray, J.W., Chang, H.Y., Werb, Z. (2012) The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. *Cancer Discov.*, 2(7):638-51. PMC3546490
314. Daemen, A., Wolf, D.M., Korkola, J.K., Griffith, O.L., Frankum, J.R., Brough, R., Jakkula, L.R., Wang, N.J., Natrajan, R., Reis-Filho, J.S., Lord, C.J., Ashworth, A., Spellman, P.T., Gray, J.W., van 't Veer, L.J. (2012) Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. *Breast Cancer Res. Treat.*, 135(2):505-17. PMC3429780
315. Petrillo, L.A., Wolf, D.M., Kapoun, A.M., Wang, N.J., Barczak, A., Xiao, Y., Korkaya, H., Baehner, F., Lewicki, J., Wicha, M., Park, J.W., Spellman, P.T., Gray, J.W., van 't Veer, L., Esserman, L.J. (2012) Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. *Breast Cancer Res. Treat.*, 135(3):913-22. PMC3873871
316. Hill, S.M., Lu Y., Molina, J., Heiser, L.M., Spellman, P.T., Speed, T.P., Gray, J.W., Mills, G.B., Mukherjee, S. (2012) Bayesian inference of signaling network topology in a cancer cell line. *Bioinformatics*, 1;28(21):2804-2810. PMC3476330
317. Snijders, A.M., Marchetti, F., Bhatnagar, S., Duru, N., Han, J. Hu, Z., Mao, J.-H., Gray, J.W., Wyrobek, A.J. (2012) Genetic differences in transcript responses to low-dose ionizing radiation identify tissue functions associated with breast cancer susceptibility. *PLoS One*, 7(10):e45394. PMC3471924
318. Sadanandam, A., Lal, A., Benz, S.C., Eppenberger-Castori S., Scott, G., Gray, J.W., Spellman, P., Waldman, F., Benz, C.C. (2012) Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells? *Breast Cancer Res. Treat.*, 136(3):693-703. PMC3511697
319. McElwee, J.L., Mohanan, S., Griffith, O.L., Breuer, H.C., Anguish, L.J., Cherrington, B.D., Palmer, A.M., Howe, L.R., Subramanian, V., Causey, C.P., Thompson, P.R., Gray, J.W., Coonrod, S.A. (2012) Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. *BMC Cancer*, 12(1):500. PMC3571905
320. Rao, X., Evans, J., Chae, H., Pilrose, J., Kim, S., Yan, P., Huang, R.L., Lai, H.-C., Lin, H., Liu, Y., Miller, D., Rhee, J.-K., Huang, Y.W., Gu, F., Gray, J.W., Huang, Th.-M., Nephew, K.P. (2012) CpG island shore methylation regulates caveolin-1 expression in breast cancer. *Oncogene*, 32(38)4519-4528. PMC3787796
321. Ordinario, E., Han, H.-J., Furuta, S., Heiser, L.M., Jakkula, L.R., Rodier, F., Spellman, P.T., Campisi, J., Gray, J.W., Bissell, M.J., Kohwi, Y., Kohwi-Shigematsu, T. (2012) ATM Suppresses SATB1-induced malignant progression in breast epithelial cells. *PLoS One*, 7(12):e51786. PMC3519734
322. Chang, Y.H., Gray, J.W., Claire Tomlin, C. (2012) Optimization-based inference for temporally evolving networks with applications in biology. *J. Comp. Biology*, 19(12):1307-23. PMC3513986
323. Collisson, E.A., Cho, R.J., Gray, J.W. (2012) What are we learning from the cancer genome? *Nat. Rev. Clin. Oncol.*, 9(11):621-30. PMC4169265
324. Chang, H., Han, J., Borowsky, A.D., Loss, L., Gray, J.W., Spellman, P.T., Parvin, B. (2013) Invariant delineation of nuclear architecture in glioblastoma multiforme for clinical and molecular association. *IEEE Trans. Med. Imaging.*, 32(4):670-82. PMC3728287
325. Verhaak, R., Tamayo, P., Creighton, C.J., Yang, J.Y., Hubbard, D., Zhang, H., Fereday, S., Lawrence, M., Carter, S.L., Mermel, C., Kostic, A.D., Etemadmoghadam, D., Saksena, G., Cibulskis, K., Duraisamy, S., Levanon, K., Sougnez, C., Tsherniak, A., Gomez, S., Onofrio, R.C., Gabriel, S.B., Chin, L., Zhang, N., Spellman, P.T., Zhang, Y., Akbani, R., Hoadley, K.A., Kahn, A., Köbel, M., Huntsman, D.G., Soslowsky, R.A., deFazio, A., Birrer, M.J., Gray, J.W., Weinstein, J.N., Bowtell, D.D., Drapkin, R.I., Mesirov, J., Getz, G., Levine, D.A., Meyerson M. (2013) Prognostically relevant gene expression signatures of high grade serous ovarian carcinoma. *J. Clin. Invest.*, 123(1):517-25. PMC3533304

326. LeBeau, A.M., Duriseti, S., Murphy, S.T., Pepin, F., Hann, B., Gray, J.W., VanBrocklin, H.F., Craik, C.S. (2013) Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. *Cancer Res.*, 73(7):2070–81. PMC3618559
327. Sadanandam, A., Lyssiotis, C.A., Homicsko, K., Collisson, E.A., Gibb, W.J., Wullschleger, S., Ostos, L.C., Lannon, W.A., Grotzinger, C., Del Rio, M., Lhermitte, B., Olshen, A.B., Wiedenmann, B., Cantley, L.C., Gray, J.W., Hanahan, D. (2013) A colorectal cancer classification system that associates cellular phenotype and responses to therapy. *Nat. Med.*, 19(5):619–625. PMC3774607
328. Fan, P., Griffith, O.L., Agboke, F.A., Anur, P., Zou, X., McDaniel, R.E., Creswell, K., Kim, S.H., Katzenellenbogen, J.A., Gray, J.W., Jordan, V.C. (2013) c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. *Cancer Res.*, 73(14):4510-20. PMC3715569
329. Rhee, J.-K., Kim, K., Chae, H., Evans, J., Yan, P., Zhang, B.-T., Gray, J., Spellman, P., Huang, T.H., Nephew, K.P., Kim, S. (2013) Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer. *Nucleic Acids Res.*, 41(18):8464-74. PMC3794600
330. Iacovides, D.C., Johnson, A.B., Wang, N., Boddapati, S., Korkola, J., Gray, J.W. (2013) Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay. *Mol. Cell. Proteomics*, 12(11):3210-20. PMC3820934
331. Fallahi-Sichani, M., Honarnejad, S., Heiser, L.M., Gray, J.W., Sorger, P.K. (2013) Metrics other than potency reveal systematic variation in responses to cancer drugs. *Nat. Chem. Biol.*, 9(11):708-14. PMC3947796
332. Timmerman, L.A., Holton, T., Yuneva, M., Louie, R.J., Padró, M., Daemen, A., Hu, M., Chan, D.A., Ethier, S.P., van 't Veer, L.J., Polyak, K., McCormick, F., Gray, J.W. (2013) Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. *Cancer Cell*, 24(4):450-65. PMC3931310
333. Griffith, O.L., Pepin, F., Enache, O.M., Heiser, L.M., Collisson, E.A., Spellman, P.T., Gray, J.W. (2013) A robust prognostic signature for hormone-positive node-negative breast cancer. *Genome Med.*, 5(10):92. PMC3961800
334. Nan, X., Collisson, E.A., Lewis, S., Huang, J., Tamgüney, T.M., Liphardt, J.T., McCormick, F., Gray, J.W., Chu, S. (2013) Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. *Proc. Natl. Acad. Sci. USA*, 110(46):18519-24. PMC3831949
335. Daemen, A., Griffith, O.L., Heiser, L.M., Wang, N.J., Enache, O.M., Sanborn, Z., Pepin, F., Durinck, S., Korkola, J.E., Griffith, M., Hur, J.S., Huh, N., Chung, J., Cope, L., Fackler, M.J., Umbricht, C., Sukumar, S., Seth, P., Sukhatme, V.P., Jakkula, L.R., Lu, Y., Mills, G.B., Cho, R.J., Collisson, E.A., van 't Veer, L.J., Spellman, P.T., Gray, J.W. (2013) Modeling precision treatment of breast cancer. *Genome Biol.*, 14(10):R110. PMC3937590
336. Lovci, M.T., Ghanem, D., Marr, H., Arnold, J., Gee, S., Parra, M., Liang, T.Y., Stark, T.J., Gehman, L.T., Hoon, S., Massirer, K.B., Pratt, G.A., Black, D.L., Gray, J.W., Conboy, J.G., Yeo, G.W. (2013) Rbfox proteins regulate alternative mRNA splicing via evolutionarily conserved RNA bridges. *Nat. Struct. Mol. Biol.*, 20(12):1434-42. PMC3918504
337. Fan, Y., Ge, N., Wang, X., Sun, W., Mao, R., Bu, W., Creighton, C.J., Zheng, P., Vasudevan, S., An, L., Yang, J., Zhao, Y.J., Zhang, H., Li, X.N., Rao, P.H., Leung, E., Lu, Y.J., Gray, J.W., Schiff, R., Hilsenbeck, S.G., Osborne, C.K., Yang, J., Zhang, H. (2013) Amplification and overexpression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. *J. Pathol.*, 232(1):75-86. PMC3966110
338. Rantala, J., Kwon, S., Korkola, J. and Gray, J.W. (2013) Expanding the diversity of imaging based RNAi screen applications using cell spot microarrays. *Microarrays*, 2:97-114. PMC3073923
339. Wang, Y., Wen, M., Kwon, Y., Xu, Y., Liu, Y., Zhang, P., He, X., Wang, Q., Huang, Y., Jen, K.Y., LaBarge, M.A., You, L., Kogan, S.C., Gray, J.W., Mao, J.H., Wei, G. (2014) CUL4A induces epithelial-

- mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. *Cancer Res.*, 74(2):520-31. PMC3934357
340. Sadanandam, A., Wang, X., Melo, F.d.S.E., Gray, J.W., Vermeulen, L., Hanahan, D., Medema, J.P. (2014) Reconciliation of classification systems defining molecular subtypes of colorectal cancer: Interrelationships and clinical implications. *Cell Cycle*, 13(3):353-7. PMC3956531
341. Costello, J.C., Heiser, L.M., Georgii, E., Gönen, M., Menden, M.P., Wang, N.J., Bansal, M., Ammad-uddin, M., Hintsanen, P., Khan, S.A., Mpindi, J.P., Kallioniemi, O., Honkela, A., Aittokallio, T., Wennerberg, K., NCI DREAM Community, Collins, J.J., Gallahan, D., Singer, D., Saez- Rodriguez, J., Kaski, S., Gray, J.W., Stolovitzky, G. (2014) A community effort to assess and improve drug sensitivity prediction algorithms. *Nat. Biotechnol.* 32(12):1202-12. PMC4547623
342. Draz, M.S., Fang, B. A., Zhang, P., Hu, Z., Gu, S., Weng, K.C., Gray, J.W., Chen, F.F. (2014) Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. *Theranostics*, 4(9): 872-892. PMC4107289
343. Oates, C.J., Dondelinger, F., Bayani, N., Korkola, J., Gray, J.W., Mukherjee, S. (2014) Causal network inference using biochemical kinetics. *Bioinformatics*, 30(17):i468-74. PMC4147905
344. Cope, L.M., Fackler, M.J., Lopez-Bujanda, Z., Wolff, A.C., Visvanathan, K., Gray, J.W., Sukumar, S., Umbricht, C.B. (2014) Do breast cancer cell lines provide a relevant model of the patient tumor methylome? *PLoS One*, 9(8):e105545. PMC4144876
345. Fan, P., Cunliffe, H.E., Griffith, O.L., Agboke, F.A., Ramos, P., Gray, J.W., Jordan, V.C. (2014) Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. *Eur. J. Cancer*, 50(16):2877-86. PMC4210771
346. Fu, X., Creighton, C.J., Biswal, N.C., Kumar, V., Shea, M., Herrera, S., Contreras, A., Gutierrez, C., Wang, T., Nanda, S., Giuliano, M., Morrison, G, Nardone, A., Karlin, K.L., Westbrook, T.F., Heiser, L.M., Spellman, P., Guichard, S.M., Smith, P.D., Davies, B.R., Klinowska, T., Lee, A.L., Mills, G.B, Hilsenbeck, S.G., Gray, J.W., Joshi, A., Osborne, C.K., Schiff, R., Anur, P., Rimawi, M. (2014) Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. *Br. Can. Res.*, 16(5):430. PMC4303114
347. Leonoudakis, D., Huang, G., Akhavan, A., Fata, J.E., Singh, M., Gray, J.W., Muschler, J.L. (2014) Endocytic trafficking of laminin is controlled by dystroglycan and disrupted in cancers. *J. Cell Sci.*, 127(22):4894-903. PMC4231305
348. Sadanandam, A., Gray, J.W., Hanahan D. (2014) Reply to colorectal cancer classification based on gene expression is not associated with FOLFIRI response. *Nat Med.*, 20(11):1231-2. PMID: 25375919
349. Bansal, M., Yang, J., Karan, C., Menden, M.P., Costello, J.C., Tang, H., Xiao, G., Li, Y., Allen, J., Zhong, R., Chen, B., Kim, M., Wang, T., Heiser, L.M., Realubit, R., Mattioli, M., Alvarez, M.J., Shen, Y.; NCI-DREAM Community, Gallahan, D., Singer, D., Saez-Rodriguez, J., Xie, Y., Stolovitzky, G., Califano, A.; NCI-DREAM Community. (2014) A community computational challenge to predict the activity of pairs of compounds. *Nat. Biotechnol.*, 32(12):1213-22. PMC4399794
350. Zheng, C.L., Wang, N.J., Chung, J., Moslehi, H., Sanborn, J.Z., Hur, J.S., Collisson, E.A., Vemula, S.S., Naujokas, A., Chiotti, K.E., Cheng, J.B., Fassihi, H., Blumberg, A.J., Bailey, C.V., Fudem, G.M., Mihm, F.G., Cunningham, B.B., Neuhaus, I.M., Liao, W., Oh, D.H., Cleaver, J.E., LeBoit, P.E., Costello, J.F., Lehmann, A.R., Gray, J.W., Spellman, P.T., Arron, S.T., Huh, N., Purdom, E., Cho, R.J. (2014) Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes. *Cell Rep.*, 9(4):1228-34. PMC4254608
351. Chaluvally-Raghavan, P., Zhang, F., Pradeep, S., Hamilton, M.P., Zhao, X., Rupaimoole, R., Moss, T., Lu, Y., Yu, S., Pecot, C.V., Aure, M.R., Peuket, S., Rodriguez-Aguayo, C., Han, H.D., Zhang, D., Venkatanarayan, A., Krohn, M., Kristensen, V.N., Gagea, M., Ram, P., Liu, W., Lopez-Berestein, G.,

- Lorenzi, P.L., Børresen-Dale, A.L., Chin, K., Gray, J.W., Dusetti, N.J., McGuire, S.E., Flores, E.R., Sood, A.K., Mills, G.B. (2014) Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. *Cancer Cell*, 26(6):863-79. PMC4261159
352. Chang, Y.H., Gray, J.W., Tomlin, C.J. (2014) Exact reconstruction of gene regulatory networks using compressive sensing. *BMC Bioinformatics*, 15(1):400. PMC4308013
353. Chang, Y.H., Korkola, J., Amin, D.N., Moasser, M.M., Carmena, J.M., Gray, J.W., Tomlin, C.J. (2015) Disentangling multidimensional spatio-temporal data into their common and aberrant responses. *PLoS One*, 10(4):e0121607. PMC4406848
354. Daemen, A., Griffith, O.L., Heiser, L.M., Wang, N.J., Enache, O.M., Sanborn, Z., Pepin, F., Durinck, S., Korkola, J.E., Griffith, M., Hur, J.S., Huh, N., Chung, J., Cope, L., Fackler, M.J., Umbricht, C., Sukumar, S., Seth, P., Sukhatme, V.P., Jakkula, L.R., Lu, Y., Mills, G.B., Cho, R.J., Collisson, E.A., van 't Veer, L.J., Spellman, P.T., Gray, J.W. (2015) Erratum to: Modeling precision treatment of breast cancer. *Genome Biol.*, 16(1):95. PMC4426644
355. Giuliano, M., Hu, H., Wang, Y.C., Fu, X., Nardone, A., Herrera, S., Mao, S., Contreras, A., Gutierrez, C., Tao, W., Hilsenbeck, S.G., De Angelis, C., Wang, N.J., Heiser, L., Gray, J.W., Lopez-Tarruella, S., Pavlick, A., Trivedi, M.V., Chamness, G.C., Chang, J.C., Osborne, C.K., Rimawi, M.F., Schiff, R. (2015) Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. *Clin. Cancer Res.*, 21(17):3995-4003. PMC4558260
356. Nan, X., Tamgüney, T.M., Collisson, E.A., Lin, L.J., Pitt, C., Galeas, J., Lewis, S., Gray, J.W., McCormick, F., Chu, S. (2015) Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. *Proc. Natl. Acad. Sci. USA*, 112(26):7996-8001. PMC4491781
357. Ngamcherdrakul, W., Morry, J., Gu, S., Castro, D.J., Goodyear, S.M., Sangvanich, T., Reda, M.M., Lee, R., Mihelic, S.A., Beckman, B.L., Hu, Z., Gray, J.W., Yantasee, W. (2015) Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to her2+ breast cancer. *Adv. Funct. Mater.*, 25(18):2646-2659. PMC4469082
358. Korkola, J.E., Collisson, E.A., Heiser, L., Oates, C., Bayani, N., Itani, S., Esch, A., Thompson, W., Griffith, O.L., Wang, N.J., Kuo, W.L., Cooper, B., Billig, J., Ziyad, S., Hung, J.L., Jakkula, L., Feiler, H., Lu, Y., Mills, G.B., Spellman, P.T., Tomlin, C., Mukherjee, S., Gray, J.W. (2015) Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2+ breast cancer. *PLoS One*, 10(7):e0133219. PMC4504492
359. Goodspeed, A., Heiser, L.M., Gray, J.W., Costello, J.C. (2016) Tumor-derived cell lines as molecular models of cancer pharmacogenomics. *Mol. Cancer Res.*, 14(1):3-13. PMC4828339
360. Sanborn, J.Z., Chung, J., Purdom, E., Wang, N.J., Kakavand, H., Wilmott, J.S., Butler, T., Thompson, J.F., Mann, G.J., Haydu, L.E., Saw, R.P., Busam, K.J., Lo, R.S., Collisson, E.A., Hur, J.S., Spellman, P.T., Cleaver, J.E., Gray, J.W., Huh, N., Murali, R., Scolyer, R.A., Bastian, B.C., Cho, R.J. (2015) Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. *Proc. Natl. Acad. Sci. USA*, 112(35):10995-1000. PMC4568214
361. Butler, T.M., Johnson-Camacho, K., Peto, M., Wang, N.J., Macey, T.A., Korkola, J.E., Koppie, T.M., Corless, C.L., Gray, J.W., Spellman, P.T. (2015) Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease. *PLoS One*, 10(8):e0136407. PMC4552879
362. Shain, A.H., Garrido, M., Botton, T., Talevich, E., Yeh, I., Sanborn, J.Z., Chung, J., Wang, N.J., Kakavand, H., Mann, G.J., Thompson, J.F., Wiesner, T., Roy, R., Olshen, A.B., Gagnon, A., Gray, J.W., Huh, N., Hur, J.S., Busam, K.J., Scolyer, R.A., Cho, R.J., Murali, R., Bastian, B.C. (2015) Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. *Nat Genet.*, 47(10):1194-9. PMC4589486
363. Gray, J.W., and Mills, G.B. (2015) Large-scale drug screens support precision medicine. *Cancer Discov.* 5(11):1130-2. PMC4633700

364. Gu S, Hu Z, Ngamcherdtrakul, W., Castro, D.J., Morry, J., Reda, M.M., Gray, J.W., Yantasee, W. (2016) Therapeutic siRNA for drug-resistant HER2-positive breast cancer. *Oncotarget*. 7(12):14727-41. PMC4924747
365. Hill, S.M., Heiser, L.M., Cokelaer, T., Unger, M., Nesser, N.K., Carlin, D.E., Zhang, Y., Sokolov, A., Paull, E.O., Wong, C.K., Graim, K., Bivol, A., Wang, H., Zhu, F., Afsari, B., Danilova, L.V., Favorov, A.V., Lee, W.S., Taylor, D., Hu, C.W., Long, B.L., Noren, D.P., Bisberg, A.J.; HPN-DREAM Consortium, Mills, G.B., Gray, J.W., Kellen, M., Norman, T., Friend, S., Qutub, A.A., Fertig, E.J., Guan, Y., Song, M., Stuart, J.M., Spellman, P.T., Koepl, H., Stolovitzky, G., Saez-Rodriguez, J., Mukherjee, S. (2016) Inferring causal molecular networks: empirical assessment through a community-based effort *Nat. Methods*. (4):310-8. PMC4854847
366. Ngamcherdtrakul, W., Castro, D.J., Gu, S., Morry, J., Reda, M., Gray, J.W., Yantasee, W. (2016) Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. *Cancer Treat Rev*. 45:19-29. PMC4826844
367. Guest, S.T., Kratche, Z.R., Irish, J.C., Wilson, R.C., Haddad, R., Gray, J.W., Garrett-Mayer, E., Ethier, S.P. (2016) Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. *Oncotarget*. 7(24):36138-36153. PMC5094989
368. Hu, Z., Mao, J.-H., Curtis, C., Huang, G., Gu, S., Heiser, L., Lenburg, M.E., Korkola, J.E., Bayani, N., Samarajiva, S., Seoane, JA, Dane M.A., Esch, A., Feiler, H.S., Wang, N.J., Hardwicke, M.A., Laquerre, S., Jackson, J., Wood, K.W., Weber, B., Spellman, P.T., Aparicio, S., Wooster, R., Caldas, C., Gray, J.W. (2016) Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. *Breast Cancer Res*. 18(1):70. PMC4930593
369. Jacob, T., Gray, J.W., Troxell, M., Vu, T.Q. (2016) Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype. *Breast Cancer Res Treat*. 159(3):575-83. PMID: 27581127
370. Bruna, A., Rueda, O.M., Greenwood, W., Batra, A.S., Callari, M., Batra, R.N., Pogrebniak, K., Sandoval, J., Cassidy, J.W., Tufegdizic-Vidakovic, A., Sammut, S.-J., Jones, L., Provenzano, E., Baird, R., Eirew, P., Hadfield, J., Eldridge, M., McLaren-Douglas, A., Barthorpe, A., Lightfoot, H., O'Connor, M.J., Gray, J., Cortes, J., Baselga, J., Marangoni, E., Welm, A.L., Aparicio, S., Serra, V., Garnett, M.J., and Caldas, C. (2016) A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. *Cell*, 167(1): 260–274.e22. PMC5037319
371. Campbell, M.J., Baehner, F., O'Meara, T., Ojukwu, E., Han, B., Mukhtar, R., Tandon, V., Endicott, M., Zhu, Z., Wong, J., Krings, G., Au, A., Gray, J.W., Esserman, L. (2016) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. *Breast Cancer Res. Treat*. 161(1):17-28. PMC5225037
372. Fu, X., Jeselsohn, R., Pereira, R., Hollingsworth, E.F., Creighton, C.J., Li, F., Shea, M., Nardone, A., De Angelis, C., Heiser, L.M., Anur, P., Wang, N., Grasso, C.S., Spellman, P.T., Griffith, O.L., Tsimelzon, A., Gutierrez, C., Huang, S., Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff R. (2016) FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. *Proc. Natl. Acad. Sci. USA* 113(43):E6600-E6609. PMC5087040
373. Chang, Y.H., Dobbe, R., Bhushan, P., Gray, J.W., Tomlin, C.J. (2016) Reconstruction of gene regulatory networks based on repairing sparse low-rank matrices. *IEEE/ACM Trans. Comput. Biol. Bioinform*. (4):767-777 PMC5154690
374. Hill, S.M., Nesser, N.K., Johnson-Camacho, K., Jeffress, M., Johnson, A., Boniface, C., Spencer, S.E., Lu, Y., Heiser, L.M., Lawrence, Y., Pande, N.T., Korkola, J.E., Gray, J.W., Mills, G.B., Mukherjee, S., Spellman, P.T. (2016) Context specificity in causal signaling networks revealed by phosphoprotein profiling. *Cell Syst*. S2405-4712(16)30408-2. PMC5279869

375. Chang, Y.H., Azimi, V., Johnson, B., Jorgens, D., Link, J., Margolin, A., Gray, J.W., Chang, Y.H., Thibault, G. (2016) Quantitative analysis of histological tissue image based on cytological profiles and spatial statistics. *Conf. Proc. IEEE Eng. Med. Biol. Soc.* 1175-1178. PMID: 28324942
376. Gendelman, R., Xing, H., Mirzoeva, O.K., Sarde, P., Curtis, C., Feiler, H., McDonagh, P., Gray, J.W., Khalil, I., Korn, W.M. (2017) Bayesian network inference modeling identifies TRIB1 as a novel regulator of cell cycle progression and survival in cancer cells. *Cancer Res.* 77(7):1575-1585. PMC5410377
377. Morry, J., Ngamcherdtrakul, W., Gu, S., Reda, M., Castro, D.J., Sangvanich, T., Gray, J.W., Yantasee, W. (2017) Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform. *Mol. Cancer Ther.* 16(4):763-772. PMID: 28138033
378. Sears, R., Gray JW. (2017) Epigenomic Inactivation of RasGAPs Activates RAS Signaling in a Subset of Luminal B Breast Cancers. *Cancer Discov.* 7(2):131-133. PMC5312830
379. Hu, Z., Mao, J.-H., Curtis, C., Huang, G., Gu, S., Heiser, L., Lenburg, M.E., Korkola, J.E., Bayani, N., Samarajiwa, S., Seoane, J.A., Dane, M.A., Esch, A., Feiler, H.S., Wang, N.J., Hardwicke, M.A., Laquerre, S., Jackson, J., Wood, K.W., Weber, B., Spellman, P.T., Aparicio, S., Wooster, R., Caldas, C., Gray, J.W. (2017) Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. *Breast Cancer Res.* 19(1):17. PMC5301377
380. Tsujikawa, T., Kumar, S., Borkar, R.N., Azimi, V., Thibault, G., Chang, Y.H., Balter, A., Kawashima, R., Choe, G., Sauer, D., El Rassi, E., Clayburgh, D.R., Kulesz-Martin, M.F., Lutz, E.R., Zheng, L., Jaffee, E.M., Leyshock, P., Margolin, A.A., Mori, M., Gray, J.W., Flint, P.W., Coussens, L.M. (2017) Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. *Cell Rep.* 19(1):203-217. NIHMS861493
381. Rahman, M., MacNeil, S.M., Jenkins, D.F., Shrestha, G., Wyatt, S.R., McQuerry, J.A., Piccolo, S.R., Heiser, L.M., Gray, J.W., Johnson, W.E., Bild, A.H. (2017) Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes. *Genome Med.* 9(1):40. PMC5406893
382. Xu, X., De Angelis, C., Burke, K.A., Nardone, A., Hu, H., Qin, L., Veeraraghavan, J., Sethunath, V., Heiser, L.M., Wang, N.J., Ng, C.K.Y., Chen, E., Renwick, A., Wang, T., Nanda, S., Shea, M., Mitchell, T., Rajendran, M., Waters, I., Zabransky, D.J., Scott, K.L., Gutierrez, C., Nagi, C., Geyer, F.C., Chamness, G.C., Park, B.H., Shaw, C., Hilsenbeck, S.G., Rimawi, M.F., Gray, J.W., Weigelt, B., Reis-Filho, J.S., Osborne, C.K., Schiff, R. (2017) HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer. *Clin. Cancer Res.* [Epub ahead of print] PMID: 28487443

Books and Monographs

1. Gray, J.W. and Mayall, B. Monoclonal Antibodies Against Bromodeoxyuridine, Alan R. Liss, 1985.
2. Gray, J.W. and Darzynkiewicz, Z. Techniques in Cell Cycle Analysis, Humana Press, 1987.
3. Gray, J.W. Flow Cytogenetics, Academic Press, Inc.: San Diego, CA, 1989.
4. Gray, J.W. and van der Ploeg, M., Analytical Cytogenetics, Wiley-Liss, 1989.
5. Nishiya, I., Cram, L.S., Gray, J.W. Flow Cytometry and Image Analysis, Excerpta Medica: New York, 1991.
6. Mendelsohn, J., Howley, P.M., Israel, M.A., Gray, J.W., Thompson, C.B. The Molecular Basis of Cancer, 3rd Edition, Saunders / Elsevier: Philadelphia, PA, 2008.
7. Mendelsohn, J., Howley, P.M., Israel, M.A., Gray, J.W., Thompson, C.B. The Molecular Basis of Cancer, 4th Edition, Saunders / Elsevier: Philadelphia, PA, 2014.

Invited Articles and Reviews

1. Van Dilla, M.A., Gray, J.W., Carrano, A.V., Minkler, J.L., Steinmetz, L.L. (1976) New directions for flow cytometry: Chromosome analysis. In: *Pulse Cytometry*, pp. 57-62. European Press: Ghent, Belgium
2. Gehring, U., Gray, J.W., Tomkins, G.M. (1976) Corticosteroid effect on the cell cycle. In: *Pulse Cytophotometry*, pp. 284-9. European Press: Ghent, Belgium
3. Heby, O., Marton, L.J., Gray, J.W., Lindl, P.A., Wilson, C.B. (1976) Polyamine metabolism in synchronously growing mammalian cells. In: *Proc. 9th Cong. of the Nordic Society for Cell Biology* (F. Bierring, ed.), pp. 155-64. Odense University Press
4. Coffino, P., Gray, J.W., Lemaire, I., Insel, P.A. (1976) Growth regulation of cyclic AMP in mouse lymphoma cells. In: *Cyclic Nucleotides and Regulation of Cell Growth* (M. Abov-Save, ed.), Part V, pp. 267-77. Dowden, Hutchinson and Ross, Inc.: Stroudsburg, PA
5. Van Dilla, M.A., Carrano, A.V., Gray, J.W. (1976) Flow karyotyping current status and potential development. In: *Automation of Cytogenetics*, pp. 145-64. Asilomar Workshop, Nov. 30 - Dec. 1, 1975. ERDA Conf-751158
6. Gray, J.W., Dean, P.N., Mendelsohn, M.L. (1977) Quantitative cell cycle analysis: Flow cytometry and sorting. In: *Flow Cytometry and Sorting* (M.L. Mendelsohn, P. Mullaney, and M. Melamed, eds.), pp. 383-407. John Wiley & Sons: New York
7. Mendelsohn, M.L., Carrano, A.V., Gray, J.W., Mayall, B.H., Van Dilla, M.A. (1977) Image analysis, flow fluorometry and flow sorting of mammalian chromosomes. In: *Molecular Biology of the Mammalian Genetic Apparatus* (P. Ts'o, ed.), Ch. 17, pp. 191-204. Elsevier North-Holland Biomedical Press
8. Carrano, A.V., Gray, J.W., Van Dilla, M.A. (1977) Flow cytogenetics: Progress toward chromosomal aberration detection. In: *Proceedings of the Symposium on Actions of Physical and Chemical Mutagens on the Somatic Chromosomes of Man*, pp. 326-38. Edinburgh Univ. Press
9. Heby, O., Andersson, G., Gray, J.W., Marton, L.J. (1978) Accumulation of rat brain tumor cells in G1 and of ehrlich ascites tumor cells in G2 by partial deprivation of cellular polyamine content. In: *Advances in Polyamine Research* (R.A. Campbell, et al., eds.), 1:127-31. Raven Press: New York
10. Pallavicini, M.G., Cohen, A.M., Dethlefsen, L.A., Gray, J.W. (1978) Dispersal of solid tumors for flow cytometer (fcm) analysis. In: *Pulse Cytophotometry III* (D. Lutz, ed.), pp. 473-82. European Press: Ghent, Belgium
11. Carrano, A.V., Van Dilla, M.A., Gray, J.W. (1979) Flow cytogenetics: A new approach to chromosome analysis. In: *Flow Cytometry and Sorting* (M.L. Mendelsohn, P. Mullaney, and M. Melamed, eds.), pp. 421-51. John Wiley & Sons: New York
12. Gray, J.W. and Coffino, P. (1979) Cell cycle analysis by flow cytometry. In: *Methods of Enzymology* (W.B. Jakoby and I.H. Pastan, eds.), pp. 233-47. Academic Press: New York
13. Hoshino, T., Gray, J.W., Nomura, K. (1979) Flow cytometry of isolated nuclei prepared from 9l rat brain tumor. In: *Laboratory Investigations*, 41(1):72-6. William & Wilkins Publishers: Baltimore, MD
14. Baisch, H., Beck, H.-P., Christensen, I.J., Hartmann, N.R., Fried, J.R., Dean, P. N., Gray, J.W., Jett, J.H., Johnston, D.A., White, R.A., Nicolini, C., Zietz, S., Watson, J.V. (1979) A comparison of evaluation methods for DNA histograms measured by flow cytometry. In: *Flow Cytometry IV* (O. Laerum, T. Lindmo, and E. Thorud, eds.), pp. 152-5. Universitetsforlaget: Bergen, Norway
15. Gray, J.W. and Dean, P.N. (1980) Display and analysis of flow cytometric data. *Ann. Rev. Biophys. Bio.*, 9:509-39
16. Gray, J.W. (1980) Using cell-cycle kinetics to improve cancer therapy. In: *Energy and Technology Review*, July, Lawrence Livermore National Laboratory Report 52000-80-7, pp. 10-16

17. Gray, J.W. (1980) Flow cytometry and cell kinetics: Relation to cancer therapy. In: Flow Cytometry IV (O.D. Laerum, T. Lindmo, and E. Thorud, eds.), pp. 485-91. Universitetsforlaget: Bergen, Norway
18. Gray, J.W., Lucas, J.N., Pinkel, D., Peters, D., Ashworth, L., Van Dilla, M.A. (1980) Slit scan flow cytometry: Analysis of Chinese hamster M3-1 chromosomes. In: Flow Cytometry IV (O.D. Laerum, T. Lindmo, and E. Thorud, eds.), pp. 249-55. Universitetsforlaget: Bergen, Norway
19. Gray, J.W. (1980) Rapid quantitative cell cycle parameter estimation by rc analysis. *Medical Tribune*, 2:17-20
20. Gray, J.W. and Pallavicini, M.G. (1981) Quantitative cytogenetic analysis reviewed. In: *Biomathematics and Cell Kinetics* (M. Rotenburg, ed.), pp. 107-23. Proceedings of Workshop at Asilomar, CA, Mar. 4-6, 1981. Elsevier/North-Holland Biomedical Press: Amsterdam
21. Lucas, J.N. and Gray, J.W. (1982) Slit-scan flow cytometry: A promising new cytogenetic tool. In: *Energy and Technology Review*, pp. 26-31. Lawrence Livermore National Laboratory Report, UCRL 52000-82-4
22. Gray, J.W., Carrano, A.V., Langlois, R., Lucas, J., Yu, L.-C., Van Dilla, M.A. (1982) Flow cytogenetics: Chromosome classification and purification by flow cytometry and sorting. In: *The Future of Prenatal Diagnosis* (H. Galjaard, ed.), pp. 33-40. Churchill Livingstone, Robert Stevenson House: Edinburgh, UK
23. Gray, J.W. and Pallavicini, M.G. (1982) Ara-C scheduling: Theoretical and experimental considerations. *Med. Pediatr. Oncol.*, 10(S1):93-108
24. Pallavicini, M.G. and Gray, J.W. (1982) Ara-C cytokinetic studies in normal tissues in vivo. *Med. Pediatr. Oncol.*, 10(S1):109-23
25. Carrano, A.V., Gray, J.W., Langlois, R.G., Yu, L.-C. (1983) Flow cytogenetics: Methodology and applications. Chapter 11 in: *Chromosomes and Cancer* (J.D. Rowley, J.E. Ulmann, and M. Gordon, eds.), pp. 195-209. Academic Press Inc.: New York
26. Gray, J.W. (1983) Quantitative cytogenetics: Cellular response to cell cycle specific agents. *Pharmacol. Ther.*, 22(2):163-97
27. Peters, D.C. and Gray, J.W. (1984) High-speed cell sorting: A tenfold increase in sorting rate. *Energy and Technology Review*, March, pp. 13-21
28. Yu, L.-C., Gray, J.W., Langlois, R., Van Dilla, M.A., Carrano, A.V. (1984) Human chromosome karyotyping and molecular biology by flow cytometry. In: *Research Perspectives in Cytogenetics* (R.S. Sparks and F.F. de la Cruz, eds.), pp. 63-74. University Park Press: Baltimore, MD
29. Gray, J.W., Lucas, J., Yu, L.-C., Langlois, R. (1984) Flow cytometric detection of aberrant chromosomes. In: *Biological Dosimetry: Cytometric Approaches to Mammalian Systems* (W.G. Eisert and M.L. Mendelsohn, eds.), pp. 25-35. Springer Verlag: Heidelberg
30. Cram, L.S., Bartholdi, M., Wheelless, L., Gray, J.W. (1985) Morphological analysis by scanning flow cytometry. In: *Progress in Flow Cytometry*, pp. 164-94. Academic Press: New York
31. Gray, J.W. and Langlois, R.G. (1986) Chromosome classification and purification using flow cytometry and sorting. *Ann. Rev. Biophys. Biophys. Chem.*, 15:195-235
32. Pallavicini, M.G., Summers, L.J., Matsson, P.N., Dolbear, F., Gray, J.W. (1986) Flow cytometric analyses of heterogeneous tissues in vivo. In: *Biological Regulation of Cell Proliferation* (R. Baserga, P. Foa, D. Metcalf, and E.E. Polli, eds.), 34:353-61. Ares-Serono Symposium Proceedings
33. Gray, J.W., Dolbear, F., Pallavicini, M.G., Vanderlaan, M. (1987) Flow cytogenetics. In: *Techniques in Cell Cycle Analysis* (J.W. Gray and Z. Darzynkiewicz, eds.), pp. 93-137. Humana Press, Inc.: Clifton, NJ
34. Gray, J.W., Lucas, J., Peters, D., Pinkel, D., Trask, B., van den Engh, G., Van Dilla, M. (1987) Flow karyotyping and sorting of human chromosomes. *Cold Spring Harb. Symp. Quant. Biol.*, 51 Pt 1:141-9

35. Deaven, L.L., Van Dilla, M.A., Bartholdi, M.F., Carrano, A.V., Cram, L.S., Fuscoe, J.C., Gray, J.W., Hildebrand, C.E., Moyzis, R.K., Perlman, J. (1986) Construction of human chromosome-specific DNA libraries from flow sorted chromosome. *Cold Spring Harb. Symp. Quant. Biol.*, 51 Pt 1:159-68
36. Pinkel, D., Gray, J.W., Trask, B., van den Engh, G., Fuscoe, J., van Dekken, H. (1986) Cytogenetic analysis by in situ hybridization with fluorescently labeled nucleic acid probes. *Cold Spring Harb. Symp. Quant. Biol.*, 51 Pt 1:151-7
37. Gray, J.W., Lucas, J., Straume, T., Pinkel, D. (1987) Analytical cytology applied to detection of induced cytogenetic abnormalities. In: *Radiation Research, Proc. 8th Int. Cong. Rad. Res.*, Edinburgh, July 1987 (E.M. Fielden, J.F. Fowler, J.H. Hendry, and D. Scott, eds.), 2:574-9. Taylor & Francis: London
38. Gray, J.W., Pinkel, D., Trask, B., van den Engh, G., Pallavicini, M., Fuscoe, J., Mullikin, J., van Dekken, H. (1989) Analytical cytology applied to detection of prognostically important cytogenetic aberrations: Current status and future directions. In: *Tumor Treatment Response* (J.D. Chapman, L.J. Peters, and H.R. Withers, eds.), pp. 111-26. Pergamon Press
39. Gray, J.W. and van den Engh, G. (1989) Instrumentation for chromosome analysis and sorting. In: *Flow Cytogenetics* (J.W. Gray, ed.), pp. 17-34
40. Van Dilla, M.A., Deaven, L.L., Albright, K.L., Allen, N.A., Bartholdi, M.F., Brown, N.C., Campbell, E.W., Carrano, A.V., Christensen, M., Clark, L.M., Cram, L.S., Dean, P.N., de Jong, P., Fawcett, J.J., Fuscoe, J.C., Gray, J.W., Hildebrand, C.E., Jackson, P.J., Jett, J.H., Killa, S., Longmire, J.L., Lozes, C.R., Luedemann, M.L., McNinch, J.S., Mendelsohn, M.L., Meyne, J., Meincke, L.J., Moyzis, R.K., Mullikin, J., Munk, A.C., Perlman, J., Pederson, L., Peters, D.C., Silva, A.J., Trask, B.J., van den Engh, G. (1989) The national laboratory gene library project. In: *Flow Cytogenetics* (J.W. Gray, ed.), pp. 257-74. Academic Press
41. Gray, J.W., Pinkel, D., Trask, B., van den Engh, G., Seagraves, R., Collins, C., Andreeff, M., Haimi, J., Perle, M.A. (1988) Application of flow karyotyping and fluorescence in situ hybridization to detection of chromosome aberrations. In: *Proceedings of the Prouts Neck Symposium Cytopathology/Flow Cytometry and Prognostic Indicators of Prostate Cancer* (J. Kerr, D. Coffee, and W. Gardiner, eds.), pp. 304-13
42. Gray, J.W., Trask, B., van den Engh, G. (1989) Bivariate flow karyotyping. In: *Flow Cytogenetics* (J.W. Gray, ed.), pp. 137-50
43. Gray, J.W. (1989) Quantitative cytogenetics: Cellular response to cell cycle specific agents. *Pharmacol. Ther.*, 22(2):163-97
44. Van Dilla, M.A., Dean, P.N., Fuscoe, J.C., Gray, J.W., Lucas, J.N., Peters, D.C., Trask, B.J., van den Engh, G.J. (1989) Flow cytometric analysis and sorting of chromosomes. Chapter 13 in: *New Trends in Genetic Risk Assessment* (G.J. Jolles and A. Cordier, eds.), pp. 225-45. Academic Press
45. Lucas, J.N., Tenjin, T., Straume, T., Pinkel, D., Gray, J.W. (1989) Rapid detection of human chromosome aberrations using fluorescence in situ hybridization. In: *Multilevel Health Effects Research: From Molecules to Man* (J.F. Park and R.A. Pelroy, eds.), pp. 149-55. Battelle Press: Richland, WA
46. Gray, J.W., Dolbeare, F., Pallavicini, M. (1990) Quantitative cell-cycle analysis. In: *Flow Cytometry and Sorting* (M. Melamed, T. Lindmo, and M. Mendelsohn, eds.), pp. 445-68
47. Gray, J.W. and Cram, S. (1990) Flow karyotyping and sorting. Chapter in: *Flow Cytometry and Cell Sorting, 2nd Edition* (J.W. Gray and Z. Darzynkiewicz, eds.), pp. 503-29
48. Gray, J.W., Trask, B., van den Engh, G. (1989) Bivariate flow karyotyping. Chapter in: *Flow Cytogenetics* (J.W. Gray and Z. Darzynkiewicz, eds.), pp. 137-50
49. Gray, J.W., Kuo, W.-L., Liang, J., Pinkel, D., van den Engh, G., Trask, B., Tkachuk, D., Waldman, F., Westbrook, C. (1990) Analytical approaches to detection and characterization of disease-linked chromosome aberrations. *Bone Marrow Transplant*, 6 Suppl 1:14-9

50. Dolbeare, F., Kuo, W.-L., Beisker, W., Vanderlaan, M., Gray, J.W. (1990) Using monoclonal antibodies in bromodeoxyuridine-DNA analysis. Chapter in: *Methods in Cell Biology: Flow Cytometry* (Z. Darzynkiewicz and H.A. Crissman), 33:207-16
51. Weier, H.-U., Reitsma, M., Gray, J.W. (1990) Detection of fetal cells by in vitro amplification. In: *Advances in Analytical Cellular Pathology* (G. Burger, M. Oberholzer, and P. Vooijs, eds.), pp. 105-6. Excerpta Medica: New York
52. Gray, J.W., Kuo, W.-L., Lucas, J., Pinkel, D., Weier, H.-U., Yu, L.-C. (1991) Molecular cytogenetics using fluorescence in situ hybridization. In: *Flow Cytometry and Image Analysis* (I. Nishiya, L.S. Cram, and J.W. Gray, eds.) pp. 73-82. Excerpta Medica: New York
53. Tkachuk, D.C., Pinkel, D., Kuo, W.-L., Weier, H.-U., Gray, J.W. (1991) Clinical applications of fluorescence in situ hybridization. *Genet. Anal. Tech. Appl.*, 8(2):67-74. PMID: 2064821
54. Gray, J.W., Lucas, J., Kallioniemi, O., Kallioniemi, A., Kuo, W.-L., Straume, T., Tkachuk, D., Tenjin, T., Weier, H.-U., Pinkel, D. (1991) Applications of fluorescence in situ hybridization in biological dosimetry and detection of disease-specific chromosome aberrations. *Prog. Clin. Biol. Res.*, 372:399-411
55. Gray, J.W., Kuo, W.-L., Pinkel, D. (1991) Molecular cytometry applied to detection and characterization of disease-linked chromosome aberrations. In: *Bailliere's Clinical Hematology: Minimal Residual Disease in Leukemia* (S. J. Proctor, ed.), 4(3):683-93
56. Gray, J.W. (1991) Instrumentation is the key to mapping, sequencing. *Hum. Genome News*, 3:1-4
57. Gray, J.W., Awa, A., Kallioniemi, A., Kallioniemi, O., Kuo, W.-L., Lucas, J., Matsumura, K., Pinkel, D., Sakamoto, M., Straume, T., Vooijs, M., Waldman, F. (1992) Molecular cytogenetics approaches to biological dosimetry and to characterization of specific genetics changes in human tumors. In: *Radiation Research II* (W. Dewey, M. Edington, M. Fry, E. Hall, and G. Whitmore, eds.), pp. 166-71. Academic Press: New York
58. Pinkel, D., Sakamoto, M., Matsumura, K., Kallioniemi, A., Kallioniemi, O., Waldman, F., Gray, J.W. (1992) Application of fluorescence in situ hybridization to detection of chromosomal aberrations. *Cytometry Res.*, 2:1-11
59. Awa, A.A., Nakano, M., Ohtaki, K., Kodama, Y., Lucas, J., Gray, J.W. (1992) Factors that determine the in vivo dose-response relationship for stable chromosome aberrations in A-bomb survivors. *J. Radiat. Res.*, 33 Suppl:206-14. PMID: 1507170
60. Gray, J.W., Lucas, J., Pinkel, D., Awa, A. (1992) Molecular cytogenetics and biological dosimetry. *Proceedings of the National Council on Radiation Protection and Measurements. Proceedings No. 13, Genes, Cancer and Radiation Protection* (M.L. Mendelsohn, ed.), pp. 111-20. NCRPM: Bethesda, MD
61. Gray, J.W. and Pinkel, D. (1992) Molecular cytogenetics in human cancer diagnosis. *Cancer*, 69(S6):1536-42. PMID: 1540892
62. Gray, J.W., Lucas, J.N., Pinkel, D., Awa, A. (1992) Structural chromosome analysis by whole chromosome painting for assessment of radiation-induced genetic damage. *J. Radiat. Res.*, 33 Suppl:80-6. PMID: 1380556
63. Gray, J.W. (1993) Molecular cytogenetic analysis of human tumors. *Ann. NY Acad. Sci.*, 677:194-8. PMID: 8494208
64. Kallioniemi, O.-P., Kallioniemi, A., Sudar, D., Rutovitz, D., Gray, J.W., Waldman, F., Pinkel, D. (1993) Comparative genomic hybridization: A rapid new method for detecting and mapping DNA amplification in tumors. *Semin. Cancer Biol.*, 4(1):41-46. PMID: 8448377
65. Gray, J.W. and Pallavicini, M.G. (1993) Molecular cytogenetics: Solid tumors and leukemia. *Blood Cells*, 19(3):677-83. PMID: 8018948

66. Gray, J.W., Waldman, F., Pinkel, D. (1994) Molecular cytogenetic approaches to early cancer detection. In: *Early Detection of Cancer: Molecular Markers* (S. Srivastava, S.M. Lippman, and W.K. Hong, eds.), pp. 155-61. Futura Publishing: Armonk, New York
67. Gray, J.W., Pinkel, D., Brown, J.M. (1994) Fluorescence in situ hybridization in cancer and radiation biology. *Radiat. Res.*, 137(3):275-89. PMID: 8146269
68. Collins, F.S., Benjamin L.J., Botstein, D., Cox, J.R., Davidson, N., Gray, J.W., Holtzman, N.A., Houseman, D.E., Jamison, K.R., Nelkin, D., Rothstein, R., Smith, D.C., Smith, L.M., Spence, M.A., Tilghman, S.M. (1994) Statement on use of DNA testing for presymptomatic identification of cancer risk. *JAMA*, 271(10):785. PMID: 8114217
69. Gray, J.W., Moore, D., Piper, P., Jensen, R. (1995) Molecular cytogenetic approaches to development of biomarkers. In: *Biomarkers and Occupational Health: Progress and Perspective* (M. Mendelson, J. Peeters, and M. Normandy, eds.), pp. 194-215. Joseph Henry Press
70. Weier, H.-U., Pinkel, D., Gray, J.W. (1995) Whole chromosome staining by fluorescence in situ hybridization. *Encyclopedia of Molecular Biology and Biotechnology* (R.A. Meyers, ed.), pp. 965-8. VCH Publishers
71. Gray, J.W., Collins, C., Henderson, I.C., Isola, J., Kallioniemi, A., Kallioniemi, O.-P., Nakamura, H., Pinkel, D., Stokke, T., Tanner, M., and Waldman, F. (1995) Molecular cytogenetics of human breast cancer. *Cold Spring Harb. Symp. Quant. Biol.*, 59:645-52
72. DeVries, S., Gray, J.W., Pinkel, D., Waldman, F.M., Sudar, D. (1995) Comparative genomic hybridization. In: *Current Protocols in Human Genetics*, Suppl. 6, Unit 4.6, pp. 1-18. John Wiley & Sons, Inc.
73. Gray, J.W., Chin, K., Waldman, F. (1996) A molecular cytogenetic view of chromosomal heterogeneity in solid tumors. In: *Proceedings of the Eighth Pezcoller Symposium: Genomic Instability and Immortality in Cancer* (E. Mihich and L. Hartwell, eds.), pp. 13-32. Plenum Press: New York
74. Weier, H.-U., Pinkel, D., Gray, J.W. (1997) Whole-chromosome complementary probe fluorescence staining. *Encyclopedia of molecular biology and molecular medicine* (R.A. Meyers, ed.), pp. 253-7. VCH Publishers: Weinheim, New York
75. Xu, Y., Fang, X.J., Furui, T., Sasagawa, T., Pustilnik, T., Lu, Y., Shen, Z., Wiener, J.R., Shayesteh, L., Gray, J.W., Bast, R.C., Mills, G.B. (1998) Regulation of growth of ovarian cancer cells by phospholipid growth factors. *Ovarian Cancer* 5 (F. Sharp, T. Blackett, J. Berek, and R.C. Bast, eds.), 10:109-20. ISIS Medical Media: Oxford, UK
76. Umayahara, K., Cheneviex-Trench, G., Daneshvar, L., Yang-Feng, T., Collins, C., Gray, J.W. (1998) Molecular cytogenetic studies. *Ovarian Cancer* 5 (F. Sharp, T. Blackett, J. Berek, and R.C. Bast, eds.), 10:17-24. ISIS Medical Media: Oxford, UK
77. Gray, J.W., Collins, C., Pinkel, D., Shayesteh, L., Lu, Y., Mills, G. (1998) Genome scanning and gene discovery in breast and ovarian cancer. *Proceedings of the Ninth Annual Pezcoller Symposium on the Biology of Tumors* (E. Mihich and C. Croce, eds.), pp. 65-72. Plenum Press: New York
78. Gray, J.W., Collins, C., Daneshvar, L., Rommens, J., Kuo, W.L., Tanner, M., Palazzolo, M., Martin, C., Hwang, S., Kowbel, D., Mills, G., Albertson, D., Pinkel, D. (1998) Genome scanning to genes: Positional cloning at 3q26 and 20q13.2. In: *Cancer Genomics: Extended Abstracts for the 28th International Symposium of the Princess Takamatsu Cancer Research Fund* (C. Croce, Y. Nakamura, M. Ohki, T. Sugimura, M. Terada, and R.L. White, eds.), pp. 95-98. Princess Takamatsu Cancer Research Fund: Japan
79. Lockett, S.J., Fernandez, C., Rodriguez, E., Wesselmann, U., Bastian, B., Sudar, D., Pinkel, D., Gray, J.W. (1998) Interactive system for registering adjacent tissue sections. *Proceedings of the SPIE*
80. Yu, Y., Xu, F., Peng, H., Fang, X., Zhao, S., Xia, W., Kuo, W.-L., Gray, J.W., Siciano, M., Hogg, D., Berchuck, A., Hunt, K., Mills, G., Bast, R. (1999) ARHI (NOEY2), an imprinted tumor suppressor gene

in epithelial ovarian cancer. In: Book of Proceedings from the Helene Harris Memorial Trust 7th Biennial International Forum on Ovarian Cancer

81. Ortiz de Solórzano, C., García Rodríguez, E., Jones, A., Pinkel, D., Gray, J.W., Sudar, D., Lockett, S.J. (1999) Segmentation of confocal microscope images of cell nuclei in thick tissue sections. *J. Microscopy*, 193(3):212-26. PMID: 10199001
82. Mills, G.B., Lu, Y., Shayestri, L., Pinkel, D., Gray, J.W. (1999) From genetics to therapeutic targets: Phosphatidylinositol 3' kinase (PI3K) in ovarian and breast cancer. In: *Cancer: Investigación Básica y Aplicaciones Clínicas* (M. Barbacid Erika Med, ed.), pp. 6-16
83. Mills, G.B., Lu, Y., Fang, X., Wang, H., Eder, A., Mao, M., Swaby, R., Cheng, K.W., Stokoe, D., Siminovitch, K., Jaffe, R., Gray, J. (2001) The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. *Semin. Oncol.*, 28(5 Suppl. 16):125-4. PMID: 11706404
84. Massion, P. and Gray, J.W. (2002) Molecular cytogenetics and human genome function. In: *Genomic Technologies: Present and Future* (D. Gallas and S. McCormick, eds.), pp. 11-42. Caister Academic Press: Wymondham, UK
85. Pinkel, D., Hamilton, G., Brown, N., Segraves, R., Huey, B., Snijders, A., Blackwood, S., Hinde, K., Law, S., Gray, J.W., Jain, A., Hanson, J., Nordmeyer, R., Albertson, D. (2002) Technical approaches for efficient, high precision nucleic acid analysis using DNA microarrays. In: *Biomedical Nanotechnology Architectures and Applications* (D. Bornhop, D. Dunn, R. Mariella, Jr., C. Murphy, D. Nicolau, S. Nie, and R. Raghavachari, eds.), 4626:82-88. Proceedings of the SPIE
86. Lu, Y., Shayestri, L., Lapushin, R., Yu, S., Cuevas, B., Fang, X., Eder, A., Furui, T., Plikoff, D., Kuo, W.-L., Baldocchi, R., Vanhaesebroeck, B., Pinkel, D., Siminovitch, K., Jaffe, R., Gray, J., Mills, G.B. (2002) Phosphatidylinositol 3' kinase as a target in selected ovarian cancers: From genomics to therapeutics. In: *Ovarian Cancer 6* (F. Sharp, T. Blackett, J. Berek, and R.C. Bast, eds.). ISIS Medical Media: Oxford, UK
87. Yu, Y., Xu, F., Peng H., Fang, X., Zhao, S., Li, Y., Cuevas, B., Kuo, W.-L., Gray J., Siciliano, M., Pershad, R., Hogg, D., Berchuk, A., Hunt K., Mills, G.B., Bast, R.C. (2002) ARHI (NOEY2) an imprinted tumor suppressor gene in epithelial ovarian cancer. In: *Ovarian Cancer 6* (F. Sharp, T. Blackett, J. Berek, and R.C. Bast, eds.). ISIS Medical Media: Oxford, UK
88. Mills, G.B., Fang, X., Lu, Y., Hasegawa, Y., Eder, A., Erickson, J., Brewer, M., Fidler, I.J., Schmandt, R., Lu, K., Dubeau, L., Kavanagh, J., Gershenson, D., Shaw, P.A., Auersperg, N., Jaffe, R.B., Kohn, E., Gray, J.W., Bast, R.C. (2002) Molecular therapeutics of ovarian cancer. In: *Biology of Ovarian Cancer* (R. Freedman and J. Kavanagh, eds.). ISIS Press: New York
89. Hodgson, J.G., Chin, K., Collins C., Gray, J.W. (2003) Genome amplification of chromosome 20 in breast cancer. *Breast Cancer Res. Treat.*, 78(3):337-45. PMID: 12755492
90. Gray, J.W. (2003) Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. *Cancer Cell*, 4(1):4-6. PMID: 12892707
91. Gray, J.W., Suzuki, S., Kuo, W.-L., Polikoff, D., Deavers, M., Smith-McCune, K., Berchuck, A., Pinkel, D., Albertson, D., Mills, G.B. (2003) Specific keynote: Genome copy number abnormalities in ovarian cancer. *Gynecol. Oncol.*, 88(1 Pt 2):S16-24
92. Neve, R., Schaefer, C., Buetow, K., Gray, J.W. (2004) Genomic events in breast cancer progression. In: *Diseases of the Breast, 3rd Edition* (J. Harris, M. Lippman, M. Morrow, and K. Osborne, eds.), pp. 393-6. Lippincott, Williams, and Williams
93. Cram, L.S., Gray, J.W., Carter, N.P. (2004) Cytometry and genetics. *Cytometry A*, 58(1):33-6. PMID: 14994217
94. Stilwell, J.W., Guan, Y., Neve, R., Gray, J.W. (2006) Assays and applications of high content screening. In: *High Content Screening: A Powerful Approach to Systems Cell Biology and Drug Discovery* (D.L. Taylor, J.R. Haskins, and K.A. Giuliano, eds.). Humana Press

95. Wang, N. and Gray, J.W. (2008) Comparative genomic hybridization and copy number abnormalities in breast cancer. In: Pharmacogenetics of Breast Cancer: Towards the Individualization of Therapy (B. Leyland-Jones, ed.). Informa Healthcare
96. Spellman, P.T., Costello, J.F., Gray, J.W. (2008) Cancer genomics. In: The Molecular Basis of Cancer, 3rd Edition (J. Mendelsohn, P.M. Howley, M.A. Israel, J.W. Gray and C.B. Thompson, eds.), pp. 267-282. Philadelphia: Saunders / Elsevier
97. Korkola, J., Gray, J.W. (2010) Genetic and cellular mechanisms of oncogenesis, Breast cancer genomes — form and function. *Curr. Opin. Genet. Dev.*, 20:4-14. PMID: 20060285
98. Gray, J.W. (2010) Cancer: Genomics of metastasis. *Nature, News & Views*, 464(7291):989-990. PMID: 20393550
99. Spellman, P., Gray, J.W. (2011) A new treasure in the breast cancer gene hunt. *Nature Med.*, 17:422-423. PMID: 21475233
100. Gray, J. and Druker, B. (2012) Genomics: the breast cancer landscape. *Nature*, 486(7403):328-9. PMID: 22722187
101. Esserman, L., Barker, A., Woodcock, J., Buxton, M., Berry, D., Patterson, R., Jolly, K., DeMichele, A., Hylton N., Rubin E., Parkinson, D., Wholley, D., van 't Veer, L., Yee, D., Park, J., Tripathy, D., Perlmutter, J., Buetow, K., Hogarth, M., Gray, J.W., and Dilts, D. (2012) A model for accelerating identification and regulatory approval of effective investigational agents. *Curēus*, 4(12): e76
102. Neve, R., Schaefer, C., Buetow, K., Gray, J.W. (2004) Genomic events in breast cancer progression. In: *Diseases of the Breast*, 3rd Edition (J. Harris, M. Lippman, M. Morrow, and K. Osborne, eds.), pp. 393-6. Lippincott, Williams, and Williams
103. Spellman, P.T., Stuart, J., Gray, J.W. (2014) Understanding and using information about cancer genomes. In: *The Molecular Basis of Cancer*, 4rd Edition (J. Mendelsohn, P.M. Howley, M.A. Israel, J.W. Gray and C.B. Thompson, eds.), pp. 357-368. Philadelphia: Saunders / Elsevier
104. Spellman, P.T. and Gray, J.W. (2014) Detecting cancer by monitoring circulating tumor DNA. *Nat. Med.*, 20:474–475. PMID: 24804754
105. Gray, J.W. (2016) PI3 Kinase pathway mutations in human cancers *JAMA Oncol.* 2(12):1543-1544. PMID: 27387578
106. Hassan, S., Heiser, L.M., Gray, J.W., (2017) *Systems Biology and Genomics In: Holland-Frei Cancer Medicine*, 9th Edition (R.C. Bast Jr., C.M. Croce, W.N. Hait, W.K. Hong, D.W. Kufe, M. Piccart-Gebhart, R.E. Pollack, R.R. Weichselbaum, H. Yang, and J.F. Holland, eds.), pp. 247-254. John Wiley & Sons, Inc., Hoboken, N.J.
107. López, C.S., Bouchet-Marquis, C., Arthur, C.P., Riesterer, J.L., Heiss, G., Thibault, G., Pullan, L., Kwon, S., Gray, J.W. (2017) A Fully Integrated, Three Dimensional Fluorescence to Electron Microscopy Correlative Workflow In: *Correlative Light and Electron Microscopy III, Methods in Cell Biology*, Volume 140 (P. Singh, A. Das and R. Li, eds.). Elsevier: Philadelphia, PA.

PATENTS

Issued US patents (80 total)

Finding leaks in a tandem Van de Graff accelerator

Gray, J.W., Hartnell, G.W., and Legg, J.C. Method of locating defects in a high-voltage insulating tube. U.S. Patent #3,761,720 (1974)

Flow cytometry and sorting

Gray, J.W., Alger, T.W., and Lord, D. Fluidic assembly for an ultra-high-speed chromosome flow sorter. U.S. Patent #4,361,400 (1982)

Gray, J.W., Hirschfeld, T.B., and Norgren, R.M. Method and apparatus for fringe-scanning chromosome analysis. U.S. Patent #4,596,036 (1986)

BrdUrd/DNA analysis

Dolbeare, F. and Gray, J.W. Flow cytometric measurement of total DNA and incorporated halodeoxyuridine. U.S. Patents #4,585,736 (1986); #4,780,406 (1988); #4,812,394 (1989)

Fluorescence in situ hybridization (FISH)

Gray, J.W. and Pinkel, D. Methods of preparing and applying single stranded DNA probes to double stranded target DNAs in situ. U.S. Patent #5,028,525 (1991)

Gray, J.W. and Pinkel, D. Methods for chromosome-specific staining. U.S. Patents #5,447,841 (1995); #6,596,479 (1995); #6,607,877 (2003); #6,872,817 (2005)

Gray, J.W., Pinkel, D., and Tkachuk, D. Method of detecting genetic translocations identified with chromosomal abnormalities (BCR/ABL translocation). U.S. Patent #6,280,929 (2001)

Gray, J.W. and Pinkel, D. Methods of biological dosimetry employing chromosome-specific staining. U.S. Patent #6,132,961 (2000)

Gray, J.W., Pinkel, D., Kallioniemi, O.-P., Kallioniemi, A., and Sakamoto, M. Methods of staining target chromosomal DNA employing high complexity nucleic acid probes. U.S. Patent #7,115,709 (2006)

Pinkel, D., Kallioniemi, O.-P., Kallioniemi, A., Waldman, F., Gray, J.W., and Sakamoto, M. Genomic probing. U.S. Patent #5,856,097 (1995)

Weier, H.-U., and Gray, J.W. Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using. U.S. Patent #5,427,932 (1995)

Gray, J.W., Stokke, T., and Pinkel, D. Detection of amplified or deleted chromosomal regions. U.S. Patents #5,472,842 (1995); #5,633,365 (1997).

Gray, J.W. and Weier, H.-U. Y-Chromosome specific nucleic acid probe and method for determining the y-chromosome in situ. U.S. Patents #5,840,482 (1998); #5,888,730 (1999); #6,300,066 (2001)

Gray, J. and Weier, H.-U. Quantitative DNA fiber mapping. U.S. Patent #5,851,769 (1998)

Comparative genomic hybridization (CGH)

Pinkel, D., Gray, J.W., Kallioniemi, A., Kallioniemi, O.-P., and Waldman, F. Comparative genomic hybridization (CGH). U.S. Patent #5,665,549 (1997); #5,721,098 (1998); #5,965,362 (1999); #5,976,790 (1999); #6,159,685 (2000); #6,335,167 (2002); #7,238,484 (2007), #7,537,895 (2009)

Pinkel, D., Gray, J.W., Kallioniemi, A., Kallioniemi, O.-P., Waldman, F. and Sakamoto, M. Detection of chromosomal abnormalities associated with breast cancer U.S. Patent #8,021,837 (2011).

Pinkel, D., Albertson, D., and Gray, J.W. Comparative fluorescence hybridization to nucleic acid arrays. U.S. Patents #5,830,645 (1998); #6,562,565 (2003)

Pinkel, D. and Gray, J.W. High density array fabrication and readout method for a fiber optic biosensor. U.S. Patents #5,690,894 (1997); #6,146,593 (2000); #6,417,506 (2002)

Pinkel, D., Albertson, D.G., and Gray, J.W. Array-based detection of genetic alterations associated with disease. U.S. Patents #6,210,878 (2001); #7,267,947 (2007); #7,776,536 (2010)

Gray, J.W., Pinkel, D., Albertson, D., Collins, C.C., and Baldocchi, R. Comparative fluorescence hybridization to oligonucleotide microarrays. U.S. Patent #6,465,182 (2002)

Pinkel, D., Albertson, D.G., Gray, J.W., Hamilton, G., Brown, N.W., and Clark, S.M. High-efficiency microarray printing device. U.S. Patent #6,855,538 (2005)

Albertson, D., Pinkel, D., Fridyland, J., Huey, B., Snijders, A., Gray, J.W., Kallioniemi, A., Kallioniemi, O., Waldman, F. Detection of nucleic acid differences by comparative genomic hybridization. U.S. Patent #7,534,567 (2009)

Diagnostic markers

Christman, M.F., Gray, J.W., Levin, N.A., Brzoska, P., and Nakamura, H. Genetic alterations that correlate with lung carcinomas. U.S. Patent #5,670,314 (1997)

Gray, J.W., Pinkel, D., Collins, C., Kallioniemi, O.-P., and Tanner, M. Amplification of chromosomal region 20q13 as prognostic indicator in breast cancer. U.S. Patents #5,801,021 (1998); #6,268,184 (2001); #8,993,251 (2015)

Gray, J., Collins, C., Godfrey, T., Kowbel, D., Hwang, S., and Rommens, J. Genes from the 20Q13 amplicon and their uses. U.S. Patents #5,892,010 (1999); # 6,808,878 (2005); # 7,049,424 (2006); # 7,413,899 (2008); # 7,811,986 (2010); #8,101,370 (2012)

Shayesteh, L. and Gray, J.W. Genetic aberrations associated with cancer (PIK3CA). U.S. Patents #6,110,673 (2000); #6,277,563 (2001); #6,475,732 (2002); #6,537,761 (2003); # 7,670,767 (2010)

Gray, J.W., Pinkel, D., Kallioniemi, O.-P., Kallioniemi, A., and Sakamoto, M. Chromosome-specific staining to detect genetic rearrangements associated with chromosome 3 and/or chromosome 17. U.S. Patents #6,475,720 (2002); #6,344,315 (2002); #RE40,929 (2009)

Gray, J.W., Pinkel, D., Tkachuk, D., and Westbrook, C. Chromosome specific staining to detect genetic rearrangements. U.S. Patent Application #09/765,291 (2001, amendment filed 2007); #8,415,464 (2013)

Gray, J.W., Pinkel, D., Tkachuk, D. Method of detecting genetic deletions identified with chromosomal aberrations. #8,592,155 (2013)

Gray, J.W. and Pinkel, D. Methods and compositions for chromosome 21-specific staining. U.S. Patent #6,500,612 (2002)

Albertson, D.G., Pinkel, D., Collins, C., and Gray, J.W. Amplicon in the 20q13 region of human chromosome 20 and uses thereof. U.S. Patent #6,664,057 (2003)

Giacomini, K.M., Gray, J.W., Lapuk, A.V., and Zhang, S. Use of organic cation transporters for cancer diagnosis and therapy. U.S. Provisional Patent Application #60/793,803 (2006)

Albertson, D., Pinkel, D., Collins, C., Gray, J.W., Ystra, B. Detecting CYP24 expression level as a marker for predisposition to cancer. U.S. Patent #7,648,826 (2010); #8,173,602 (2012) #8,685,929 (2014)

Hu, Z., Kuo, W.-L., Neve, R.M., Gray, J.W. Annexin A9 (ANXA9) biomarker and therapeutic target in epithelial cancer. U.S. Patent #8,198,254 (2012)

Gray, J.W., Guan, Y., Kuo, W.-L., Fridyland, J., Mills, G.B. Predictive and therapeutic markers in ovarian cancer. U.S. Patent #8,404,829 (2013)

Spellman, P.T., Gray, J.W., Sadanandam, A., Heiser, L.M., Gibb, W.J., Kuo, W.-L., Wang N.J. Molecular predictors of therapeutic response to specific anti-cancer agents. U.S. Patent #9,506,926 (2016)

End sequence profiling (ESP)

Collins, C., Volik, S., and Gray, J.W. End sequence profiling. U.S. Patent #6,785,614 (2004)

Mass spectrometric imaging of mass tag labeled specimens

Felton, James S., Wu, Kuang Jen J., Knize, Mark G., Kulp, Kristen S., Gray, Joe W. Imaging mass spectrometer with mass tags. US Patent #7,728,287 (2010); #8,362,415 (2013)

Others

Ginzinger, D., Godfrey, T., Jensen, R., and Gray, J.W. Quantitative PCR method to enumerate DNA copy number. U.S. Patent #6,180,349 (2001)

Fulwyler, M.J. and Gray, J.W. Capillary array and related methods. US Patents #6,610,499 (2003); #6,818,184 (2005); #6,898,237 (2006); #7,741,104 (2010); # 8,003,376 (2011)

MEETINGS ORGANIZED (1991 TO PRESENT)

Program Committee, 9th International Congress on Radiation Research; Toronto, Ontario, Canada, 7-12 July 1991

Program Committee, 15th Congress of the International Society for Analytical Cytology; 26-30, August, Bergen, Norway, 1991

Founder and Chairman, Gordon Research Conference on Molecular Cytogenetics; Ventura, California, 2-6 March 1992

Program Committee, Molecular Cytogenetics Symposium, International Congress of Histochemistry; Maastricht, Netherlands, 31 August- 3 September 1992

Co-organizer, Genomics Technology and Mutation Analysis; Santa Fe, New Mexico, 10-11 September 1992

Organizing Committee, 5th International Workshop on Chromosomes in Solid Tumors; Tucson, Arizona, 10-12, January 1993

Plenary Session Chairman, Organizing Committee, 16th Congress of the International Society for Analytical Cytology; Colorado Springs, Colorado 21-26 March 1993

Discussion Session Chairman/Organizer (Novel Genetic Approaches to Cancer) AAAS: Science Innovation; Boston, Massachusetts, 6-10 August 1993

Discussion Leader, Gordon Conference on Molecular Cytogenetics; Plymouth, New Hampshire, 12-18 June 1994

Plenary Session Chairman, 17th Congress of the International Society for Analytical Cytology; Lake Placid, New York, 18-21 October 1994

Scientific Program Chairman, 18th Congress of the International Society for Analytical Cytology; Rimini, Italy, 13-18 April 1996

Organizing Committee, Spring Biomedical Sciences Graduate Program Symposium: Genomics Technology (Physical maps: Resources for disease gene localization and identification), UCSF, San Francisco, California, May 1997

President, 18th Congress, International Society for Analytical Cytology, Colorado Springs, Colorado, February 1998

Organizer – Bioinformatics workshop, NCI SPORE Program, Washington D.C., November 2001

Co-organizer – Breast SPORE/Mouse Models of Human Cancer Joint Meeting, Santa Fe, NM, February 2002

Co-organizer – ISAC 4th Annual Samuel A. Latt Conference, Yosemite Park, CA, November 2003

Co-organizer – Biotechnology Resource for Interdisciplinary Discovery and Genome Engineering (BRIDGE), San Francisco, CA, April 2004

Co-organizer – NCI/LBNL Nanobiotechnology Workshop, Half Moon Bay, CA, August 2004

Co-organizer – n Chromosomes: Progress in Cytogenetics, Bethesda, MD, June 2006

Co-organizer – LBNL / UCSF Physics and Therapeutic Radiology Circa 2012, Berkeley, CA, February 2007

Co-organizer – Gulliver Multiscale Imaging Workshop, Berkeley, CA, May 2007

Co-organizer – Mathematical Sciences Research Institute – Integrated Cancer Biology Program Workshop, Berkeley, CA, October 2007

Co-organizer – Integrated Cancer Biology Program – 2nd Data Integration Workshop, San Francisco, CA, May 2008

Co-organizer – Multiscale Imaging Workshop, Berkeley, CA, June 2008

Organizer – Life Sciences Division Scientific Retreat, Berkeley, CA September 2008

Organizer – 2009 siRNA Consortium meeting, Berkeley, CA, January 2009

Co-organizer – 2009 AACR Translation of the Cancer Genome Special Conference, Boston, MA, February 2009

Co-chair – NCI Transient Molecular Complexes Workshop, San Francisco, CA, August 2009

Organizer – Transformational Genomics, A Symposium in Honor of Dan Pinkel, Ph.D., San Francisco, CA, February 2010

Co-organizer – Mina J. Bissell Cancer and Complexity Symposium & 70th Birthday, A Systems Approach to Personalized Cancer Treatment, Berkeley, CA, May 2010

Organizer – Stand Up to Cancer (SU2C) Bioinformatics Face-to-Face, Berkeley, CA, June 2011

Organizer – 2012 Biomedicine in 4 Dimensions, Integrated –omics and Systems Microscopy: Turning images and models into therapeutic targets, Portland, OR, March 2012

Organizer – Integrative Cancer Biology Program, Days of Science: the Sequel, Portland, OR, June 2012

Co-organizer – Stand Up to Cancer (SU2C) – American Association for Cancer Research (AACR) Progress Review

Team Visit, An Integrated Approach to Targeting Breast Cancer: Molecular, Subtypes and Their 'Resistance' Phenotypes, Santa Cruz, CA, July 2012

Organizer – Cellular Imaging at the Nanoscale, Portland, OR, June 2013

Organizer – Bioimaging at the Nanoscale, Portland, OR, June 2014

Co-organizer – CDCB OCSSB Retreat, Stevenson, WA, July 2014

Co-organizer – Genomic Instability and Cancer: Early Detection and Novel Therapeutics, Portland, OR, October 2014

Co-organizer – NCI Workshop: Recent Advances in Cryo-electron Microscopy: Opportunities and New Frontier, Bethesda, MD, December 2014

Co-organizer – Genomic Instability Mini Symposium 2015, Portland, OR, March 2015

Organizer – OHSU OSU Joint Research / Graduate Education Program Retreat, Portland, OR, April 2015

Organizer – Microenvironment Perturbations (MEP): Library of Integrated Network-Based Cellular Signatures (LINCS) Outreach Retreat, Portland, OR, May 2015

Organizer – CDCB OCSSB Joint Retreat, Stevenson, WA, August 2015

Organizer – National Institutes of Health, National Cancer Institute, Department of Health and Human Services, 9th Meeting of the Frederick National Laboratory Advisory Committee (FNLAC), Bethesda, MD, September, 2015

Co-organizer – NCI OHSU Tumor Heterogeneity Workshop, Portland, OR, October 2015

Organizer – Microenvironment Perturbations (MEP): Library of Integrated Network-Based Cellular Signatures (LINCS) Outreach Retreat, Portland, OR, April 2016

Organizer – National Institutes of Health, National Cancer Institute, Department of Health and Human Services, 10th Meeting of the Frederick National Laboratory Advisory Committee (FNLAC), Bethesda, MD, May 2016

Co-organizer – Cancer Prevention & Control / Quantitative Oncology Retreat, Portland, OR, June 2016
Co-organizer – Oregon Health & Science University (OHSU) & Cancer Research UK (CRUK) Sondland Durant Early Detection of Cancer Conference, Portland, OR, June 2016
Co-Organizer – 30th International Association for Breast Cancer Research Conference, Early Detection of Lethal Breast Cancers, Portland OR, August 2016
Organizer – Microenvironment Perturbations (MEP): Library of Integrated Network-Based Cellular Signatures (LINCS) Outreach Retreat, Portland, OR, November 2016
Organizer – SMMART “Mechanisms of Resistance” Research Retreat (SMoRRR), Newberg, OR, January 2017

INVITED LECTURES, CONFERENCE PRESENTATIONS OR PROFESSORSHIPS

Invited presentations (since 1993)

International

5th International Workshop on Chromosomes in Solid Tumors, Tucson, AZ, 1993
Blood Cell Symposium/Human Leukemia, Paris, France, 1993
Canadian Genetic Diseases Network, Val Morin, Quebec, Canada, 1993
Annual Meeting of Japan Cytometry Society, Tokyo, Japan, 1993
The Royal College of Physicians and Surgeons of Canada: Symposium on Cancer Cytogenetics, Vancouver, Canada, 1993
AACR Special Conference, Cancer, Perturbations in Cell Cycle Control and Genomic Integrity, Alberta, Canada, 1994
International Symposium on Breast Cancer, San Francisco, CA, 1994
International Society for Analytical Cytology, Lake Placid, NY, 1994
Nordic Workshop on the Human Genome, Oslo, Norway, 1994
Sasaki Institute Kyoundo Hospital, Tokyo, Japan, 1994
International Workshop for Biological Applications of Molecular Cytogenetics, Hilton Head Island, SC, 1995
National Cancer Center Research Institute, Tokyo, Japan, 1995
Today and Tomorrow Symposium, Hiroshima, Japan, 1995
Laboratory Medicine '95: 11th IFCC European Congress of Clinical Chemistry, Tampere, Finland, 1995
Japan Dermatological Society in Morioka, Morioka Iwate, Japan, 1995
Princess Takamatsu Symposium, Genetic Instability and Carcinogenesis, Tokyo, Japan, 1995
Molecular Cytogenetics Gordon Conference, Barga, Italy, 1996
Human Tumor Heterogeneity, Kananaskis, Alberta, Canada, 1996
Pezcoller Foundation Symposium, Genomic Instability and Immortality in Cancer, Roverto, Italy, 1996
International Symposium on Comparative Genomic Hybridization, Memorial Sloan-Kettering Cancer Center, Department of Human Genetics, New York, NY, 1996
Seventh International Workshop on Chromosomes in Solid Tumors, Arizona Cancer Center, The University of Arizona, Tucson, AZ, 1997
Pezcoller Foundation Symposium, The Biology of Tumors, Roverto, Italy, 1997

6th International Forum on Ovarian Cancer, Helene Harris Memorial Trust, Los Angeles, CA, 1997

Peter Heimann Lecture, Advances in Cytogenetics - Surgical Relevance, International Surgical Week ISW97, Acapulco, Mexico, 1997

The 1st Joint meeting of the Japan Cytometry Society and the International Society for Analytical Cytology, Hachimantai National Park, Iwate, Japan, 1997

The 2nd Peter MacCallum Symposium, New Strategies for Cancer Detection and Therapy, Copeland Theater, University of Melbourne, Melbourne, Australia, 1997

The Princess Takamatsu Cancer Research Fund International Symposium, Palace Hotel, Tokyo, Japan, 1997

International Society for Analytical Cytology XIX Congress, Colorado Springs, CO, 1998

Breast Cancer Symposium Think Tank 8, Tobago, West Indies, 1998

The 25th Silver Jubilee FEBS Meeting, The Bella Center, Copenhagen, Denmark, 1998

NSABP, Toronto, Ontario, Canada, 1999

Breast Cancer Think Tank 9, St. Thomas, U.S. Virgin Islands, 1999

19th International Symposium of Sapporo Cancer Seminar, Sapporo, Japan, 1999

National Surgical Adjuvant Breast and Bowe Project Group Meeting, Toronto, Ontario, Canada, 1999

The Molecular Biology of Breast Cancer Symposium, Lillehammer, Norway, 2000

31st Annual Meeting of the Environmental Mutagen Society, New Orleans, LA, April 2000

NCI/EORTC Meeting on Molecular Markers in Cancer, Nyborg, Denmark, 2000

Gordon Research Conferences, Molecular Cytogenetics, Oxford, England, 2000

Leiden University Medical Center (7 lectures), Leiden, the Netherlands, 2000

Delft Technical University, Delft, the Netherlands, 2000

Max Planck Institute for Molecular Biophysical Chemistry, Göttingen, Germany, 2000

Netherlands Cancer Institute, Amsterdam, the Netherlands, 2000

8th International Workshop on Chromosomes in Solid Tumors, Arizona Cancer Center, Tucson, AZ, 2000

2nd Annual International Conference on Ovarian Cancer, New York, NY, 2000

Gordon Conference on Molecular Cytogenetics, Oxford, England, July 2000

Breast Cancer Think Tank 11, Dominican Republic, January 2001

Helene Harris Memorial Trust, 8th International Forum on Ovarian Cancer, Houston, TX, March 2001

48th Annual Meeting of the Radiation Research Society, San Juan, Puerto Rico, April 2001

14th International Congress of Cytology, Amsterdam, the Netherlands, May 2001

XIII Annual Pezcoller Symposium, Focusing Analytical Tools on Complexity in Cancer, Trentino, Italy, May 2001

5th Cancer Research Campaign, Beatson International Cancer Conference and Data Analysis for Microarrays Workshop, Glasgow, Scotland, July 2001

Division of Medical Sciences National Cancer Center, Health Ministry Development Plan, Ministry of Health, Singapore, August 2001

Breast Cancer Symposium Think Tank, Saint Maarten, the Netherlands Antilles, January 2002

Distinguished Lecture Series, Vancouver BC Cancer Research Center, Vancouver, Canada, May 2002

18th UICC International Cancer Congress, Oslo, Norway, June/July 2002

7th Course in Genetics, Bertinoro, Italy, August/September 1, 2002

New Leads in Exp and Clinical Gene Targeting in Cancer, Sao Paulo, Brazil, November 2002

High throughput genomic analysis in cancer research, Hong Kong, December 2002

Japan Society of Cytomics Symposium 2003, Yamaguchi University School of Medicine, Tokyo, Japan, October 2003

Breast Cancer Symposium, Think Tank 14, Saint Kitts, Caribbean, January 2004

International Society for Analytical Cytology (ISAC) XXII, Montpellier, France, May 2004

Gordon Conference – Molecular Cytogenetics, Oxford, England, July 2004

Ovchinnikov Symposium, Moscow, Russia, October 2004

Breast Cancer Symposium, Think Tank 15, Curacao, Netherlands, January 2005

22nd International Papillomavirus Conference and Clinical Workshop, Vancouver, Canada, May 2005

Molecular Biology of Breast Cancer, Molde, Norway, June 2005

Breast Cancer Symposium, Think Tank 16, Grand Cayman Islands, British West Indies, January 2006

Federation of European Cancer Societies, 19th Meeting of the European Association for Cancer Research, Budapest, Hungary, July 2006

25th International Association of Breast Cancer Research, Montreal, Canada, September 2006

National Cancer Institute of Canada, Eagan Program Project Review, Toronto, Ontario, Canada, February 2007

British Columbia Cancer Agency, Genome Sciences Centre, Scientific Advisory Board Meeting, Vancouver, Canada, February 2007

Centre of Excellence on Translational Genome-Scale Biology, Biomedicum, Helsinki, Finland, March 2007

2007 Beatson International Cancer Conference, Molecular Cancer Therapies: New Challenges and Horizons, Glasgow, Scotland, June 2007

Nelly Auersperg Symposium, Vancouver, Canada, September 2007

The European Cancer Conference, Federation of European Cancer Societies (FECS), European Cancer Organization (ECCO 14) Keynote address, Barcelona, Spain, September 2007

Centro Nacional de Investigaciones Oncológicas - Nature Symposium, Oncogenes and Human Cancer: The Next 25 Years, Keynote address, Madrid, Spain, October 2007

American Association for Cancer Research Centennial Conference on Translational Cancer Medicine: Technologies to Treatment, Keynote address, Suntec, Singapore, November 2007

20th Meeting of the European Association for Cancer Research, “Drug targets screening” Lyon, France, July 2008

Japanese Cancer Association – American Association of Cancer Research Special Joint Conference on Breast Cancer, The Latest Advances in Breast Cancer Research: From Basic Science to Therapeutics, Keynote address, Hyogo, Japan, July 2008

International Meeting of the Microarray and Gene Expression Data Society (MGED 11), Keynote address, Trento, Italy, September 2008

National Cancer Research Institute Cancer Conference, Plenary address, Birmingham, England, October 2008

Rosalind & Morris Goodman Cancer Centre, McGill University Lecture, Montreal, Canada, October 2008

Medical College Fudan University, Shanghai, China; Soochow University Suzhou, China; Simcere Pharmaceutical R&D Co., Ltd., Nanjing, China, Keynote address in each city, “Marker guided therapy - Models to humans” September 2009

Joint National Cancer Institute and Chinese Academy of Medical Sciences Meeting, Cancer Genomics: State-of-the-Science and Future Directions, Beijing, China, November 2009

Biomedicum Helsinki Seminar, “Omic approaches to improved cancer management” Helsinki, Finland, November 2009

Keystone Symposium on New Paradigms in Cancer Therapeutics, “Omics based approaches to predict cancer therapy” Victoria, British Columbia, Canada, March 2010

Second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, “New technologies for early cancer detection” Dead Sea, Jordan, March 2010

Research in Computational Molecular Biology (RECOMB) Satellite Workshop on Computational Cancer Biology, Keynote lecture on “Breast cancer systems biology” Oslo, Norway, June 2010

21st Annual Meeting, “A systems approach to identification of therapy response subsets in breast cancer” Oslo, Norway, June 2010

Beatson International Cancer Conference, Multiple Tiers of RNA Regulation in Cancer, Keynote lecture: “A systems approach to identification of therapy response subtypes in breast cancer” Glasgow, Scotland, July 2010

European Society for Medical Oncology (ESMO), IMProving cAre and Knowledge through Translational research (IMPAKT) 2011 Breast Cancer Conference, Keynote lecture: “Breast cancer genomes - making sense of complexity” Brussels, Belgium, May 2011

Cambridge Research Institute Annual International Symposium, Keynote lecture: “Systems biology approaches to predictive markers in breast cancer” Cambridge, England, November 2011

Leadership Conference, HPC for Life Sciences, “Understanding complex biological systems: Genomics and beyond” Brussels, Belgium, May 2012

University of Helsinki, Institute for Molecular Medicine (FIMM) Special Guest Seminar, “Systems approaches to breast cancer management - genomics and beyond” Helsinki, Finland, August 2012

University of Turku and Åbo Akademi University 22nd Annual BioCity Symposium, Personal Genomics – From Technologies to Applications, “Systems approaches to breast cancer management - genomics and beyond” Turku, Finland, August 2012

Japanese Breast Cancer Society 10th Breast Cancer Frontier Meeting, Translational genomic research in breast cancer management, Special Invited Lecture, “A systems approach to improving breast cancer management” Tokyo, Japan, November 2012

Think Tank 23 – Breast Cancer Symposium, “Functional interpretation of breast cancer genomes” Cap Cana, Dominican Republic, January 2013

Samsung Advanced Institute for Technology (SAIT), “Spatial systems biology and cancer” Seoul, South Korea, June 2013

Daegu Gyeongbuk Institute of Science and Technology (DIGST) Distinguished Lecture “Functional interpretation of cancer genomes” Daegu, South Korea, June 2013

23rd Annual Meeting of the Japan Cytometry Society, “Cytometry and cancer-enabling: a systems view of breast cancer” Tokyo, Japan, June 2013

72nd Annual Meeting of the Japanese Cancer Association, AACR Joint Symposium “Cancer Research Providing Hope to Fight Against Cancer, “Genomics by sequencing, today and future” Yokohama, Japan, October 2013

17th Fritz Bender-Foundation International Symposium: Progress Towards Individualized Cancer Treatments, Vall D'Hebron Institute of Oncology, Session IV: Therapeutic Targets I "A multiscale architectural analysis of cancer genome aberration function" Barcelona, Spain, November 2013

British Columbia Cancer Research Centre (BCCRC), Canada Bennett Family Distinguished Lecturer Series, "Spatial systems biology of cancer" Vancouver, BC, Canada, March 2014

High Performance Computing for Life Science Conference, "A biomedical perspective on big data – managing and interpreting exascale information" Brussels, Belgium, May 2014

29th International Association for Breast Cancer Research (IABCR) / National Breast Cancer Foundation Conference 2014, Session 1: Understanding and Exploiting Tumour Heterogeneity, "Assessing and managing differentiation state heterogeneity in breast cancer"; Session 4: International Perspectives on the Future of Breast Cancer Research and Therapy, Panelist, Manly, New South Wales, Australia, September 2014

Princess Margaret Cancer Centre, "Spatial systems biology & cancer" Toronto, Ontario, Canada, December 2014

Think Tank 25 – Breast Cancer Symposium, "Measuring and managing cancer complexity at multiple scales" Grand Cayman, Cayman Islands, January 2015

Cold Spring Harbor Asia, Precision Cancer Biology and Medicine, "Linking the ome to multiscale structure in cancer" Suzhou, China, May 2015

Think Tank 26 – Breast Cancer Symposium, "A multiscale view of HER2 signaling" Frigate Bay, St. Kitts West Indies, January 2016

Personalized Cancer Care (PCC) Symposium, Session IV: Targeted Therapy "Understanding and managing breast cancer as a complex adaptive system" Oslo, Norway, May 2016

Think Tank 27 – Breast Cancer Symposium, "Microenvironmental influences on HER2+ cancer biology and therapeutic response" Windjammer Landing in Saint Lucia, January 2017

RECOMB 2017, The 21st Annual International Conference on Research in Computational Molecular Biology, Keynote lecture, "Early cancer detection and therapy" Hong Kong, China, May 2017

National

Yale University, Department of Genetics, New Haven, CT, 1993

President's Cancer Panel, UCSF, San Francisco, CA, 1993

Dean Seminar Series, University of Wisconsin-Madison, Madison, WI, 1993

University of North Carolina, Chapel Hill City, NC, 1993

Institute of Pathology, Cleveland, OH, 1993

Analytical Cytology Lecture Series, University of Rochester, Rochester, NY, 1993

Computer Applications for Early Detection and Staging of Cancer, Bethesda, MD, 1993

Science Innovation 1993, Boston, MA, 1993

National Academy of Sciences Meeting on Biomarkers, Washington, D.C., 1993

Correlative Sciences Committee, Cancer and Leukemia Group B, Research Triangle Park, NC, 1993

SIOP, San Francisco, CA, 1993

American Society of Cytology Annual Meeting, Houston, Texas, 1993

Seminar, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1994

American Association of Cancer Research: Multidisciplinary Program that Links Basic Cancer Investigations, San Francisco, CA, 1994

Applications of Biomarkers in Medicine, Santa Fe, NM, 1994

Radiation Research Society, Nashville, TN, 1994

Symposium: Molecular Genetics of Cancer, Cold Spring Harbor, NY, 1994

Gordon Research Conference on Molecular Cytogenetics, Session Chair, Plymouth, NH, 1994

College of American Pathologists, Snowbird, UT, 1994

Microscopy Society of America, New Orleans, LA, 1994

Roswell Park Cancer Institute, Buffalo, NY, 1994

US-Japan Radiation Oncology Meeting, San Francisco, CA, 1995

Radiation Therapy Oncology Group Annual Meeting, San Francisco, CA, 1995

Nakamura Lectureship: Scripps Clinic and Research Foundation, La Jolla, CA, 1995

Flow Cytometry Course, Los Alamos National Laboratory, Los Alamos, CA, 1995

Cancer Gordon Research Conference, Newport, RI, 1995

AACR Special Conference: Cancer the Interface between Basic & Applied Research, Baltimore, MD, 1995

The Eccles Institute of Human Genetics and The Department of Human Genetics, Salt Lake City, UT, 1995

Keystone Symposium, Breast and Prostate Cancer, Taos, NM, 1996

Histochemical Society Annual Meeting, Bethesda, MD, 1996

Medical Grand Rounds, MD Anderson Tumor Institute, Houston, TX, 1996

15th Annual AMA Science Reporters Conference, San Francisco, CA, 1996

Colloquium Series Talk, Department of Human Oncology and University of Wisconsin Comprehensive Cancer Center, Madison, WI, 1996

American Association for the Advancement of Science, Science Innovation Exposition, Seattle, WA, 1997

Cambridge Symposium: Genetic Approaches to Breast Cancer, Lake Tahoe, CA, 1997

Advanced Molecular Biology Techniques, American Lung Association/American Thoracic Society International Conference, San Francisco, CA, 1997

Gordon Conference on Cancer, Salve Regina University, Newport, RI, 1997

Genome Scale Analysis of Genetic Aberrations of Cancer, Association of Medical Laboratory Immunologists Tenth Annual Meeting, San Francisco, CA, 1997

College of American Pathologists: Fall National Meeting, PA, 1997

Dana-Farber Cancer Institute & the Jimmy Fund, 50th Anniversary Scientific Symposium, Boston, MA, 1997

Army Breast Cancer Meeting, Renaissance Hotel, Washington, D.C., 1997

American Society for Investigative Pathology, Genome Instability in Cancer, Marriott Hotel, San Francisco, CA, 1998

Cancer Genetics and Biology Symposium, Roswell Park Cancer Institute, Buffalo, NY, 1998

Breast Cancer in the 21st Century, City of Hope Comprehensive Cancer Center, Duarte, CA, 1998

Wendy & Emery Reves International Breast Cancer Symposium, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 1998

The New York Pathological Society, New York Academy of Medicine, New York, NY, 1999
Fred Hutchinson Cancer Center, Seattle, WA, 1999
Molecular Genetics Gordon Conference, Newport, RI, 1999
Symposium on Biomedical Optics, SPIE, San Jose, CA, 1999
AACR Meeting, Biology and the Mutant Mouse, Keystone, CO, 1999
Shiffer Award Lecture, Cell Proliferation Society, Baltimore, MD, 1999
Environmental Mutagen Society, Washington, D.C., 1999
AACR Annual Meeting, Philadelphia, PA, 1999
Fred Hutchinson Cancer Research Center, Seattle, WA, 1999
Translating Comprehensive Molecular Technologies: Issues & Barriers, Rockville, MD, 1999
American Cancer Society, 14th Annual Excalibur Round Table Meeting, San Francisco, CA, 1999
Yale Cancer Center Grand Rounds, New Haven, CT, 1999
National Cancer Institute Prostate Cancer State of the Science Workshop: Molecular Targets for Future Therapy of Prostate Cancer, Washington, D.C., 1999
Roswell Park Cancer Institute Lecture, Buffalo, NY, 1999
American Association for Cancer Research Special Conference, DNA Repair Defects, San Diego, CA, 2000
Huntsman Cancer Institute Ovarian Cancer Research Group, University of Utah, Ovarian Cancer Talk, Salt Lake City, UT, 2000
Society for Gynecologic Investigation, Ovarian Cancer Symposium, Chicago, IL, 2000
National Cancer Institute Ovarian Cancer Prevention Workshop, San Francisco, CA, 2000
Fragile Sites, Gene Amplification and Cancer, Rochester, MN, August 2000
Gordon Conference on Cancer, Newport, RI, August 2000
Colorado State University, Fort Collins, CO, September 2000
CTCR Breast Cancer Meetings, San Antonio, TX, December 2000
AACR meeting, Modifiers of Cancer Susceptibility, Lake Tahoe, NV, February 2001
National Institute of Standards and Technology, Gaithersburg, MD, May 2001
Whitehead Institute, MIT Center for Genome Research, Cambridge, MA, May 2001
3rd Samuel A. Latt / Motown Microarray Meeting, Genomics and Proteomics in Cancer, Detroit, MI, May 2001
The University of Texas Health and Science Center at San Antonio, Seminar Department of Cellular and Structural Biology, San Antonio, TX, May 2001
The University of Michigan, Ann Arbor, MI, June 2001
Pathobiology, Oncology, and Molecular Medicine Seminar Series, University of Rochester Medical Center, Rochester, NY, September 2001
Symposium of Oncological Sciences, Roswell Park Cancer Center, Buffalo, NY, November 2001
Pennsylvania State University, Cell Molecular Biology, Harrisburg, PA, November 2001
Oncology Rounds, Lombardi Cancer Center, Georgetown University, Washington, D.C., December 2001
Mammary MMHCC/Breast SPORE Exploratory Workshop (Co-chair), Santa Fe, NM, February 2002
Baylor College of Medicine, Houston, TX, April 2002

Frank S. Moran Endowed Lecture, Field of Dreams Breast Cancer Symposium, Dearborn, MI, April 2002

Distinguished Lecture Series, Vancouver BC Cancer Research Center, Vancouver, Canada, May 2002

American Association of Pharmaceutical Scientists (AAPS) First Annual National Biotechnology Meeting, San Diego, CA, June 2002

Lecture UNMC Eppley Institute, Omaha, NE, October 2002

MMHCC Workshop, Newport Beach, CA, December 2002

CFR Breast Scientific Conference, HI, January 2003

Dana-Farber Cancer Institute Oncology Seminar Series, Boston, MA, February 2003

Edward Rotan Seminar Series, The University of Texas, MD Anderson Cancer Center, Houston, TX, February 2003

Wendy and Emery Reves International Breast Cancer Symposium, Arlington, TX, February 2003

University of California San Diego Annual Cancer Center Retreat, Anza-Borrego Desert, CA, April 2003

Washington University, The Genetics Department Seminar Series, St. Louis, MO, May 2003

ASCO 2003 industry-sponsored satellite Symposium, Chicago, IL, May 2003

Breast Cancer Symposium, The Cancer Institute of New Jersey, NJ, June 2003

Gordon Research Conference, New Frontiers in Cancer Detection and Diagnosis, Andover, NH, August 2003

Imaging in 2020, Jackson Hole, WY, September 2003

University of Texas, McDermott Center for Human Growth and Development, Human Genetics Lecture Series, Dallas, TX, September 2003

US Department of Energy, BER Medical Sciences, Workshop on Targeted Radionuclide Therapy of Solid Tumors, Washington, D.C., September 2003

American Society for Therapeutic Radiology and Oncology (ASTRO) 45th Annual Meeting, Salt Lake City, UT, October 2003

National Institutes of Health, Genome Reviewers Meeting, Bethesda, MD, October 2003

University of Southern California, 8th Annual Symposium of the Institute for Genetic Medicine, Los Angeles, CA, November 2003

Ohio State University, Mathematical Biosciences Institute, Cell Proliferation and Cancer Therapy, Columbus, OH, November 2003

AstraZeneca R&D Boston, Breast Cancer Symposium, Waltham, MA, November 2003

University of Texas, MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology and Gastrointestinal Cancer Research Program Seminar Talk, Houston, TX, January 2004

NIH, NCI Nanotechnology Conference: Visualizing and Targeting Cancer, La Jolla, CA, March 2004

University of California, San Diego Seminar, San Diego, CA, April 2004

National Cancer Institute, National Human Genome Research Institute, Workshop, Exploring Cancer through Genomic Sequence Comparisons, Bethesda, MD, April 2004

Cold Spring Harbor Laboratory, Breast Cancer Research: A Critical Review for Future Strategies, Cold Spring Harbor, NY, May 2004

General Motors Cancer Research Foundation Conference on Genome Integrity and Cancer, Bethesda, MD, June 2004

Early Detection Research Network, Rockville, MD, June 2004

Gordon Research Conference – Molecular Therapeutics of Cancer, New London, NH, July 2004
Presidents Cancer Panel, San Francisco, CA, August 2004
Abbott Laboratories, Chicago, IL, September 2004
Human Heritable Mutation Workshop, Bar Harbor, ME, October 2004
Fox Chase Cancer Center, Philadelphia, PA, December 2004
University of Toronto, Toronto, Canada, December 2004
ASIP Experimental Biology Meeting, San Diego, CA, April 2005
New York University Cancer Institute, New York, NY, April 2005
AACR Annual Meeting, Genomics Symposium, Anaheim, CA, April 2005
Colorado Cancer Center, Denver, CO, May 2005
Gordon Research Conference, Mammary Gland Biology, Newport, RI, June 2005
Cold Spring Harbor Symposium on Molecular Approaches to Controlling Cancer, Cold Spring Harbor, NY, June 2005
University of Michigan Medical School, Genomics Medicine Lecture, Ann Arbor, MI, September 2005
AACR Special Conference, Advances in Breast Cancer Research, La Jolla, CA, September 2005
GlaxoSmithKline Medical Genetics & Oncology Lecture, Philadelphia, PA, October 2005
Predictive Models of Cancer Susceptibility: Integrated Strategies, Newport Beach, CA, December 2005
Timberline Symposium on Epithelial Biology, Epithelial Cancer: Regulation by Intrinsic and Microenvironmental Factors, Timberline, OR, February 2006
Baylor College of Medicine, Breast Disease Research Seminar, Houston, TX, February 2006
Expedition Inspiration Tenth Annual Laura Evans Memorial Breast Cancer Symposium, Sun Valley, ID, March 2006
New York University, Cancer Institute Seminar Series, New York, NY, March 2006
AACR 97th Annual Meeting, Washington, D.C., April 2006
General Motors Cancer Research Conference, Genomics and Cancer, Washington, D.C., June 2006
NIH, NCI, Innovative Molecular Analysis Technologies (IMAT) Program, Keynote, Washington, D.C., September 2006
Dana Farber Harvard Breast SPORE Seminar Series, Boston, MA, September 2006
GRC New Frontiers in Cancer Detection & Diagnosis, Ventura, CA, January 2007
University of Alabama, Birmingham, Birmingham, AL, March 2007
University of California, Berkeley, Tumor Biology Symposium, Berkeley, CA, March 2007
AACR, 98th Annual Meeting, Los Angeles, CA, March 2007
M.D. Anderson Cancer Center, Melvin Samuels Lectureship, Houston, TX, March 2007
Massachusetts General, Cancer Research Seminar, Boston, MA, April 2007
Vanderbilt-Ingram 2007 Breast Cancer Retreat, Nashville, TN, May 2007
The Cardiovascular Research Center at Massachusetts General Hospital, Days of Molecular Medicine 2007 Symposium: Emerging Technologies and Cancer Biology, Cambridge, MA, May 2007
15th SPORE Investigators' Workshop, Baltimore, MD, July 2007

CBCRP Biennial Breast Cancer Research Symposium, Los Angeles, CA, September 2007

Institute of Medicine, National Cancer Policy Forum Workshop on Improving the Quality of Cancer Clinical Trials, Washington, D.C., September 2007

AACR Advanced Breast Cancer Research: Genetics, Biology, Clinical Applications Meeting, San Diego, CA, October 2007

Integrative Cancer Biology Program Steering Committee Meeting, Washington, D.C., November 2007

Clinical Proteomics Technologies for Cancer Retreat, Tucson, AZ, December 2007

Bebee Symposium, The Omics Revolution and Epidemiology, Keynote address to the National Academies celebrating the 60th Year Anniversary of the Atomic Bomb Casualty Commission / Radiation Effects Research Foundation (RERF), Washington, D.C., December 2007

San Antonio Breast Cancer Conference, Susan G. Komen for the Cure 2007 Brinker Award for Scientific Distinction, Recipient Acceptance lecture, San Antonio, TX, December 2007

siRNA Consortium Meeting, Houston, TX, December 2007

Breast Cancer Symposium, Think Tank 18, Kailua Kona, Hawaii, HI, January 2008

Salk Institute Seminar Series, San Diego, CA, February 2008

Arizona Cancer Center, Tucson, AZ, March 2008

Tucson Symposium, Tucson, AZ, March 2008

National Institutes of Health, National Cancer Institute, Early Detection Research Network, 5th Annual Workshop, Biomarkers at the Crossroads, Keynote address, Bethesda, MD, March 2008

Ceil Mortel Visiting Scholar in Cancer Research Lecture, Hershey, PA, March 2008

AACR Annual Meeting, Translating the Latest Discoveries into Cancer Prevention and Cures, San Diego, CA, April 2008

Baylor University, Dan L. Duncan Cancer Center, Houston, TX, April 2008

ICG Lecture, Columbia University, New York, NY, April 2008

CCMB Distinguished Lecture, Brown University, Providence, RI, April 2008

Scripps Cancer Affinity Group lecture, La Jolla, CA, May 2008

National Institutes of Health, National Cancer Institute, The Role of Biomedical Informatics in Overcoming Current Barriers in Cancer Research, Workshop, Keynote address, Columbus, OH, May 2008

American Society of Clinical Oncology, (ASCO) Symposium, Advances in Translational Breast Cancer Research, Chicago, IL, June 2008

Bio International Conference, San Diego, CA, June 2008

7th Annual International Congress on the Future of Breast Cancer, Keynote address, Koloa, Kauai, HI, July 2008

Molecular Diagnostics in Cancer Therapeutic Development, Keynote address, Philadelphia, PA, September 2008

National Human Genome Research Institute, Lecture, Bethesda, MD, September 2008

61st Annual Symposium on Cancer Research Systems Biology of Cancer, Houston, TX, November 2008

Siteman Cancer Center, Basic Science Seminar, St. Louis, MO, November 2008

AVEO Pharmaceuticals, Inc., Scientific Advisory Board, Cambridge, MA, November 2008

NCI Think Tank in MicroRNA in Cancer Biology, Bethesda, MD, December 2008

CTCR-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 2008

Systems Biology Meeting, New Approaches to Personalized Medicine: Inflammation, Healing, and Regeneration as Prototypes “Pathophysiology and systems biology approaches in breast cancer” Keynote address, University of California, Riverside, CA, January 2009

National Cancer Institute (NCI), Integrative Cancer Biology Program (ICBP) and Tumor Microenvironment Network (TMEN) Joint Meeting, “RTK signaling in single cells” Keynote address, Bethesda, MD, January 2009

AACR Translation of the Cancer Genome Special Conference, “Omics and Predictive Biomarkers” Keynote address, Boston, MA, February 2009

AACR 100th Annual Meeting, HER2-Targeting Therapies, Resistance, and Counter-Acting Strategies Session, Chairperson: Dihua Yu, “Novel and not so novel biomarkers of response and resistance to inhibitors of HER2 (ErbB2)” Denver, CO, April 2009

American Society of Clinical Oncology, (ASCO) Symposium, Systems Biology, Cancer Therapeutics, and Personalized Medicine, “Systems biology approaches to marker guided therapy in breast cancer” Orlando, FL, June 2009

Herbert Irving Comprehensive Cancer Center, Columbia University Distinguished Scientist Lecture, “Marker guided therapy in breast cancer” New York, NY, June 2009

AACR Pathobiology of Cancer Workshop, “Systems approaches to marker guided therapy” Snowmass, CO, July 2009

NCI Clinical Proteomic Technologies Strategy Workshop, Keynote address, “Biologically informed biomarkers: Handling the multifaceted essence of cancer” Bethesda, MD, September 2009

Oregon Health & Science University, Scientific Seminar, “Omics, systems biology & marker guided therapy” Portland, OR, September 2009

National Functional Genomics Consortium Meeting, Keynote address, Oncogenomics Session, “A systems approach to improved breast cancer management” Clearwater, FL, September 2009

American Society of Human Genetics Annual Conference, Session on Impact of Large-scale Genomics on Target Discovery in Cancer, Co-Moderators: Daniela S. Gerhard and Joseph G. Vockley, “Translation of discoveries from large-scale genomics studies in ovarian cancer” Honolulu, HI, October 2009

2nd Annual Beth Israel Deaconess Cancer Center Symposium, “Omics approaches to breast cancer detection and treatment” Boston, MA, November, 2009

Breast Cancer Symposium, Think Tank 20, “Pharmacogenomic insights from assessments of responses to 20 drugs in 50 breast cancer cell lines” Bridgetown, Barbados, January 2010

Translating Scientific Breakthroughs to the Radiation Oncology Patient, Gordon Research Conference, Keynote Address “Translating insights from the cancer genome into clinical practice” Galveston, TX, January 2010

First Annual Cancer Biology Retreat, Keynote Address “Insights on predictive markers from preclinical models” University of Colorado, Denver, Anschutz Medical Campus, Denver, CO, February 2010

Huntsman Cancer Institute Scientific Seminar, “Systems approaches to marker guided therapy in breast cancer” Salt Lake City, UT, March 2010

Society of Gynecologic Oncologists (SGO) Annual Meeting on Women’s Cancer, Hugh R.K. Barber MD Endowed Lectureship: Presidential Speaker, Translational Cancer “Omics” Focus on Breast and Ovarian Cancer, “An ‘omic’ approach to personalized cancer management” San Francisco, CA, March 2010

AACR 101st Annual Meeting, Meet the Expert Session: “Functional breast cancer genomics;” Forum on Molecular Diagnostics “Advancing cancer biomarkers to cancer diagnostics: Increasing the pace of progress;” Major symposium, Breast Cancer Systems Biology, “Applications of systems biology approaches to cancer” Washington DC, April 2010

Herbert Irving Comprehensive Cancer Center Annual Symposium on Advances in Cancer Research; Systems Approaches to Cancer, "In vitro systems approaches to breast cancer" New York, NY, May 2010

Mouse Models of Human Cancer Consortium Steering Committee meeting, "Lessons from The Cancer Genome Atlas project" Rockville, MD, June 2010

Origins of Cancer Symposium, Keynote address "A Systems genomics approach to personalized cancer management" Grand Rapids, MI, June 2010

AACR Conference on Molecular Diagnostics, "An in vitro system to model therapeutic response to breast cancer" Denver, CO, September 2010

University of Chicago: Personalize Cancer Therapeutics Symposium, Keynote Address, "A systems approach to maker guided therapy in breast cancer" Chicago, IL, October 2010

Novartis Oncology and Dana Farber 2009 Annual Joint Retreat, Keynote Address "An omics approach to marker guided therapy" Incline Village, NV, October 2009

MD Anderson Cancer Center: Symposium on Cancer Research, Personalized Cancer Therapy and Prevention: Keynote address, "A systems approach to maker guided therapy in breast cancer" Houston, TX, October 2010

NIH NCI Innovative Molecular Analysis Technologies (IMAT) Program, Keynote address "Concept, challenges, and paradigms in molecularly informed cancer care" San Francisco, CA, October 2010

Association for Molecular Pathology (AMP) Meeting, Panel: Plenary Session I, Solid Tumors, Molecular Diagnosis and Prognosis for Breast Cancer, "Genomic approaches to predictive and prognostic markers in breast cancer" San Jose, CA, November 2010

Hollings Cancer Retreat, "A systems approach to maker guided therapy in breast cancer" Charleston, SC, November 2010

SU2C Summit Meeting, "An integrated approach to targeting breast cancer" Miami, FL, January 2011

Cancer Genetics and Epigenetics Gordon Research Conference, Keynote address "Therapeutic insights from an integrated genomics" Ventura Beach, CA, January, 2011

AACR-NCI Cancer Systems Biology Meeting, "Modeling molecular diversity in breast cancer" La Jolla, CA, February 2011

AACR Annual Meeting, Major Symposia: A Systems Biology Approach to Cancer Therapeutics, "A systems approach to identification of genomic determinants of therapeutic response" Orlando, FL, April 2011

Breast Cancer Research Program Annual Retreat, "A systems approach to predictive markers in breast cancer" Houston, TX, April 2011

University of California, San Diego, Pharmacology Seminar Series, "Linking the clinic and the 'ome' - systems approaches to marker guided therapy" San Diego, CA, April 2011

Pacific Northwest National Laboratory, Frontiers in Biological Sciences Lecture Series, "A systems approach to breast cancer - carcinogenesis to therapy" Richland, WA, April 2011

2011 ASCO Annual Meeting, "The future of genomics in directing personalized cancer therapy" Chicago, IL, June 2011

University of Pittsburgh Cancer Institute Scientific Retreat, Keynote address: "Systems approaches to predictive markers in breast cancer" Pittsburgh, PA, June 2011

Association Pathology Chairs Summer Meeting, "What is coming in proteomics and translational research" Monterey, CA, July 2011

NCI Translational Science Meeting, Keynote address: "Translational Science – Genomics and Beyond" Washington, DC, July 2011

U.S. Department of Defense's Era of Hope Conference, “Early Detection of metastasis prone breast cancers” Orlando FL, August 2011

Norris Grand Rounds, University of Southern California, Keynote address, “A systems approach to breast cancer management – omics and beyond” Los Angeles, CA, September 2011

Selventa Sponsored Symposium, Keynote address: “A systems approach to breast cancer management - omics and beyond” Princeton, NJ, September 2011

Translation of Cancer Genome Conference, “Models and processes to facilitate preclinical to clinical translation” San Francisco, CA, October 2011

Southwest Oncology Group, Keynote address: “Next generation sequencing: Where can SWOG get involved?” San Antonio, TX, October 2011

San Antonio Breast Cancer Symposium, William L. McGuire Memorial Award Lecture, “Translating genomic insights into improved breast cancer management” San Antonio, TX, December 2011

Spore at Mayo Clinic, Keynote address: “A systems biology approach to breast cancer” Rochester, MN, January 2012

UCSF Breast Oncology Program Scientific Retreat, “Spatial systems biology” San Francisco, CA, February 2012

NCI Quantitative Imaging Network Annual Meeting, “Imaging and correlation with genomics” Bethesda, MD, March 2012

AACR Annual Meeting, Methods Workshop Session: Omics Approach to Adaptive Clinical Trials, “Omics and systems biology analysis strategies in I-SPY”; Scientist↔Survivor Program, “Physical & Biological Sciences”, Major Symposium: Interrogating the Logic of the Cancer Cell: Lessons From Integrative and Systems Biology Approaches, “Novel models and treatments targeting the HER-AKT pathway in cancers that overexpress HER2”; Minisymposium: Steroid Hormone Receptors in Breast and Prostate Cancer, “Critical mediation of E2-induced apoptosis through c-Src in long-term estrogen deprived breast cancer cells”; Science Policy Session: Evolution of Translational Omics: Lessons Learned and the Path Forward, “Best practices in omics-based clinical discovery”; SU2C Special “Open” Session: Maximizing Innovation Through Translational Research and Team Science, “An integrated approach to targeting breast cancer molecular subtypes” Chicago, IL, April 2012

Stanford CCSB Seminar Series, “A systems approach to breast cancer - genomics and beyond” Stanford, CA, April 2012

Roswell Park Cancer Institute, Keynote Address: “Systems approaches to breast cancer - genomics and beyond” Buffalo, NY, May 2012

Arizona State University Complex Adaptive Systems Initiative (CASI) and the University of Southern California Physical Sciences Oncology Center (USC-PSOC), Complex Adaptive Systems (CAS): Leveraging Advances in the CAS Sciences, “A complex disease – cancer” Scottsdale, AZ, June 2012

SU2C-AACR Progress review team visit, An Integrated Approach to Targeting Breast Cancer Molecular Subtypes and Their 'Resistance' Phenotypes, “Bio discovery / Informatics” Santa Cruz, July, 2012

I-SPY Science Retreat, San Francisco, CA, July 2012

NIH National Cancer Institute – Frederick Advisory Committee (NFAC) Advisory Committee Meeting, Bethesda, MD, September 2012

Physical Sciences in Oncology National Cancer Institute Site Visit, Session II: Translating Fundamentals. Deliverables: Model Systems, Screens, Drug Discovery, “Dynamic measurement and modeling of spatially complex signaling networks” San Francisco, CA, September 2012

Department of Defense, Congressionally Directed Medical Research Programs (CDMRP), Breast Cancer /Ovarian Cancer Research Programs (BC/OCRP) Panel Chairperson, Grant Peer Review, Reston, VA, September 2012

SU2C Team Meeting, An Integrated Approach to Targeting Breast Cancer Molecular Subtypes and Their “Resistance” Phenotypes, Bioinformatics and Discovery Subgroup Update: Part 2 – Database and Sequencing, Dallas, TX, September 2012

International Conference on Genomics (ICG), The Children’s Hospital of Philadelphia (CHOP), “Genomic approaches to predicting responses to breast cancer treatment” Philadelphia, PA, September 2012

Simon M. Shubitz Award Lecture, University of Chicago, “The impact of measurement science on cancer management” Chicago, IL, October 2012

Lawrence Livermore National Laboratory, 60th Anniversary Science Day, Induction into the Entrepreneurs’ Hall of Fame, Livermore, CA, October 2012

National Academy of Science, Institute of Medicine Annual Meeting, Washington, DC, October 2012

University of California, San Diego, Nature / Institute for Genomic Medicine, Session I: Cancer Genomics, “Understanding and translating the breast cancer genome” San Diego, CA, November 2012

Intel, Meet the European Exascale Labs, “Genomics and spatial systems biomedicine: Cancer as a use case” presentation with Dr. Paul Spellman, Santa Clara, CA, November 2012

International Society for Computational Biology, RECOMB Conference on Regulatory and Systems Genomics, with DREAM Challenges, Keynote address “An in vitro system for identification of predictive markers” Redwood City, CA, November 2012

NCI Breast Cancer Models Summit, University of Pennsylvania Cancer Center, Philadelphia, PA, November 2012

Colorado School of Mines, Commencement Address, Denver, CO, December 2012

AACR Special Conference, Tumor Invasion and Metastasis, Session 8: Treatment of Metastatic Cancer, “Omic and imaging approaches to understanding breast cancer progression” San Diego, CA, January 2013

University of California, San Francisco, Breast Oncology Program Scientific Retreat, Tumor Heterogeneity (session moderator), San Francisco, CA, January 2013H. Lee *Moffitt Cancer Center* & Research Institute presentation, “Biomarkers in breast cancer” (remotely) Tampa, FL, January 2013

Personalized Medicine World Conference “Understanding and translating the breast cancer genome” Mountain View, CA, January 2013

Stand Up to Cancer (SU2C) Scientific Summit, Breast Cancer Dream Team Progress Report presentation; “Sharing of Genome and Other Research Data” Panelist, Phoenix, AZ, January 2013

National Cancer Institute, Frederick Advisory Committee Meeting, Berkeley, CA, February 2013

20th Molecular Medicine Tri-Conference presentation, “Pre-clinical models for prediction of therapeutic response in breast cancer” San Francisco, CA, February 2013

Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research, Signaling and Systems Biology Session, “A systems approach to understanding and predicting therapeutic response” Maui, HI, February 2013

National Cancer Institute, Systems Biology Think Tank, Cambridge, MA, February, 2013

Susan G. Komen Peer Review and Scholars Meeting, “A Future for breast cancer research” Grapevine, TX, March 2013

Case Western Reserve University, Cancer Center Seminar Series, “System approaches to breast cancer management” Cleveland, OH, March 2013

9th Annual Breast International Group (BIG) and the North American Breast Cancer Group (NABCG) Meeting, Washington DC, April 2013

AACR Annual Meeting, SU2C/PI3K Group, “PI3K Analysis: micro and nano architecture of signaling”; The Breast Cancer Genome and its Implications for Therapy, Chairpersons: José Baselga and Joe W. Gray, presentation “In vitro approaches to functional assessment of breast cancer "omic" features: *Concepts from spatial systems biomedicine*”; Update and Dialogue: A Meeting with the Chair and Co-Chairs of the SU2C Scientific Advisory Committee (SAC); Komen Tissue Bank Think Tank, Rational Therapy for Breast Cancer (RATHER) Scientific Board Meeting; Washington DC, April 2013

Institute of Electrical and Electronics Engineers (IEEE) International Symposium on Biomedical Imaging (ISBI): From Nano to Macro: “Systems biology and cancer management” San Francisco, April 2013

Integrative Cancer Biology Program Annual Principal Investigators Meeting, Rockville, MD, May 2013

XXVIII Congress of the International Society for Advancement of Cytometry (CYTO 2013), Innovation, Discovery and Translation, Wallace H. Coulter Centennial Lecture, “Spatial systems biology” San Diego, CA, May 2013

Wayne State University, Karmanos Cancer Institute, Grand Rounds, “Spatial systems biology and cancer” Detroit, MI, May 2013

H. Lee Moffitt Cancer Center & Research Institute presentation, “New approaches to breast cancer Management: From genomics to architectural therapeutics” Tampa, FL, June 2013

The Innovation Economy: Information Revolution Transforming Health Care Through Big Data, Bipartisan Policy Center, Panelist, Examples of How Big Data Has Driven Improvements in Health and Health Care: The Opportunities and the Challenges, keynote remarks, Washington, DC, June 2013

The 28th Annual Aspen Cancer Conference, Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy” presentation, “Spatial systems biomedicine and breast cancer” Aspen, CO, July 2013

Fifth Annual Next Generation Dx Summit: Moving Assays to the Clinic, Chair, 6th Annual Cancer Molecular Markers to Guide Therapy, Biomarker Discovery session; Keynote Presentation, Biomarker Analysis Session, “Identifying tumor intrinsic and extrinsic predictive markers” Washington, DC, August 2013

59th Radiation Research Society Annual presentation, “Spatial systems biomedicine – toward a multi scale, structural interpretation of the cancer ‘ome’” New Orleans, LA, September 2013

University of New Mexico Cancer Center, UNM Cancer Center Lectureship Series, “Spatial systems biology of cancer” Albuquerque, NM, October 2013

Tulane Cancer Center, Louisiana Cancer Research Center Seminar Series, “Spatial systems biology of cancer” New Orleans, LA, October 2013

University of Notre Dame, College of Science, Nieuland Lecture Series, “A systems biology view of breast cancer”; “From genome to structure: Spatial systems biology of cancer" and "Impact of technology on science" South Bend, IN, October 2013

Vanderbilt University, NCI Current Topics in Cancer Systems Biology: Tumor Cell Heterogeneity Workshop, “Understanding and managing heterogeneity in differentiation status” Nashville, TN, December 2013

National Cancer Institute 2014 Intramural Scientific Investigators Retreat, 18th Annual Alfred G. Knudson Award Lecture in Cancer Genetics, “Exploiting the cancer ‘ome’—from molecular markers to architectural therapeutics” Washington, DC, January 2014

University of Virginia, Department of Biomedical Engineering Seminar Series, “Spatial systems biology of cancer” Charlottesville, VA, January 2014

Health Care Innovation Day 2014, Ignite Talks: Stakeholder Perspectives session, “Research data sharing – Technical issues impacting genomics & cancer research” Washington, DC, February 2014

Ventana Medical Systems 10th Annual Tucson Symposium, Chair, Session on Innovations in Technology, and presentation “Spatial systems biology of cancer” Tucson, AZ, February 2014

University of Texas MD Anderson, Institute for Personalized Cancer Therapy, External Advisory Board review and Department of Bioinformatics and Computational Biology presentation, “Spatial systems biology of cancer” Houston, TX, March 2014

AACR 105th Annual Meeting, “Impact of the microenvironment on cancer biology and therapeutic response” in Phenotyping and Function of Solid Tumor Stroma Session, “Genomics and beyond – taking a systems view of cancer” for Scientist↔Survivor Program, Session Chairperson: Quantitative Models of Tumor Heterogeneity: From Clonal Diversity to Epigenetic Drift to the Microenvironment, Current Concepts in Diagnostics and Therapeutics Research, San Diego, CA, April 2014

Genentech, Translational Oncology, Research, Special Lecture, “Spatial systems biology of cancer” South San Francisco, CA, April 2014

Helen Diller Family Comprehensive Cancer Center, Novartis Distinguished Cancer Research Lecture, “Spatial systems biology of cancer” San Francisco, CA, April 2014

Institute for Systems Biology, Session 4: Technology, “Spatial systems biology of cancer” Seattle, WA, April 2014

United States House Energy and Commerce Committee, Roundtable discussion - medicine, computers and social networks - 21st Century Cures, Washington, DC, May 2014

FEI’s Fourth Technology Conference, Enabling our Customers to Create a Better World. Workflow Solutions to Promote Innovation in Science & Technology, Life Sciences BU keynote presentation, “Exploring cancer ‘inner space’: New measurement tools lead to new approaches to cancer management” Grand Ronde, OR, May 2014

37th Annual Course in Cytometry, Methods and Applications, “Systems biology, cytometry and cancer” Bowdoin College, Brunswick, ME, June 2014

Kavli Institute for Theoretical Physics, University of California, “A spatial systems biology approach to therapeutic resistance in cancer” Santa Barbara, CA, September 2014

Fred Hutchinson Cancer Center, Division of Human Biology Seminar, “A spatial systems biology perspective on cancer management” ~ Seattle, WA, September 2014

24th Beckman Symposium, New Horizons on Oncogenesis, “Spatial systems biology of cancer” Duarte, CA, November 2014

Murdock Trust, Partners in Science National Conference, UC San Diego, “Measuring and managing cancer complexity at multiple scales” San Diego, CA, January 2015

AACR Special Conference on Computational and Systems Biology of Cancer “Spatial systems biology and cancer” San Francisco, CA, February 2015

AACR Annual Meeting, 18th Annual Grant Writing Workshop “Foundations: Susan G. Komen”, Personalized Cancer Discussion, Posters (co-author): Therapeutic Resistance in Hormone-Sensitive Cancers “Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer,” and Tumor- and Blood-based Genotyping , “Consensus molecular subtyping through a community of experts advances unsupervised gene expression-based disease classification and facilitates clinical translation,” SESSION: Meet-the-Expert, “Understanding cancer: Microenvironment Interactions at Multiple Scales” Scientist↔Survivor Program: Special Interest Session “Cancer at the nanoscale” Philadelphia, PA, April 2015

University of Colorado, Department of Pathology and the Cancer Biology Program, first DW and ME King Endowed Lecture Seminar Series, Insights on Cancer Complexity-Insights from the bench to the bedside, “Measuring and managing cancer complexity at multiple scales” Boulder, CO, April 2015

MD Anderson Cancer Center, John H. Blaffer Lecture Series, sponsored by the Center for Genetics and Genomics, “Spatial system biology and cancer - from omics to architecture” Houston, TX, April 2015

Center for Domain-Specific Computing / InTrans Project Semi-Annual Meeting, “Measuring and managing cancer complexity at multiple scales” Los Angeles, CA, April 2015

Komen Scholars Annual Meeting, Leadership Conference, Scientific Advisory Board plenary session, “Image based approaches to understanding and managing epigenomic heterogeneity” Ft. Worth, TX, June 2015

SAMSI Ideas Lab, “Current developments in cancer precision medicine” Research Triangle Park, NC, July 2015

Dana Farber Cancer Institute, Seminars in Oncology, “Understanding & managing cancer heterogeneity” Boston, MA, September 2015

Library of Integrated Network-Based Cellular Signatures (LINCS) Year One Face-to-Face Meeting, “High-throughput image-based assessment of cellular phenotypes modulated by microenvironment perturbagens” Washington, DC, September 2015

University of Minnesota, Biomedical Engineering Graduate Seminar, “Measuring and modeling heterogeneity in breast cancer” Minneapolis, MN, November 2015

University of Pittsburgh Drug Discovery Institute, Executive Advisory Board meeting, Pittsburgh, PA, November 2015

Massachusetts Institute of Technology, Langer Lab Seminar, “Measuring and modeling heterogeneity in breast cancer” Cambridge, MA, November 2015

Antibody Association Annual Meeting, Antibody Engineering & Therapeutics, “A spatial systems biological view of cancer” San Diego, CA, December 2015

University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, T32 Mini-Symposium & Friday Seminar, “Spatial systems biology of breast cancer” San Francisco, CA, January 2016

Translational Medicine Summit VII, Scottsdale, AZ, March 2016

12th Annual Tucson Symposium, Ventana Medical Systems, Keynote Lecture “Managing and interpreting information in the precision medicine era” Tucson AZ, March 2016

Library of Integrated Network-Based Cellular Signatures (LINCS) Retreat and Outreach Meeting, “Microenvironment”; Hands on with LINCS, getting familiar with LINCS data, “Imaging considerations for iPS, neural, and common cells” (Gray, Finkbeiner, Sorger), Newport Beach, CA, March 2016

Oregon Health & Science University Foundation and Doernbecher Children’s Hospital Foundation Annual Spring Conference, “Honing in on precision medicine” Palm Desert, CA, March 2016

Intel Cloud Day, TEN Talks, Software Defined Infrastructure in the Enterprise, “The Collaborative Cancer Cloud (CCC): Taking precision medicine into the mainstream” San Francisco, CA, March 2016

Systems Approaches to Cancer Biology Conference, Woods Hole, MA, April 2016

Personalized Cancer Medicine: From High throughput Data to Optimal Drug Therapies, “Understanding and managing personalized drug treatments of heterogeneous, adaptive systems” Atlanta, GA, April 2016

AACR Annual Meeting, Introduction of Fellows of the AACR Academy; Scientist↔Survivor Program, Forging Partnerships to Accelerate Progress Against Cancer, “Special Interest Session: Genomics” New Orleans, LA, April 2016

AACR Special Conference on Engineering and Physical Sciences in Oncology, Chairperson, Plenary Session 1: Cancer Modeling/Systems Biology, “An integrated omic-multiscale imaging view of breast cancer” Boston, MA, June 2016

Antibody Technology Resource Center (ATRC) Symposium, “Exploring the biology of cancer cell communication and control: Use cases for antibody technology development” San Francisco, CA, October 2016

Second Annual APOBEC Cancer Program Workshop, Minneapolis, MN, October 2016

22nd Annual Cancer Symposium, Biomedical Engineering and its Application to Cancer, Penn State Hershey Medical Center, “Hyperspace, The new fourth-dimension approach to cancer research” Penn State College, PA, October 2016

Executive Advisory Board, Center for Causal Discovery Meeting, Pittsburgh, PA, November 2016

CASE Advisory Board, (College of Applied Science and Engineering) meeting, Colorado School of Mines, Golden, CO, November 2016

Neon Therapeutics / Tango Meetings, “Getting SMMART* about mechanisms of resistance *serial measurements of molecular and architectural responses to therapy” Cambridge, MA, March 2017

IBM Research – visit to Almaden Lab, San Jose, CA, March 2017

External Scientific Advisory Committee, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, April 2017

Regional and Local

Department of Laboratory Medicine, UCSF, Retreat, San Francisco, CA, 1993

Diagnostic Pathology Seminar, UCSF, San Francisco, CA, 1993

Gallo Center Seminar, SFGH, San Francisco, CA, 1993

President’s Cancer Panel, UCSF, San Francisco, CA, 1993

Breast Cancer SPORE seminar, UCSF, San Francisco, CA, 1993

Human Genetics seminar, UCSF, San Francisco, CA, 1993

Department of Laboratory Medicine, UCSF, Course on Molecular Cytogenetics in Cancer (Genetic aberrations and cancer progression), San Francisco, CA, 1993

Department of Laboratory Medicine, UCSF, Course on Molecular Cytogenetics in Cancer (An overview of the Human Genome Program and the Resource for Molecular Cytogenetics), San Francisco, CA, 1993

Stanford University Genetics Seminar, Stanford, CA, 1994

Department of Ophthalmology, UCSF, Grand Rounds Lecture, San Francisco, CA, 1994

University of California, Davis, Cancer Center, Sacramento, CA, 1994

Department of Obstetrics & Gynecology, UCSF, Seminar, San Francisco, CA, 1994

Stanford University Genetics Seminar, Stanford, CA, 1994

Genentech Inc. Seminar, South San Francisco, CA, 1994

Grand Rounds, Department of Laboratory Medicine, UCSF, San Francisco, CA, 1995

Gynecology-Oncology Research Group, UCSF, San Francisco, CA, 1995

Gladstone Institute of Cardiovascular Disease, San Francisco General Hospital, San Francisco, CA, 1996

Friday Research Seminar, Hellman Conference Center (Positional Cloning of Genes Involved in Solid Tumor Progression), UCSF, San Francisco, CA, 1996

Dean’s Research Seminar, UCSF, San Francisco, CA, 1996

Department of Laboratory Medicine, UCSF, Biophysics Course (Positional Cloning of Tumor Genes), San Francisco, CA, 1996

Future Directions in Cytometry, Palo Alto Cytometry Users Group (History of Flow Cytometry), Stanford University, Palo Alto, CA, 1996

Program in Cellular and Molecular Medicine, San Francisco General Hospital (Genome Scanning in Breast and Ovarian Cancer), UCSF, San Francisco, CA, 1997

University of California Cancer Center Inaugural Symposium, UCSF, San Francisco, CA, 1997

Grand Rounds, Department of Laboratory Medicine (Breast and Ovarian Cancer Amplicons: PI3K and Zinc Finger Genes), UCSF, San Francisco, CA, 1997

Spring Biomedical Sciences Graduate Program Symposium: Genomics Technology (Physical maps: Resources for disease gene localization and identification), UCSF, San Francisco, CA, 1997

Gladstone Institute Retreat, Pajaro Dunes, CA, 1997

Hematology and Oncology: Concepts and Controversies, Radisson Miyako Hotel, San Francisco, CA, 1998

Cancer Biology Course: Molecular and Cellular Biology of Cancer (Amplified Genes in Cancer at Cancer Biology Course), Stanford University, Stanford, CA, 1998

Second Annual UCSF Cancer Center Symposium, (Cancer Genomics: Genomes to Genes), Cole Hall, UCSF, San Francisco, CA, 1998

UC Davis Symposium on Optical Biology, University House, UC Davis, Davis, CA, 1998

Human Genetics Research Talk, UCSF, San Francisco, CA, 1998

Department of Laboratory Medicine: Grand Rounds, UCSF, San Francisco, CA, 1998

Symposium on Biomedical Optics: Molecular Imaging: Reporters, Dyes, Markers and Instrumentation, San Jose, CA, 1999

Tumor Biology Seminar Series, Stanford University, Stanford CA, 1999

Advances in Genomic Research Symposium, SFSU, San Francisco, CA, 1999

Laboratory Medicine and Pathology Grand Rounds, UCSF, San Francisco, CA, 2000

Breast Oncology Program Seminar, UCSF, San Francisco, CA, 2000

Stanford University Cancer Biology Course, Palo Alto, CA, 2000

Bay Area Cancer League, Piedmont, CA, October 2000

UC Irvine Avon Breast Cancer meeting, Irvine, CA, November 2000

UC Irvine Molecular Genetics Seminar, Irvine, CA, May 2001

Berlex Laboratories, Inc., Richmond, CA, August 2001

Course lecture, "Study and treatment of cancer" Stanford University, Stanford, CA, November 2001

UCSF Biophysics and Biochemistry Retreat, Asilomar, CA, December 2001

Annual meeting of American Society of Breast Disease, Keynote Talk, San Francisco, CA, April 2002

UCSF Brain Tumor Research Center (BTRC) - Scientific Symposium, UCSF, San Francisco, CA, September 2002

Lawrence Livermore National Laboratory Science Day: Science Day 2002 - Our Heritage, Our Future, Livermore, CA, September 2002

UCI/AVON Symposium, UC Irvine, Irvine, CA, October 2002

24th Congress of the International Association for Breast Cancer Research, Sacramento, CA, November 2003

Mathematical Sciences Research Institute, Genetics of Complex Disease Workshop, Berkeley, CA, January 2004

Genentech Presentation and Roundtable Discussion, South San Francisco, CA, February 2004

UC Presidents Council Presentation, LBNL, Berkeley, CA, February 2004

LBNL Life Sciences Division Retreat, Asilomar, CA, April 2004

Avon Foundation, Second Annual Symposium, Delivering the Continuum of Breast Cancer Care to the Underserved, San Francisco, CA, May 2004

Photonic Applications, Systems and Technologies (PhAST) Conference Keynote Address, San Francisco, CA, May 2004

California State Senate Joint Committee, Preparing California for the 21st Century, Emerging Biotechnology, Sacramento, CA, May 2004

High Content Imaging, San Francisco, CA, January 2005

Kansas State University, Manhattan, KS, March 2005

Medical Grand Rounds, Genentech Inc., South San Francisco, CA, March 2005

LBNL Life Sciences Division Retreat, Berkeley, CA, March 2005

Amgen Seminar, South San Francisco, CA, July 2005

American Society for Human Genetics Mentor Program, Terra Linda, CA, April 2006

2006 International Brain Tumor Research and Therapy Meeting, Napa, CA, April 2006

Novel Trial Designs in the Setting of Neoadjuvant Therapy for Breast Cancer, St. Helena, CA, April 2006

Mathematical Sciences Research Institute, Mathematical Systems Biology of Cancer, Berkeley, CA, May 2006

Workshop on Statistics for Genome-Wide Copy Number Analysis in Cancer Research, Palo Alto, CA, September 2006

University of California, San Francisco Molecular Pathology and Biology of Neoplasia Course, San Francisco, CA, January 2007

NIH, National Cancer Institute, Translational Research Working Group, San Francisco, CA, January 2007

NIH, NCI, Ductal Carcinoma In Situ, Tumor Biology & Population Sciences, San Francisco, CA, February 2007

University of California, Berkeley, Tumor Biology Symposium, Berkeley, CA, March 2007

American Association of Cancer Research, Translational Cancer Medicine Think Tank, Santa Rosa, CA, July 2007

Mathematical Sciences Research Institute – Integrated Cancer Biology Program Workshop, Berkeley, CA, October 2007

Third Annual Personalized Medicine Meeting, San Francisco, CA, November 2007

Stanford Seminar, Stanford, CA, January 2008

I-SPY 2 Workshop, St. Helena, CA, February 2008

Roche Molecular Systems Seminar, Pleasanton, CA, March 2008

Genentech Seminar, South San Francisco, CA, April 2008

Pancreas Cancer SPORE External Advisory Board Retreat, San Francisco, CA, May 2008

Integrative Cancer Biology Program (ICBP) Data Integration Workshop, San Francisco, CA, May 2008

Applied Biosystems Seminar, Foster City, CA, June 2008

UCSF Breast, Cervical and Colon Cancer Surveillance Conference, San Francisco, CA, August 2008

UCSF Imaging Cancer: From Cell to Man, San Francisco, CA, December 2008

Cambridge Healtech Institute 16th International, Molecular Medicine Tri-Conference, Cancer Profiling & Pathways Conference, Keynote Address, San Francisco, CA, February 2009

UCSF Breast Cancer SPORE, Internal and External Advisory Board Meeting, San Francisco, CA, April 2009

Canary Foundation Early Detection Symposium, Stanford University, Stanford, CA, May 2009

NIH, National Cancer Institute, Integrative Cancer Biology Program Steering Committee, Stanford, CA, June 2009

Pfizer / UCSF / LBNL Collaboration, San Francisco, CA, July 2009

Molecular Therapeutics of Cancer Research Conference, Cancer Molecular Therapeutics Research Association, Stanford, CA, July 2009

Personalized Medicine, Silicom Ventures, “New diagnostic approaches to tailoring treatment to specific patients” Mountain View, CA, August 2009

Berkeley Lab’s Summer Lecture Series, “Genome science and personalized cancer treatment” Berkeley, CA, August 2009

Gray Lab Retreat, Cancer Detection, Treatment, and Biology: What We’ve Learned and Where We’re Going, Pacific Grove, CA, October 2009

BiPar Sciences Presentation, South San Francisco, CA, October 2009

2010 Breast Oncology Program Retreat, “Preclinical models for response prediction” San Francisco, CA, January 2010

Pinkel Symposium on Transformational Genomics, “Personalized breast cancer treatment: Insights from an in vitro cell line system” San Francisco, CA, February 2010

Lawrence Berkeley National Laboratory, Life Sciences and Genomics Division Seminar, “Therapeutic insights into breast cancer treatment from a preclinical systems biology approach” Berkeley, CA, April 2010

Cancer, Complexity and the Microenvironment: A Scientific Symposium and Celebration in Honor of Mina Bissell, “A systems approach to personalized cancer treatment” and Closing Remarks, Berkeley, CA, May 2010

AACR Translational Cancer Medicine, “New indications for old (and new) drugs” San Francisco, CA July 2010

Center for Cancer Nanotechnology Excellence (CCNE) and Molecular Imaging Program Seminar, “An omic view of signaling in breast cancer” Stanford, CA, August 2010

NIH NCI Integrative Cancer Biology Program (ICBP) Mathematical Modeling Meeting, Berkeley, CA, October 2010

NIH NCI Small Business Information Research Investor (SBIR) Forum, Panel: “Game changers in oncology: What’s on the horizon?” Stanford, CA, November 2010

Gray Laboratory Retreat, Napa, CA, December 2010

University of California, San Francisco, Breast Oncology Program Scientific Retreat, San Francisco, CA, January 2011

Oregon Health & Science University and Agilent Partnership Meeting, Santa Clara, CA, February 2011

2011 Northwest Regional Cytometry Meeting, “Spatial systems biology – the central role of cytometry in the interpretation of the genome” Portland, OR, March 2011

Oregon Health & Science University Lecture, “Genomics and beyond – a rationale for spatial systems biomedicine” Portland, OR, April 2011

Oregon Health & Science University Knight Cancer Institute, Solid Tumors and Hematologic Malignancies Translational Retreat, Translational Research Challenges and Opportunities Panel, “Multidisciplinary teams in breast cancer”; and presentation “Modeling mechanisms of response to RTK targeted therapies in breast cancer” Portland, OR, June 2011

Program in Molecular and Cellular Biosciences, Keynote address, Welches (Mt. Hood), OR, September 2011

Oregon Bioscience Association Annual Conference 2011, Platforms, Pathways and Pioneers: Oregon's Bioscience Progress, Keynote presentation, “Translational cancer research - Genomics and beyond” Portland, OR, September 2011

Providence Cancer Center Presentation, “Genomics and beyond – a case for spatial systems biomedicine” Portland, OR, September 2011

Mirabella Retirement Community Presentation, Portland, OR, October 2011

World Presidents’ Organization Presentation, “Exploring the Newest Dimension in Cancer Research: OHSU Center for Spatial Systems Biomedicine” Portland, OR, November 2011

Oregon Health & Science University Knight Cancer Center 4th Annual Esophageal Cancer Research Forum Presentation, “Team science: Promoting collaborative research with UGI cancer to promote personalized cancer” Portland, OR, January 2012

FEI Board Meeting Living Lab Vision Presentation, Hillsboro, OR, February 2012

Oregon Health & Science University 2012 Heart Research Center Scientific Retreat, Keynote presentation, “Spatial Systems Biomedicine, Cancer as a use case example” Portland, OR, March 2012

Portland State University Physics Department Lecture, “Learning through measuring – the impact of technology on cancer research” Portland, OR, March 2012

National Association of Cancer Center Development Officers (NACCDO), PAN Conference, Plenary Speaker, Portland, OR, May 2012

Gray / Spellman Laboratory Retreat, Gleneden Beach, OR, June 2012

Fred Hutchinson Cancer Research Center, Pacific Northwest Prostate Cancer Research Specialized Programs of Research Excellence (SPORE) presentation, “Functional interpretation of cancer genomes” Videoconference from Portland, OR, to Seattle, WA, July 2012

University of Oregon, Institute of Molecular Biology (IMB), Research, Innovation and Graduate Education (RIGE) Seminar Series, “Spatial systems biology and cancer” Portland, OR, October 2012

West Coast Association of Core Directors Conference, Building Bridges for Shared Resources Innovation, Keynote address, “Measuring better to understand better” Portland, OR, November 2012

Oregon Health & Science University, Marquam Hill Lecture, “Creating a google map of cancer: New ways of looking at and managing cancer” Portland, OR, March 2013

Multnomah Athletic Club, “Creating a google map of cancer?” Portland, OR, August 2013

Oregon Health & Science University, Shriners Research Center Retreat, “From the genome to structure - A multidisciplinary approach to the development of architectural therapeutics” Portland, OR, September 2013

Portland State University, Biology Department, “Spatial systems biology of cancer - from genome to architecture” Portland, OR, November 2013

Oregon Health & Science University, Surgery Grand Rounds, “New approaches to managing treatment of heterogeneous cancers” Portland, OR, December 2013

Oregon Biosciences Association, Ending Cancer as We Know It, Portland, OR, January 2014

Oregon Health & Science University, Dinner for Knight Challenge, “Harnessing technology to fight cancer” Portland, OR, April 2014

Oregon Health & Science University, Division of Environmental and Biomolecular Systems, Institute for Environmental Health Seminar, “Spatial systems biology of cancer” Portland, OR, April 2014

Oregon Health & Science University, Brain Awareness Series Lectures, Building Brain Bridges, The brain and cancer: How does your brain affect cancer — and its future treatments? “Cancer OF the brain: Cancer AND the brain” Portland, OR, May 2014

Portland Business Journal, Health Care of the Future, panelist “Innovation and Transformation in Health Care” panelist, Portland, OR, October 2014

EDCO’s Central Oregon Technology Forum, “Advances in imaging - Changing the detection and treatment of cancer” Bend, OR, February, 2015

Oregon Health & Science University / Oregon State University Joint Research / Graduate Education Program Retreat, “Understanding and managing the complexity of cancer and other diseases” Portland, OR, April 2015

FEI Supplier Day, University Club of Portland, “A nanoscale view of cancer: EM opportunities in precision medicine” Portland, OR, January 2016

Oregon State University / Oregon Health & Science University, Early Cancer Detection / Engineering Faculty Meeting, “Teaming up to fight cancer with knowledge” Portland, OR, January 2016

Oregon Health & Science University, Biomedical Engineering Seminar, “Recent progress in spatial systems biology – new capabilities and new insights” Portland, OR, January 2016

Oregon Health & Science University, Oregon National Primate Research Center Scientific Retreat, Keynote address “Multiscale view of cancer” Stevenson, WA, March 2016

Surgeon’s Travel Club, “Understanding and managing personalized drug treatments of heterogeneous, adaptive systems” Portland, OR, May 2016

Oregon Health & Science University, Molecular and Medical Genetics Grand Rounds, “Measuring and managing tumor heterogeneity” Portland, OR, June 2016

30th International Association for Breast Cancer Research Conference, Early Detection of Lethal Breast Cancers, Chair, Technologies for Early Detection and Characterization, “Multiscale characteristics of breast cancer” Portland OR, August 2016

International Federation of Placenta Associations, New Methods for Exploring Multiscale Placental Architecture, Keynote address “Understanding better by measuring better: Developing a “Google earth” approach to biology” Portland OR, September 2016

Oregon Health & Science University, School of Medicine Research Retreat, “Comparative analyses of normal and disease tissues”, Portland, OR, October 2016

Microenvironment Perturbations (MEP): Library of Integrated Network-Based Cellular Signatures (LINCS) Outreach Retreat, “Biology applications and use cases” Portland, OR, November 2016

Scientific Research Panel, M. J. Murdock Charitable Trust, Vancouver, WA, January 2017

Allen Institute for Cell Science / Oregon Health & Science University Collaboration Meeting, “OCSSB imaging Allen Institute”, Seattle, WA, January 2017

Serial Measurement of Molecular and Architectural Responses to Therapy (SMMART) “Mechanisms of Resistance” Research Retreat (SMORRR), Newberg, OR, January 2017

Oregon Health & Science University, Knight Cancer Research Group Seminar, the Quantitative Oncology Program, “Getting SMMART* about Mechanisms of Resistance *Serial Measurements of Molecular and Architectural Responses to Therapy”, Portland, OR, March 2017

Oregon Health & Science University – University of Oregon Research Collaboration Summit, Monmouth, OR, April 2017

CURRICULUM DEVELOPMENT

Students Supervised

1. Maria Pallavicini, Ph.D. (Provost, University of the Pacific)
2. Larry Scherr, Ph.D. (Ph.D. advisor)
3. Glenn Rice, Ph.D. (Research advisor; CEO and President, Bridge Pharmaceuticals)
4. David Benaron, M.D. (Research advisor; Assistant Professor of Pediatrics, Stanford University)
5. John Halamka, M.D., M.S. (Research advisor; Chief Information Officer, Harvard Medical School; Chief Information Officer, Beth Israel Deaconess Medical Center; Chair, New England Health Electronic Data Interchange Network (NEHEN); Chief Information Officer, Harvard Clinical Research Institute (HCRI); Associate Professor, Emergency Medicine, Harvard Medical School)
6. Mary Helen Barcellos-Hoff, Ph.D. (Professor, Departments of Radiation Oncology and Cell Biology, NYU Langone Medical Center, New York, NY)
7. Ms. Karen Han (Thesis committee, 1992)
8. Jennifer Fung, Ph.D. (Thesis committee, 1992-1996)
9. Laleh Daneshvar, Ph.D. (Ph.D. advisor, 1993-1998)
10. Nalin Gupta, M.D., Ph.D. (Thesis committee, 1993; Director, Pediatric Neurological Surgery Program, UCSF)
11. Brian Patrick Harmon, Ph.D. (Thesis committee chair, 1998-2002)
12. Gregory Frost, Ph.D. (Thesis committee chair, 1999)
13. Robert Otilar, Ph.D. (Thesis committee, 2000-2001)
14. Hosein Kouros-Mehr, Ph.D. (MSTP student rotation, 2001; Medical Student, UCSF)
15. Dr. David Rosen (BMS rotation student, 2002)
16. Mr. Alike Maunakea (BMS rotation student, 2002)
17. Anil Patwardhan, Ph.D. (Thesis committee, 2003; Senior Scientist, Panasonic San Jose Laboratory)
18. Ms. Monica Miranda (Thesis committee, 2005)
19. Jean-Philippe Coppé, Ph.D. (Thesis committee, 2005; Member, Campisi Lab, Lawrence Berkeley National Laboratory)
20. Dr. Christopher Kingsley (Thesis committee, 2006)
21. Ms. Molly Klein-McDowell (Thesis committee, 2008)
22. Ms. Jenny Hung (Graduate student intern, 2009)
23. Ms. Katherine Schultz (High school student, 2009)
24. Ms. Thea Atwater (High school student, 2009)
25. Ms. Zhiyuan Li (Graduate student intern, 2010)
26. Mr. Chun-Han Lin (Graduate student, 2010)

27. Mr. Timothy Butler (Thesis committee, 2012)
28. Mr. Spencer Watson, BS (Graduate Student, 2012; Thesis committee, 2015; Dissertation committee 2016-2017)
29. Mr. Worapol Ngamcherdtrakul (Thesis committee, 2012; Dissertation committee, 2015)
30. Mr. Ted Laderas (Thesis committee, 2013-2014)
31. Ms. Danielle Jorgens (Dissertation committee, 2013)
32. Ms. Lillian Klug (Welch, maiden name) (Qualifying committee, 2013)
33. Ms. Xiaoming Ouyang (Thesis committee, 2014)
34. Ms. Madeline Midgett (Thesis committee, 2014)
35. Mr. Tyler Ryson (Dissertation committee, 2015)
36. Ms. Yerim Lee (Dissertation committee, 2015)
37. Ms. Cheryl Claunch-Rabe (Dissertation committee, 2015)

Supervision

1. Heinz-Ulrich Weier, Ph.D. (Staff Scientist, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA)
2. Wen-Lin Kuo, Ph.D. (Retired Scientist, Former Gray Laboratory Manager, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA)
3. Damir Sudar, M.S. (Biophysicist Staff Scientist, Division Deputy for Technology, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA)
4. Toshihiro Tenjin, M.D. (Second Department of Surgery, Nippon Medical School, Tokyo, Japan)
5. Hisako Tenjin, M.D. (Gynecologist, Nippon Medical School, Tokyo, Japan)
6. Mayumi Matsuta, M.D. (Professor of Dermatology, Iwate Medical University, Morioka, Japan)
7. Morimasa Matsuta, M.D. (Medical Doctor, Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan)
8. Douglas Tkachuk, M.D. (Department of Laboratory Medicine and Pathobiology, University of Toronto; Toronto Medical Laboratories, Princess Margaret Hospital, University Health Network, Toronto)
9. Herman van Dekken, M.D., Ph.D. (Professor of Pathology, Erasmus Universiteit, Rotterdam, Netherlands)
10. Barbara Trask, Ph.D. (Director, Fred Hutchinson Cancer Research Center Human Biology Division; Professor of Molecular Biotechnology, Genome Sciences, University of Washington)
11. Jacob Aten, Ph.D. (Department of Cell Biology and Histology, Center for Microscopical Research, University of Amsterdam, Netherlands)
12. Dr. James Landegent (Kreatech Diagnostics, Amsterdam, The Netherlands)
13. Masaru Sakamoto, M.D. (Deputy Director of Gynecology, Sasaki Institute, Tokyo, Japan)
14. Olli Kallioniemi, M.D., Ph.D. (Director, SciLifeLab, Stockholm, Sweden; Professor and Director, Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Finland)
15. Anne Kallioniemi, M.D., Ph.D. (Professor of Cancer Genomics, Institute of Medical Technology, University of Tampere, Finland)

16. Haruhiko Nakamura, M.D., Ph.D. (Department of Chest Surgery, Atami Hospital, International University of Health and Welfare, Shizuoka, Japan)
17. Curtis Thompson, M.D. (Dermatopathologist, Curtis M. Thompson, M.D. and Associates, LLC, Portland, OR; Clinical Assistant Professor, Department of Dermatology, School of Medicine, Oregon Health & Science University, Portland, OR)
18. Hotaka Sakunaga, M.D. (Department of Gynecology, Sasaki Institute, Kyoundo Hospital, Tokyo, Japan)
19. Mary Hintz, Ph.D. (Faculty, Department of Chemistry and Biochemistry, Middlebury College, Middlebury, VT)
20. Trond Stokke, Ph.D. (Senior Scientist, Department of Radiation Biology, Comprehensive Cancer Center, Norwegian Radium Hospital, Oslo, Norway)
21. Nikki Levin, M.D., Ph.D. (Dermatologist, University of Massachusetts Memorial Medical Center, Worcester, MA)
22. Colin Collins, Ph.D. (Senior Research Scientist, Vancouver Prostate Center; Director, The Laboratory for Advanced Genome Analysis (LAGA), Vancouver, British Columbia, Canada; Professor, Department of Urologic Sciences, University of British Columbia)
23. Hiroshi Iwabuchi, M.D. (Department of Gynecology, Sasaki Institute, Kyoundo Hospital, Tokyo, Japan)
24. Shunsuke Hiraguri, M.D., Ph.D. (Department of Thoracic Surgery, Hachioji Medical Center, Tokyo Medical University)
25. Maija Wessman, Ph.D. (Research Scientist, Department of Diabetes Genetics, University of Helsinki, Finland)
26. Tony Godfrey, Ph.D. (Associate Professor, Department of Surgery, and Research Associate Professor, the University of Rochester Medical Center, Rochester, NY)
27. Jack Cronin, Ph.D. (Research Director, Alza, Palo Alto, CA)
28. Carsten Brandt, M.D., Ph.D. (Institute of Human Genetics, University of Aarhus, Aarhus, Denmark)
30. Kenji Umayahara, M.D. (Department of Obstetrics and Gynecology, Yamaguchi University School of Medicine, Yamaguchi, Japan)
31. Marlena Schoenberg-Fejzo, Ph.D. (Division of Hematology / Oncology, Department of Medicine, UCLA School of Medicine, Los Angeles, CA)
32. Soo-In Hwang, Ph.D. (Manager, Genomics, PE GenScope, Foster City, CA)
33. Genevieve Nonet, Ph.D. (Senior Scientist, Xoma, Berkeley, CA)
34. Kristina Arheden, Ph.D. (Department of Clinical Genetics, University Hospital, Lund, Sweden)
35. Gayatry Mohapatra, Ph.D. (Instructor in Pathology, Harvard Medical School; Assistant in Molecular Pathology, Massachusetts General Hospital, Boston, MA)
34. Russ Baldocchi, Ph.D. (Dako North America, Inc., Carpinteria, CA)
35. Seiji Suzuki, M.D. (Second Department of Internal Medicine, Nagoya City University Medical School, Nagoya, Japan)
36. Pierre Massion, M.D. (Professor of Medicine, Allergy, Pulmonary & Critical Care and Cancer Biology, Cornelius Vanderbilt Chair in Medicine, Vanderbilt University; Pulmonary and Critical Care Medicine Doctor, Director, Cancer Early Detection and Prevention Initiative, Vanderbilt-Ingram Cancer Center, Nashville, TN)
37. J. Graeme Hodgson, Ph.D. (Senior Principal Scientist, Oncology Research Unit, Pfizer, La Jolla, CA)

38. Janyaporn Phuchareon, Ph.D. (Department of Pathology, School of Medicine; UCSF Helen Diller Family Comprehensive Cancer Center and Cancer Research Institute, San Francisco, CA)
39. Kyosuke Yamada, M.D. (Department of Obstetrics and Gynecology, Jikei University School of Medicine, Tokyo, Japan)
40. Richard Neve, Ph.D. (Senior Research Scientist, Gilead Sciences, Foster City, CA)
41. Anna Lapuk, Ph.D. (Vancouver Prostate Centre, Vancouver, British Columbia, Canada)
42. Yinghui Guan, Ph.D. (Senior Research Associate, Genentech, South San Francisco, CA)
43. Hirokuni Takano, M.D., Ph.D. (Department of Obstetrics and Gynecology, Jikei University School of Medicine, Tokyo, Japan)
44. Alistaire MacDonald, Ph.D. (Research position)
45. Anguraj Sadanandam, Ph.D. (Assistant Professor, The Institute of Cancer Research (ICR), London, England)
46. William J. Gibb, Ph.D. (Sr. Bioinformatics Scientist, Genomic Health, Redwood City, CA)
47. Heidi S. Feiler, Ph.D. (Research Associate Professor, Deputy Director of the OHSU Center for Spatial Systems Biomedicine, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
48. Laura Heiser, Ph.D. (Assistant Professor, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
49. Lakshmi Jakkula, Ph.D. (Former Research Scientist, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA)
50. Denise Wolf, Ph.D. (Bioinformatics Specialist, University of California, San Francisco, CA)
51. Mara Jeffress, Ph.D. (Associate Consultant, Kantar Health, San Francisco, CA)
52. Raymond Cho, M.D., Ph.D. (Assistant Clinical Professor, Department of Dermatology, University of California, San Francisco, CA)
53. Steffen Durinck, Ph.D. (Scientist, Bioinformatics, Genentech, South San Francisco, CA)
54. Nicholas Wang, Ph.D. (Senior Scientist, Cepheid Inc., Portland, OR)
55. James Korkola, Ph.D. (Assistant Professor, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
56. Zhi Hu, Ph.D. (Senior Research Associate, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
57. Eric Collisson, M.D. (Associate Professor in Residence, Divisions of Hematology and Oncology, University of California, San Francisco, CA)
58. Jing Huang, Ph.D. (Former Postdoctoral Fellow, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA)
59. Demetris Iacovides, Ph.D. (Research Fellow, Department of Biological Sciences, University of Cyprus, Greece)
60. Xiaolin Nan, Ph.D. (Assistant Professor, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
61. François Pepin Ph.D. (Bioinformatics Scientist, Genia Technologies, Santa Clara, CA)
62. Obi Griffith, Ph.D. (Assistant Professor of Medicine and Assistant Director at The Genome Institute, Washington University, St. Louis, MO)
63. Anneleen Daemen, Ph.D. (Computational Biologist II, Genentech, South San Francisco, CA)

64. John Muschler, Ph.D. (Research Associate Professor, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
65. Amanda Esch, Ph.D. (Senior Product Application Specialist, Fluidigm, Toronto, Canada)
66. Juha Rantala, Ph.D. (Founder and CEO, Misvik Biology Corporation, Turku, Finland)
67. Summer Gibbs, Ph.D. (Assistant Professor, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
68. Shanta Boddapati, Ph.D. (Bioprocess Scientist, Seattle Genetics, Portland, OR)
69. Trevor Levin, Ph.D. (Chief Executive Officer, Urology Diagnostics, Inc. San Francisco, CA)
70. Joseph Garay, Ph.D. (Postdoctoral Fellow, Chuck Perou Laboratory, University of North Carolina, Chapel Hill, NC)
71. Koei Chin, M.D., Ph.D. (Research Associate Professor, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
72. Claudia López, Ph.D. (Research Assistant Professor, Biomedical Engineering Department, Multi-scale Microscopy Core (MMC) Manager, Oregon Health & Science University, Portland, OR)
73. Sunjong Kwon, Ph.D. (Research Assistant Professor, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
74. Kristiina Iljin, Ph.D. (Senior Scientist, VTT Technical Research Centre of Finland, Espoo, Finland)
75. Kimberly Beatty, Ph.D. (Assistant Professor, Biomedical Engineering Department and Physiology & Pharmacology Department, Oregon Health & Science University, Portland, OR)
76. Anke Mulder, Ph.D. (Customer Success Manager, Biotechnology, Thermo Fisher Scientific, formerly FEI, San Francisco Bay Area)
77. Danielle Jorgens, M.S., Ph.D. (Research Assistant Professor, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
78. Brett Johnson, Ph.D., (Postdoctoral Fellow, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
79. Annette Kolodzie, J.D., Ph.D. (Assistant Director, Serial Measurement of Molecular and Architectural Responses to Therapy (SMMART) Treatments Program, Center for Spatial Systems Biomedicine (OCCSB), Oregon Health & Science University, Portland, OR)
80. Craig Yoshioka, Ph.D. (Research Assistant Professor, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
81. Hongmei Zhang, Ph.D. (Postdoctoral Fellow), Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
82. Mehmet Gönen, Ph.D. (Assistant Professor of Industrial Engineering and Computational Biology, Koc University, Istanbul, Turkey; Research Assistant Professor, Biomedical Engineering Department, Oregon Health & Science University)
83. Jessica Riersterer, Ph.D. (Staff Scientist, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)
84. Zuzana Tatárová, Ph.D. (Postdoctoral Fellow, Biomedical Engineering Department, Oregon Health & Science University, Portland, OR)

Visiting faculty supervised

1. Manabu Takahashi, M.D., Yamaguchi University, Ube, Japan

2. Marshall Edgell, Ph.D., Distinguished Professor, Department of Microbiology and Immunology, University of North Carolina
3. Gerrit van den Engh, Ph.D., Research Professor, School of Oceanography, University of Washington, Seattle; President CTO, Cytopia, Seattle, WA
4. Frederic Waldman, M.D., Ph.D., Professor, Laboratory Medicine and Urology, University of California, San Francisco, CA
5. Kohsuke Sasaki, M.D., Professor, Iwate Medical University, Morioka, Japan
6. Adrian Begg, Ph.D., Professor, Molecular Radiobiology, Radboud University Medical Center, Nijmegen, Netherlands; Head, Radiobiology Group, The Netherlands Cancer Institute, Amsterdam, Netherlands
7. Lars Bolund, M.D., Professor of Clinical Genetics, Institute of Human Genetics, University of Aarhus, Aarhus, Denmark
8. Kurt Hirschhorn, M.D., Mt. Sinai Hospital, New York, NY
9. Marc Lenburg, Ph.D., Associate Professor of Pathology and Laboratory Medicine; Adjunct Associate Professor, Bioinformatics Program; Co-Director, Microarray Resource, Boston University School of Medicine, Boston MA
10. Jeffrey E. Green, M.D., Chief, Transgenic Oncogenesis and Genomics Section, Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD
11. Juan Carlos Martinez, M.D. & M.Sc., Candidate, Biochemistry and Molecular Biology, Universidad Peruana Cayetano Heredia, UPCH, Lima, Peru
12. Saima Hassan, M.D., Ph.D., F.R.C.S.C., Surgeon-Scientist, Breast Surgical Oncology, Assistant Professor, Centre Hospitalier de l'Université de Montréal, Québec, Canada
13. William J. Muller, Ph.D., Professor, Department of Biochemistry, Rosalind and Morris Goodman Cancer Centre, Canada Research Chair, Molecular Oncology, McGill University, Montreal, Canada
14. Do Hee Lee, Ph.D., Department of Biotechnology, College of Natural Sciences, Seoul Women's University, Republic of Korea
15. Norbert Reich, Ph.D., Professor, Department of Chemistry and Biochemistry, University of California, Santa Barbara